T2 Biosystems
... T3D Therapeutics .... Tabula
... Taconic
BioSciences ..... Tactical
Engineering and Analysis .... Tactile
Systems Technology ... Tactiva
Therapeutics
..... TAI
Diagnostics
..... Talaris Therapeutics
.... Talecris
Biotherapeutics ... Talee
Bio .... Taligen
Therapeutics
... Talima Therapeutics ... Talis Biomedical .... Tal Medical .. Talon
Therapeutics ... Talus
Bioscences ...
Tandem Diabetes
Care ... Tangen
Biosciences .... Tango
Therapeutics .... Tanox
... Tantaline
... TapImmune .... Tarari
... Targacept
... Targazyme .... TargeGen
... Targ-Anox
... Targanta ... Targeson
... Targeted Genetics
... Targeted Growth
... Taris
Biomedical ... Tarsa
Therapeutics ... Tarveda
Therapeutics
.... Tascent
.... Tauriga
Sciences
.... Taxa Biotechnologies
..... Taxon Biosciences
..... Taxus Cardium (formerly
Cardium
Therapeutics) ... Taylor
Devices .... Taysha
Gene Therapies ..... TCR²
Therapeutics
....
T2 Biosystems (Lexington, MA; no SBIR) has a rapid coronavirus diagnostic test: the T2SARS-CoV-2 Panel, which provides sample-to-answer results in less than two hours. It is being commercially distributed after validation and meeting requirements for an Emergency Use Authorization request to the FDA. [BostInno, Jun 30, 20]
The IPO window is still open, sort of, but life sciences companies are not getting through unscathed. Tobira Therapeutics (San Francisco, CA; no SBIR) and Microlin Bio (New York, NY; no SBIR) postponed their offerings after T2 Biosystems (Lexington, MA; no SBIR) and Switzerland’s Auris Medical slashed the terms of their Nasdaq IPOs this week. [Bruce Bigelow, xconomy.com, Aug 7, 14]
T2 Biosystems, (Lexington, MA; no SBIR) diagnostics company with no products yet on the market, announced the completion of a $40 million financing that will support the testing and commercialization of technology designed to rapidly identify fungal infections such as sepsis. [Chris Reidy,Boston Globe, Mar 29, 13]
In support of progressing its medical diagnostic technology toward regulatory approval and growing its partner program, T2 Biosystems (Lexington, MA; no SBIR) has completed a $23 million Series D funding round ... pushing its T2MR diagnostic technology through clinical trials, and the company noted in a press release that it expects to submit it for FDA approval in the second half of 2012. The assay is intended to detect Candida, a fungal pathogen linked to bloodstream infections, in less than two hours, rather than the typical one or more days that also requires sample purification and blood culture growth. [Michelle Lang, Mass High Tech, Aug 11, 11]
T2 Biosystems (Cambridge, MA; no SBIR) developing next-generation clinical diagnostic products, said it has raised about $15 million in a Series C financing. [Boston Globe, May 25, 10]
VC awards in the [NC] Triangle: G1 Therapeutics (Research Triangle Park, NC; no SBIR) an oncology drug developer raised $47 million in Series C funding in May; Spyryx Biosciences, (Durham, NC; no SBIR) a lung disease therapy developer $4.5 million; T3D Therapeutics (Research Triangle Park, NC; $1.8M SBIR), an Alzheimer’s disease therapy developer $3 million; and Advanced Animal Diagnostics, (Morrisville, NC; one SBIR) livestock farming diagnostics company $1.8 million. [John Murawski, Raleigh News & Observer, Jul 15, 16]
T3D Therapeutics (Research Triangle Park, NC; no SBIR) founded by [former GlaxoSmithKline executive] John Didsbury – received [FDA] approval to start a small trial testing its experimental drug T3D-959 in 36 patients with Alzheimer’s disease. ... a disease that has for years frustrated drug developers big and small. Already the drug has proved safe in humans and shown efficacy when tested in diseased animals, ... total amount raised by T3D to about $4 million, a figure that includes $300,000 from the N.C. Biotechnology Center. [Jason deBruyn, Triangle Business Journal, Jun 26, 15]
Tabula (Santa Clara, CA; no SBIR, 120 employees) semiconductor company that has raised more than $200 million, will close its doors March 24, according to a state filing. ... Its technology aimed to make chips more efficient, more capable and cheaper. It competed against major heavyweights Xilinx and Altera. ... analyst Jim McGregor, founder and principal analyst at Tirias Research, told the publication at the time. "If they do shut down, it would just be another in a long line of tech startups with good technology that just didn't make it into the market because of timing or the market dynamics." [Nathan Donato-Weinstein, Silicon Valley Business Journal, Feb 11, 15]
start-up has raised one of the biggest funding rounds in years in the semiconductor industry, a sector that many venture-capital firms have been avoiding. The $108 million infusion in Tabula (Santa Clara, CA; no SBIR), which the company plans to announce Monday, is also notable because Tabula is targeting a market niche that has attracted a number of other entrants that subsequently went out of business. [Don Clark, Wall Street Journal, Mar 28, 11] Where there are markets, there is hope.
Taconic BioSciences (formerly Taconic Farms in Germantown NY; one 1998 SBIR, founded 1952) is moving its HQ to Albany NY ... hired more than 100 employees over the past year [Albany Business Review, Dec 29, 17]
Three small businesses have been awarded spots on a potential five-year contract to support analysis and test engineering work on the U.S. Navy’s command, control, communications, computers, cyber, intelligence, surveillance and reconnaissance systems: Highbury Defense Group (San Diego, CA), Koam Engineering Systems (San Diego, CA), Tactical Engineering and Analysis (San Diego, CA). [Peter Graham, GovConWire, Oct 1, 18] None had SBIR. The whole best national talent for the job live around the flagpole in San Diego?
Tactile Systems (Minneapolis, MN; no SBIR) stock closed up 11 percent in [IPO] trading debut [Katharine Grayson, Minneapolis / St. Paul Business Journal, Jul 28, 16] Tactile Systems Technology, Inc. (“Tactile Medical”) a medical technology company that develops innovative medical devices for the treatment of chronic diseases at home, announced the closing of its initial public offering [raising $40M] [company press release, Aug 2, 16]
Tactile Systems Technology (Minneapolis, MN; no SBIR, founded 1995) that develops therapeutic medical technologies to treat chronic medical conditions, filed a to raise up to $86.3 million in an [IPO] ... makes pneumatic compression devices for treatment of lymphedema (which generally results in swollen tissue associated with a compromised lymphatic system) and venous leg ulcers. [Patrick Kennedy, Minneapolis Star Tribune, Jan 25, 16]
Fast-growing medical-device firm Tactile Systems Technology (Minneapolis, MN; no SBIR) has raised about $10.4 million in capital, which it will use to acquire a new technology and bolster its product portfolio. .... markets its device, called Flexitouch, to women suffering from lymphedema. The condition, which affects a large share of breast cancer survivors, limits the body’s ability to drain fluid from extremities, leading to swelling. The Flexitouch device mimics a manual massage process that’s commonly used to bring down swelling. Patients wear it at home instead of regularly visiting a therapist. [Katherine Grayson, Minneapolis /St Paul Business Journal, Oct 5, 12]
Tactile Systems Technology (Minneapolis, MN; no SBIR), which has developed a high-tech wrap to treat swollen limbs caused by lymphodema and other ailments, has raised $11.8M. [Minneapolis / St. Paul Business Journal, Oct 30, 07]
Tactiva Therapeutics (Buffalo, NY; no SBIR, founded 2016), development stage immuno-oncology company with a unique approach to adoptive T-cell therapy, announced it has secured a $35 million Series A financing ... to advance the clinical development of Tactiva Therapeutics’ dual enhanced adoptive cell therapy (DEACT™) platform for the treatment of Multiple Myeloma and several solid tumor type cancer indications. [company press release, Dec 4. 18]
[FDA] notified MimiVax LLC, (Buffalo, NY; no SBIR, founded 2012) a Roswell Park Cancer Institute spinoff company, that its application for orphan status for SurVaxM [a promising immunotherapy vaccine] as treatment for glioblastoma, a type of brain cancer, had been approved. [company press release, Aug 7, 17] Tactiva Therapeutics LLC, a new biotech company spun off from Roswell Park Cancer Institute, will create jobs as it develops some of the most promising concepts in the burgeoning field of cancer immunotherapy and accelerates the timeline for getting beneficial therapies to patients. ... Its lead platform involves using a patient’s own immune cells to fight their cancer. ... With annual revenue of about $800 million, the 133-bed cancer hospital in downtown Buffalo has launched more than half a dozen companies over the past decade. [press release, Feb 7, 17]
biotech TAI Diagnostics (Wauwatosa, WI; no SBIR, founded 2015) recently launched a Series B funding round in hopes of raising $15 million to $20 million, according to CEO Langley. [Andrew Weiland, Milwaukee BizTimes, Jun 5, 19]
As TAI Diagnostics (Wauwatosa, WI; no SBIR) presses forward on commercialization of its first product, a test for organ rejection in heart transplant patients, [it] recently revealed additional [$12.8 million] to support development of more tests. [Jeff Buchanan, xconomy.com. Jul 2, 18]
TAI Diagnostics (Wauwatosa, WI; no SBIR, founded 2015) startup developing a non-invasive test to monitor patients’ health after they’ve received heart transplants, plans to begin selling its test early next year, says CEO Frank Langley. .... has raised about $13 million from investors so far, [and] is currently raising more money to augment its $8.3 million Series A funding round. [Jeff Buchanan, xconomy,com, Oct 23, 17]
biotech startup TAI Diagnostics (Wauwatosa, WI; no SBIR, founded 2015 as a spinoff from the Medical College of Wisconsin) which provides non-invasive and highly sensitive diagnostic testing of transplanted organs is working to raise a $10 million Series B round of funding. ... raised an $8.2 million Series A round, led by Madison-based venture capital firm [Molly Dill, Milwaukee Businesss Times, Oct 20, 17]
TAI Diagnostics (Wauwatosa, WI; no SBIR, founded 2015) a diagnostics company focused on developing innovative diagnostic tests for monitoring the health of transplanted organs, announced the final closing of an $8.2 million Series A financing ... to further develop and commercialize patented cell-free DNA technology licensed from the Medical College of Wisconsin [Business Wire, Oct 23, 15]
Talaris Therapeutics startup founded 2002 and long known as Regenerex, has secured a $100 million Series A investment ... breathes new life into an experimental cell therapy known as FCR001, a one-time treatment meant to make it possible for patients who need a kidney transplant to get one from any donor—without the need for a life-long regimen of immunosuppressive drugs afterwards to prevent rejection of the outsider’s organ. [Ben Fidler, xconomy.com, Apr 18, 19]
Regenerex (Louisville, KY; $7M SBIR) late clinical stage biotechnology company engaged in the development of innovative cellular therapies with the goal of providing long-term durable responses eliminating the burden of chronic immunosuppression in selected organ transplant and autoimmune conditions.gets new CEO, new funding and new name: Talaris Therapeutics [Amirah Al Idrus, Fierce Biotech, Apr 18, 19]
Biopharmaceutical company Talecris Biotherapeutics Holdings Corp (RTP, NC; no SBIR) gained 11% in its initial public offering, the first pharmaceutical IPO to perform well in two years. .. makes plasma-derived treatments for diseases, including hemophilia and pediatric HIV infections. The company has years of profits under its belt; in the first six months of the year, its net revenue rose 20% to $735 million, and net income hit $117 million. [Wall Street Journal, Oct 2, 09]
Talee Bio (Philadelphia, PA; $400K SBIR) a development stage biopharmaceutical focused on developing gene therapy treatments for cystic fibrosis, announced agreements with the Cystic Fibrosis Foundation (CF Foundation) to fund the preclinical development of two mutation-agnostic gene therapy product candidates, TL-101 and TL-102. The CF Foundation committed up to $4.5 million to expedite the development of both product candidates for all people with cystic fibrosis, and particularly those individuals with no viable treatment options for the underlying cause of the disease. [company press release, Jan 23, 19]
Taligen Therapeutics (Cambridge, MA (formerly Greenwood Village, CO); $1M SBIR) has been acquired by Alexion Pharmaceuticals (Cheshire, CT; $1.6M SBIR) for $111 million in an up front cash payment. [Mass High Tech, Jan 31, 11]
Taligen Therapeutics (Cambridge, MA; $1M SBIR) added on to its Series B Round with an additional $10 million, bringing the amount up to $36 million of a planned $65 million second round [Mass High Tech, Aug 23, 10]
Taligen Therapeutics (Cambridge, MA; $1M SBIR (in Colorado)) raised $26 million of its projected $64.9 million funding round, according to federal documents. Taligen CEO Abbie Celniker confirmed that the funding is part of its Series B round and will be spent on drug development. .... new protein drugs to treat inflammation and related diseases. [Marc Songini, Mass High Tech, May 12, 09]
Nearer the Action. biotech start-up Taligen Therapeutics (Greenwood Village, CO; $1M SBIR) is moving its headquarters to Cambridge MA and hired a local Novartis AG (Swiss giant) executive to run the company, .... with just eight employees, but recently raised $65 million in VC [Bosto Globe, Jul 24, 08].
Talima Therapeutics (Santa Clara, CA; no SBIR) raised $19M in a second funding round. .. founded in 2005, has developed a micro-implant technology to enable site-specific drug delivery designed to minimize the side effects of systemic drugs [San Jose Mercury News, Jun 6]
Talis Biomedical (Chicago, IL; $350K SBIR) up 31% [Nov 14, 2023] announced it has initiated a process to explore strategic alternatives with the goal of maximizing shareholder value. [company press release, Nov 14, 2023]
Tal Medical (Boston, MA; no SBIR) has launched with $700,000 in initial funding, according to a filing with the federal government. Officially incorporated in September 2010, Tal Medical exclusively licenses Low Field Magnetic Stimulation technology from McLean Hospital in Belmont, to treat depression, the company website indicates. [Rodney Brown, Mass High Tech, Jun 14, 11]
Talon Therapeutics (San Mateo, CA; one SBIR as Hana Biosciences) won accelerated [FDA] approval regarding its cancer-fighting drug Marqibo. The company's accumulated deficit from its founding in December 2002 to the end of the first quarter? $210.4 million. ... Although 23-employee Talon continues to work on a topical lotion for skin problems caused by some cancer-fighting agents, its hopes are largely pinned on Marqibo. The drug is an injectable form of generic vincristine sulfate and helps vincristine stick around longer to attack the cancer. [Ron Leuty, San Francisco Business Times, Aug 9, 12]
Talus Bioscience (Seattle, WA; $800K SBIR) has landed $4.3 million in grant funding from [NIH] and Washington state's Andy Hill Cancer Research Endowment Fund. [Rick Morgan, Seattle Inno, Aug 28, 2023]
Tandem Diabetes Care up 13% [Nov 15, 13]
Insulin pump maker Tandem Diabetes Care (San Diego, CA; no SBIR) filed for an [IPO] of up to $100 million. .... expects to make money [after several years] by using its technology to make more products with greater speed and less expense. [Bradley Fikes, utsandiego.com, Oct 8, 13]
Tandem Diabetes Care (San Diego, CA; no SBIR) will launch its first commercial product, a compact insulin pump, in the first half of 2012, the company said [Keith Darce, signonsandiego.com, Nov 16, 11]
Tangen Biosciences (Branford, CT; $400K SBIR, founded 2013), developers of cheap and portable molecular diagnostics for outside the lab, announced that it has closed a $9 million Series A equity round [company press release, Jun 20, 19] prior funding $2M [crunchbase.com]
Two Yale professors will receive $500,000 grants from the [Connecticut Bioscience Innovation Fund] in the hopes that the money will help the researchers hasten the day their discoveries become salable products ... The state borrowed the money for both ... how much of that money will be a loan vs. a venture capital style investment is yet to be negotiated. Businesses are not eligible for grants under the terms of CBIF. ... Loon Medical (Tolland, CT; no SBIR) is developing a remote monitor for ill people who do not have caretakers on site at all times, such as people with dementia. Tangen Biosciences (Branford, CT; no SBIR) is developing an affordable, mobile diagnostic test for tuberculosis for use in the developing world. [Mara Lee, Hartford Courant, Nov 17, 14]
cancer drug developer biotech Tango Therapeutics (Cambridge, MA; no SBIR) focused on discovering and delivering the next generation of targeted cancer therapies, today announced the closing of $50 million in equity financing. also announced an expanded collaboration with Gilead Sciences, which builds on an agreement signed in 2018. Under the updated terms, Gilead will make a $125 million upfront payment to Tango and a $20 million equity investment in the company. In addition, Gilead will have the right to option up to 15 immune evasion programs for up to $410 million per program in opt-in, extension and milestone payments. Tango will also be eligible to receive up to low double-digit tiered royalties on net sales. [company press release, Aug 17, 20]
Cyteir Therapeutics (Cambridge, MA; no SBIR, founded 2012) just raised $29 million [with its] approach to treating cancer is based on research showing how cancer cells behave differently than healthy ones.... Cyteir is the latest company to emerge with the goal of broadening synthetic lethality beyond PARP. Tango Therapeutics (Cambridge, MA; no SBIR, Series A 2017) unveiled a $55 million in funding last year to back its synthetic lethality research in cancer. Repare Therapeutics (Boston, MA and Canda; no SBIR, founded 2016) raised $68 million last year to support its work. Ideaya Biosciences (South San Francisco and La Jolla, CA; no SBIR, founded 2015), which raised $46 million in 2016, is also in the mix. [Frank Vinluan, xconomy.com, Mar 8, 18]
Tanox (Houston, TX; $1.5M SBIR) is being bought by Genentech. Founder CEO Nancy Chang of the 20-year-old biotech company who was a professor at the Baylor College of Medicine says that Pharmaceutical companies are realizing that it’s so expensive to discover new drugs that they’re relying more and more on biotechs for the discovery, development and concept phases. [Southwest Economy, Dallas Federal Reserve, M/A07] Formed in 1986 and first SBIR in 1988 and last SBIR in 2000. It's a poster story SBIR - seed money for starting real innovation followed by private capital - instead of steadily feeding market-dead beneficiaries. Chang notes that the U.S. is still the one place where people value creativity. There are savvy investors and hard-driving entrepreneurs in the U.S. who are willing to invest their money, time and expertise on innovative ideas in new drug development.
Biotech Tanox (Houston, TX) will sell itself to Genentech for $919 million. [Houston Chronicle, Jan 16] SBIR $1.4M until Y2K.
Tanox up 45% on being acquired by Genentech. [Nov 10, 06] $1.4M SBIR in the 1990s.
TapImmune up 16% [Sep 12, 18]
Tap Immune down 11% [Sep 10, 18]
TapImmune up 11% [Sep 4, 18]
TapImmune up 19% [Aug 31, 18]
TapImmune up 13% [Aug 9, 18]
TapImmune up 11% [Aug 1, 18]
Tapimmuneech down 17% [Jul 24, 18]
TapImmune down 15% [Jun 27, 18]
Tapimmune up 21% [Jun 15, 18]
Tapimmune up 10% [Jun 13, 18]
Tapimmune (Jacksonville, FL no SBIR. founded 1991, market cap $71M)down 51% [Jun 8, 18] Announces Pricing of $70 Million Private Placement [to]to advance the combined company's novel T cell therapy into multiple Phase 2 clinical studies, build-out the combined company's operational and clinical facilities, and continue all ongoing and planned clinical studies for its novel T cell vaccine candidates. [company press release, Jun 8, 18] total funding $5.6M [crunchbase.com]
TapImmune up 11% [Oct 5, 17]
Tarari (San Diego,CA; no SBIR) is being sold to LSI for $85M cash – giving Tarari a large parent to support the roll out of chips that ward off computer viruses. a five-year-old company that has raised $42 million in venture capital, has been selling its chips for about two years, with customers including Cisco Systems and Secure Computing. [San Diego Union Tribune, Sep 6]
Targaceptt (Winston-Salem, NC; one SBIR, market cap $90M) and Catalyst Biosciences (San Francisco, CA; one SBIR) jointly announced today that they have entered into a definitive agreement to merge the two companies. The combined entity, to be named Catalyst Biosciences, Inc., is expected to create a financially strong company to harness the catalytic power of engineered human proteases to develop next-generation biopharmaceuticals with improved efficacy and therapeutic index to treat major diseases. [joint companies press release. Mar 6, 15] "We're not prepared to spend another $100 million on nicotinic research," Dr. Stephen A. Hill, president and CEO of Targacept ... A few years ago, Targacept had 150 employees, as Justin Catanoso, contributor to the Business Journal, reported. Now it has 20. [James Ritchie, Triad Business Journal, Mar 6, 15]
After a string of clinical trial failures, Targacept has further slimmed down its work force and is looking for new directions in its drug discovery process. ... At the end of this year, the company expects to have about $107 million in funding available. At this point the company does not have any revenue-generating products. [Matt Evans, Triad Business Journal, Aug 6, 14]
Targacept down 29% [Jul 29, 14]
Targacept down 34% [Dec 16, 13] investigational secondary treatment for schizophrenia didn't show significant improvement in negative symptoms or cognitive function in a Phase 2b trial after 24 weeks. The biopharmaceutical company said that it wouldn't pursue further development of the therapy [Tess Stynes, Wall Street Journal, Dec 16, 13]
Targacept up 11% [Sep 18, 12]
Targacept down 11% [Sep 17, 12]
Targacept (one SBIR a decade ago) announced that it will lay off 65 people, or about 46 percent of its workforce, following the failure of an antidepressant drug candidate in Phase 3 clinical trials.[Triangle Business Journal, Apr 26, 12]
Targacept up 12% [Apr 10, 12]
Targacept down 30% [Mar 20, 12] on the announcement that AstraZeneca was not going to file TC-5214 for regulatory approval. [seekingalpha.com, Mar 21]
Targacept down 36% [Dec 20, 11] said that their experimental depression drug TC-5214 failed in a second late-stage clinical trial. [AP, Dec 20]
Targacept down 60% [Nov 8, 11] announced disappointing results from a phase 3 study of a treatment, TC-5214, for major depressive order. The drug did not meet its primary endpoint of change on the Montgomery-Asberg Depression Rating Scale when used as an adjunct therapy to initial antidepressant treatment, as compared to a placebo. [Forbes, Nov 8]
Targacept up 16% [Oct 16, 09] company released the complete results of a midstage study on its drug to treat a major depressive disorder. Analysts called the results "eye popping." [Wall Street Journal, Oct 17, 09]
Targacept down 10% [Oct 12, 09]
Targacept, up 772%, led the pack in percentage gain for the second quarter. Osiris had the tenth worst quarter at -50%. [Wall Street Journal, Oct 1, 09]
Targacept down 11% [Oct 1, 09]
Targacept up 137% [Jul 15, 09] company's treatment for major depressive disorder was shown effective and safe in midstage clinical trials, paving the way for latestage trials and discussions with the Food and Drug Administration for approval. [Wall Street Journal, Jul 16]
Targacept up 28% [Jul 8, 09] AstraZeneca P.L.C. said it had agreed to make a $10 million milestone payment to Targacept because the two companies plan to conduct further development of AZD3480. ... would begin Phase IIb studies on the drug to treat attention deficit/hyperactivity disorder. [Philadelphia Inquirer, Jul 8, 09]
Targacept up 13% [Jun 24, 09]
Targacept down 12% [May 1, 09]
Targacept up 14% [Apr 29, 09]
Targacept down 11% [Apr 27, 09]
Targacept down 11% [Apr 23, 09]
Targacept up 10% [Apr 15, 09]
Targacept up 13%% [Apr 2, 09]
Targacept down 17% [Mar 27, 09]
Targacept up 27% [Mar 12, 09]
Targacept down 19% [Mar 11, 09]
Targacept up 24% [Mar 10, 09]
Targacept down 11% [Mar 5, 09]
Targacept down 17% [Feb 25, 09]
Targacept up 35% [Feb 24, 09]
Targacept down 20% [Feb 10, 09]
Targacept up 15% [Feb 3, 09]
Targacept up 20% [Feb 2, 09]
Targacept down 16% [Jan 29, 09]
Targacept up 15% [Jan 28, 09]
Targacept down 22% [Jan 22, 09]
Targacept up 28% [Jan 21, 09]
Targacept down 16% [Jan 9, 09]
Targacept up 11% [Jan 8, 09]
Targacept up 19% [Dec 31, 08]
Targacept down 17% [Dec 23, 08]
Targacept up 24% [Dec 22, 08]
Targacept up 11% [Dec 12, 08]
Targacept up 48% [Dec 8, 08]
Targacept up 38% [Dec 2, 08]
Targacept down 25% [Nov 17, 08]
Targacept down 19% [Nov 14, 08]
Targacept up 15% [Nov 13, 08]
Targacept up 21% [Nov 7, 08]
Targacept down 13% [Nov 6, 08]
Targacept down 13% [Nov 5, 08]
Targacept up 15% [Oct 31, 08]
Targacept up 11% [Oct 30, 08]
Targacept up 17% [Oct 28, 08]
Targacept down 11% [Oct 17, 08]
Targacept up 50% [Oct 16, 08]
Targacept down 35% [Oct 15, 08]
Targacept up 87% [Oct 10, 08]
Targacept down 36% [Oct 9, 08]
Targacept down 11% [Oct 8, 08]
Targacept down 14% [Oct 7, 08]
Targacept down 11% [Oct 8, 08]
Targacept down 14% [Oct 7, 08]
Targacept up 18% [Sep 25, 08]
Targacept up 37% [Sep 18, 08]
Targacept down 29% [Sep 17, 08]
Targacept down 31% [Sep 16, 08] on inconclusive study results.
Targacept up 11% [Sep 10, 08]
Targaceptup 11% [Jul 30, 08]
Targacept kept climbing the hill, up another 15%. [Nov 3, 06] Somebody knows something.
Targacept up 14% [Nov 2, 06]
Paris-based pharmaceutical giant Sanofi-Aventis agreed to pay up to $560 million for TargeGen (San Diego, CA; no SBIR) biotech company that is developing a drug to treat leukemia, lymphoma and other blood disorders. Investors have put more than $100 million into TargeGen since its founding in 2001 said its chairman [Onell Soto, signonsandiage.com, Jun 30, 10]
A handful of local life sciences companies have sprung to life over the past several months, in spite of a venture capital landscape that has sometimes looked windswept and barren. ... Companies that have successfully launched in this environment have powerful allies and a frugal mindset. Several are going after a platform that could target several diseases. Analysts say this approach gives the company several shots at profitability, making them more attractive to investors. ... Last week, Acetylon Pharmaceuticals (Cambridge, MA; no SBIR) announced its official launch with $7.25 million from private investors ... One company that did raise money from a traditional venture firm is Targ-Anox (Boston, MA; no SBIR). The company coalesced around technology discovered by Brigham and Women’s Hospital chief of medicine Joseph Loscalzo. [Mass High Tech, Aug 14, 09]
Targanta Therapeutics will be acquired by New Jersey’s The Medicines Co. in a deal that could be worth about $133.35 million, according to The Medicines Co.
Struggling Cambridge biotech Targanta Therapeutics is being bought for about $42 million by the Medicines Co., a New Jersey drug company. [Boston Globe, Jan 13, 09]
scientists at Targanta Therapeutics spent more than three years developing a powerful antibiotic to kill deadly bacteria. But these days, instead of fighting bacteria, the company is fighting for its own life, cutting jobs and watching its stock languish. Last month, the Food and Drug Administration rejected Targanta's first product, a drug called oritavancin. Regulators asked Targanta to conduct a new clinical trial that could cost another $40 million. Running out of money, Targanta said it would lay off 75 percent of its staff of 120, spread across Indiana, Massachusetts and Canada. Now the company is scrambling to find more money, a daunting task in the industry's toughest fundraising climate in 15 years. [Indianapolis Star, Jan 11, 09]
Targanta Therapeutics said today that it will have to conduct an additional study on the developing antibiotic oritavancin in order to satisfy a Food and Drug Administration review. [Boston Globe, Dec 9, 08]
Targanta Therapeutics plunged, a day after a panel of government experts voted against the benefits of the company's antibiotic. Yesterday the FDA's panel of infection experts voted 10 to 8 against the overall safety and effectiveness of the company's injectable drug, called oritavancin. Shares 81% in midafternoon trading. [Boston Globe, Nov 20, 08]
Targanta Therapeutics up 40% after federal regulators posted a favorable review of the company's antibiotic, ahead of a meeting to assess the product later this week. [Boston Globe, Nov 18, 08]
Targanta Therapeutics (Cambridge MA) went public [Oct 10, 07] for only $57M, below its planned $90M.
Antibiotics developer Targanta Therapeutics (Cambridge MA, no SBIR) priced its $90M IPO for some still future emergence. [Sep 28, 07]
Targanta Therapeutics (Cambridge MA; no SBIR). has launched a clinical trial to study less frequent dosing regimens of its lead antibiotic, four months after announcing plans for an IPO. [Mass High Tech, Sep 14]
Targanta (Cambridge MA, no SBIR)got $70M in VC money to develop a powerful antibiotic from a microbe discovered in Haitian dirt. The intellectual property comes from Eli Lily which exited the business to focus on other diseases. [Stephen Heuser, Boston Globe, Feb 9]
Targazyme (formerly America Stem Cell, Carlsbad, CA; no SBIR) is one example of a problematic startup [funded by Texas Emerging Technology Fund] that is chronicled. On paper, the San Antonio-based startup is developing stem-cell breakthroughs with 14 employees and the help of $1.25 million in state funds. But the rural address listed for its Texas headquarters [Floresville, TX] is actually a weedy horse pasture. During a recent visit by a reporter, the ex-husband of the CEO was warning his guest to watch for rattlesnakes, according to the AP. Targazyme founder Lynnet Koh said her company is moving forward but that she left Texas because Perry’s office withheld additional funding, a complaint echoed by other recipients. She now lives in California and said many of the jobs created by the company were short-term hires outside Texas, none of which is mentioned in the fund’s 2013 annual report. [Christopher Calnan, Austin Business Journal, Jul 25, 14]
Targeson (San Diego, CA; $1.6M SBIR) said it has been awarded a first-year grant of nearly $924,000 from the National Heart, Lung, and Blood Institute of the National Institutes of Health to explore the use of Targeson’s targeted microspheres in diagnostic testing for heart disease. ... the [SBIR] grant totaled $1.6 million, with the remaining portion to be funded in the second year, upon completion of first-year milestones. [Bruce Bigelow, xconomy.com, Aug 8, 13] A two-step Phase I SBIR. NIH is imaginative with its SBIR awards, and is now allowed to deal with VC-funded companies. Of course the SBIR advocates for mediocre companies fought politically to prevent the intrusion of real market economics into SBIR.
Targeson (San Diego, CA; $1.6M SBIR) said it would get $1.3 million over the next two years under a [NIH SBIR] .... exploring the use of Targeson’s microspheres as a way to delver nucleic acid therapies in kidney disease. The company plans to conduct its research in conjunction with Kumar Sharma, director of UC San Diego’s Center for Renal Translational Medicine. [Bruce Bigelow, xconomy.com, Sep 15, 11 ]
Targeted Genetics down 11% after the company proposed to combine with London-based Biocontrol. Long-struggling Targeted, whose shares trade over-the-counter since it was delisted from Nasdaq, would get a contingent of Biocontrol executives in key positions. Biocontrol shareholders would own approximately 50 percent of the combined company. Biocontrol is developing methods for controlling bacterial infections using phages, which are viruses that prey on bacteria. The company has completed some early-stage clinical trials that it says show "efficacy and safety even where conventional antibiotics have failed." [Seattle Times, Nov 12, 10]
Targeted Genetics, a 21-year-old Seattle biotechnology company that's been struggling in recent years, said it plans to deregister its stock and cease filing [SEC] reports. [Seattle Times, Jan 14, 10]
Targeted Genetics has struck a $7 million technology deal with Massachusetts-based Genzyme, extending the life of a cash-strapped Seattle biotechnology company. [Seattle Times, Sep 9, 09]
Targeted Genetics said it’s received a delisting letter from the NASDAQ Stock Market, saying the biotech isn’t in compliance with the market’s minimum listing requirements. ... hasn’t maintained a minimum of $2.5 million in shareholder’s equity [Puget Sound Business Review, Jul 29, 09]
Targeted Genetics reported that its current funds can't keep the company running beyond next month [Seattle Times, Jul 25, 09]
Targeted Genetics said it’s rapidly running out of cash and if it doesn’t find some more in a hurry, it could go out of business or declare bankruptcy. [Puget Sound Business Journal, May 8, 09]
Targeted Genetics said it’s made a couple of deals that it said should provide it with enough money “to support operations through the first half of 2009.” [Puget Sound Business Journal, Mar 2, 09]
Targeted Genetics said it has cut its payroll by 25 percent through layoffs and senior executive pay cuts, and has shifted its research efforts in a bid to survive a cash crunch. [Angel Gonzalez, Seattle Times, Dec 3,08]
Nasdaq warned Targeted Genetics that its stock could be delisted if it doesn't rise above $1 for at least 10 consecutive days within six months [Seattle Times, Apr 26, 08]
Targeted Genetics lost $16M for the year, only half its 2006 loss of $33M. [Seattle Times, Mar 26]
FDA cleared Targeted Genetics to restart its gene-therapy trial for rheumatoid arthritis after an investigation indicated the treatment did not contribute to the death of an Illinois woman. [Angel Gonzalez, Seattle Times, Nov 26]
Targeted Genetics up 11% [Oct 10, 07]
Targeted Genetics (one Phase 2 SBIR) put its leading clinical trial (of its inflammatory arthritis drug) on hold yesterday after one of the enrolled patients became seriously ill. ... also working on therapies for human immunodeficiency virus, congestive heart failure and Huntington's disease [Seattle Times, Jul 25]
Targeted Genetics completed a private-equity placement of $17.8M. [Seattle Times, Jun 29]
Targeted Genetics up 66% on news of making a profit of $800K even though a yearly loss of $34M. [Mar 29, 07]
Targeted Genetics fell 20% on news of raising $8.7M by private placement. [Jan 8, 07]
Targeted Genetics shot up more than 52 percent in trading Monday, but company officials say they don't know why the stock price skyrocketed.
Targeted Genetics up 26% after losing less than last year. [Nov 10, 06]
Targeted Genetics rocketed up a third on news of a debt deal. [Nov 7, 06]
With the two Montana Senators and governor smiling, Targeted Growth (Seattle WA; no SBIR), a renewable energy bioscience company, and Green Earth Fuels (Houston, TX; no SBIR), a vertically integrated renewable biodiesel energy company, announce the formation of a joint venture called Sustainable Oils, Inc. (www.susoils.com) at a press conference today. The new venture will produce and market up to 100 million gallons of Camelina-based biodiesel by 2010 [Targeted Growth press release, Nov 20] The seed will be grown mostly in Montana.
Johnson & Johnson announced the acquisition of TARIS Biomedical LLC (Lexingon, MA; no SBIR, founded 2008) specializing in the development of a novel drug delivery technology for the treatment of bladder diseases including cancer. The company’s lead clinical-stage product, TAR-200, uses the proprietary TARIS System, which features a silicone-based drug delivery device that allows for the continuous release of medication into the bladder. Financial terms not disclosed. [JNJ press release, Dec 20, 19]
Taris Biomedical (Lexington, MA; no SBIR) developing combination drug-device products, has taken in $18.3 million in a Series B funding round ... developing a treatment for bladder diseases. The funding will support its lead product, Lidocaine Releasing Intravesical System (LiRIS), in later-stage clinical trials [Mass High Tech, Apr 13, 11]
Taris Biomedical (Lexington, MA; no SBIR) has raised $15 million, .... based on drug-delivery technologies developed by Cambridge, Mass., scientists. [Boston Business Journal, Jun 25, 09]
Taris Biomedical (Lexington, MA; no SBIR) announced it has received a $15 million Series A round of venture financing to commence early stage trials of its bladder disease drug device. .... had been operating in stealth mode for about 10 months before emerging at a technology conference Wednesday [Mass High Tech, Jun 25, 09]
Tarsa Therapeutics (Philadelphia, PA; no SBIR, founded 2009) biopharmaceutical company developing a once-daily tablet for women suffering from postmenopausal osteoporosis has raised $1.2 million in a debt financing, according to [SEC] documents ... raised $2 million in a separate debt financing earlier this year ... has raised $100M in debt. [John George, Philadelphia Business Journal, Jul 15, 16]
Tarsa Therapeutics (Philadelphia, PA; no SBIR) biopharmaceutical company developing a once-daily tablet for women suffering from postmenopausal osteoporosis, has raised $2 million in a debt financing. [philadelphianews.net, Feb 25, 16] has developed TBRIA™ (calcitonin-salmon [rDNA origin] delayed release tablets), an oral formulation of calcitonin for the treatment of postmenopausal osteoporosis, and is seeking FDA approval. [company website]
Tarsa Therapeutics (Philadelphia, PA; no SBIR) said it has secured a $10 million [bank] loan .... biopharmaceutical company intends to use the money to support its plans to file a new drug application with the Food and Drug Administration early next year for Ostora, its experimental postmenopausal osteoporosis treatment [that] contains calcitonin, a naturally occurring hormone. [John George, Philadelphia Business Journal, Aug 13, 14]
Tarsa Therapeutics (Philadelphia, PA; no SBIR, founded 2009) raised $7 million in a private stock sale ... said the funds will be used to support its filing of a new drug application for Ostora, an experimental treatment for postmenopausal osteoporosis .... medicine formulated as a tablet containing calcitonin, which Brand said has been shown to have a "modest but consistent" positive effect on bone mineral density at the lumbar spine. [John George, Philadelphia Business Journal, May 30, 14]
Organovo (San Diego, CA; $1.6M SBIR) and Tarveda Therapeutics, (formerly Blend Thera, Watertown, MA; no SBIR) clinical stage biopharmaceutical developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin miniature drug conjugates, announced that they have entered into a definitive merger agreement under which Tarveda would merge with a wholly-owned subsidiary of Organovo in an all-stock transaction. [joint company press relese, Dec 16, 19]
One year after changing its name from Blend Therapeutics (no SBIR) and raising $38 million in financing, cancer drug developer Tarveda Therapeutics (Watertown, MA, 30 employees) has secured another $30 million round led by a San Francisco venture capital firm. [Max Stendahl, Boston Business Journal, Feb 1, 17]
Biometrics startup Tascent (Los Gatos, CA; founded 2015, about 1000 employees) raised $18.5 million in Series A funding to develop its iris recognition systems for airport and high-level security .... already has customers around the world, including Dubai International Airport, London Gatwick Airport and a few high-security facilities in the United States. ... The company recently acquired the AOptix Technologies Identity Solutions(Campbell, CA; $1.7M SBIR) business unit, which grants Tascent access to AOptix intellectual property, biometrics and iris recognition technology. [Gina Hall, Silicon Valley Business Journal, Sep 17, 15]
Tauriga Sciences (New York, NY; no SBIR) micro-robot firm [which develops technology in the microrobotics space] is acquiring startup Pilus Energy (Cincinnati, OH; no SBIR) that uses tiny bacteria robots to convert waste into electricity..... bacterial robots called BactoBots that metabolize wastewater and harvest direct current electricity to produce economically important gasses. [Andy Brownfield, Cincinnati Business Courier, Nov 26, 13] Tauriga is a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. The mission of the Company is to acquire and build a diversified portfolio of cutting edge technology assets [company website]
A nontoxic, spray-on coating called LiquiGlide (Cambridge, MA; no SBIR) makes the insides of containers so slippery that viscous liquids slide out easily, and only minuscule amounts stay behind. ... first products to use it expected this summer [Olga Kharif, Bloomberg Business Week, Jan 16, 14]
Tauriga Sciences (New York, NY; no SBIR, trading for a penny a share) micro-robot firm is acquiring startup Pilus Energy (Cincinnati, OH; no SBIR, a subsudiary of Bacterial Robotics (no SBIR) ) that uses tiny bacterial robots called BactoBots that metabolize wastewater and harvest direct current electricity to produce economically important gasses. [Andy Brownfield, Cincinnati Business Courier, Nov 26, 13]
Resistant biology. Any good story about biohacking is sure to include mention of a 2013 Kickstarter campaign that raised $484,013 to create bioluminescent plants. But there’s a problem: there is still no glowing plant. The project, which planned to add six genes into the genome of tobacco plants, was overly ambitious—not even the likes of Monsanto attempt anything as challenging. Now, out of cash and renamed as Taxa Biotechnologies, the team is acquiring more crowdfunding to create a less ambitious fragrant moss. But the tale is indicative of how DIY biohackers overestimate their abilities to bend biology to their will while working outside of big companies or academia. [MIT Tech Review, Jul 15, 16]
DuPont is buying a microbiome discovery company Taxon Biosciences (Tiburon, CA; $800K SBIR) for development of biological crop products, a move that the chemical and crop company hopes will give it an edge in an emerging agricultural market. ... did not disclose how much it is paying ... the latest in a string of acquisitions and expansions by the world's largest agrichemical companies to harness microbes, plant extracts and other natural substances to try to better control pests and improve plant health, quality and yield. [Reuters, Apr 22, 15]
Taxus Cardium (San Diego, CA; no SBIR), known until March as Cardium Therapeutics, said interim Phase 3 data from its gene therapy treatment showed significantly improved blood flow to the heart. The company, whose shares used to trade on the NYSE, reported interim results of a late-stage, multi-center study that has enrolled over 780 people with coronary artery disease. The company says the degree of improvement was comparable to bypass surgery, angioplasty, and stenting. [Alex Lash, xcononmy.com, Jun 26, 14]
Taylor Devices (N Tonawanda, NY; $400K SBIR in 1990s) [set] full-year net income record for the second consecutive year. .... coincides with the substantial completion of the expansion of our manufacturing space,” said Douglas Taylor, president. .... designs and develops shock absorption equipment. [Buffalo Business First, Aug 30, 13]
Taysha Gene Therapies (Dallas TX; no SBIR), announced it has launched with a mission to eradicate severe and life-threatening monogenic diseases of the central nervous system (CNS) by advancing its pipeline of 15 AAV (adeno-associated virus) gene therapy programs, with options to an additional four programs. The company reunites former investors and executives from AveXis, while accelerating its discovery and development efforts with the UT Southwestern Gene Therapy Program, one of the largest pediatric neurology residency programs in the U.S. ... has raised $30 million in seed financing [company press release, Apr 28, 20]
TCR² Therapeutics (Cambridge, MA; no SBIR, founded 2015) raised a $125 million Series B round to push ahead with live, cancer-fighting T cells. .... has not begun human testing, but it said today the new cash should help push two candidates, including one that targets cancers with the protein mesothelin, through Phase 2 studies. [company press release, Mar 21, 18] ]
Lingering in nursery. A small Wheat Ridge company has landed three NASA awards to develop devices that could be used on deep-space missions and for maneuvering satellites. ... TDA Research has 85 employees, serves a number of military and aerospace customers and earns a share of its $11.6 million in annual revenues from NASA projects. [Ann Shrader, Denver Post, Dec 23, 11] How touching - small company, the heartthrob of our politicians, gets government help! This touching small company has touched Uncle Sam for at least 378 SBIR projects funded with guessed average of $400K and a total guess of nearly $150M of which $6M came in 2010. Government encourages college-age kids to stay in nursery school.
US Navy awarded a $100,000,000 indefinite-delivery/indefinite-quantity multiple award contract for the development and integration of new software solutions. Companies are Dark Wolf Solutions (San Diego, CA; $2.9M SBIR); Geo4S Technologies (Catonsville, MD; $750K SBIR); ISPA Technology (Lithia, FLlorida; no SBIR); Moebius Solutions (San Diego, CA; one SBIR); Objective Function Systems (Canoga Park, CA; no SBIR); ODME Solutions (Del Mar, CA; no SBIR); Opal Soft (Sunnyvale, CA; no SBIR); Raft (Reston, VA; SBIR); TapHere! Technology (Manassas, VA; no SBIR); TDI Technologies (Coronado, CA; $1.3M SBIR); and The Marlin Alliance (San Diego, CA; no SBIR). [Naomi Cooper, govconwire, Jul 28, 2023]
Venture Capital investments in San Diego 3Q2016. Ostendo Technologies (Carlsbad, CA; one SBIR) $42 million; Tealium (San Diego; no SBIR) $35 million ; Singlera Genomics (San Diego, CA; no SBIR) $20 million; Avelas Biosciences (San Diego, CA; no SBIR) $20 million ; Fortis Therapeutics (San Diego, CA; no SBIR) $18 million ; Histogen (San Diego, CA; no SBIR) $16 million ; Medsphere Systems (Carlsbad, CA; no SBIR) $15 million; CellSavers (San Diego, CA; no SBIR) $15 million; Progenity (San Diego, CA; no SBIR) $12 million; AristaMD (San Diego, CA; no SBIR) $11 million. [Bruce Bigelow, xconomy.com, Oct 11, 16]
Six years after a blockbuster $40 million funder, TearScience (Morrisville, NC; no SBIR) is at it again, raising a new $19.3 million in equity ... flagship product, the LipiFlow, applies heat and pressure to the inner eyelids, specifically targeting what’s called Meibomian Gland Disease, or MGD. The chronic disorder, characterized by duct obstruction, affects about 300 million people worldwide. [Lauren K. Ohnesorge, Triangle Business Journal, Apr 15, 16]
TearScience (Morrisville, NC; no SBIR) medical device company, has raised $15 million in debt financing that it plans to use to commercialize the company's treatment for dry-eye disease. .... employs about 30 people, is now shifting from the development stage to making its LipiFlow system and marketing it to eye doctors. [David Bracken, Raleigh News & Observer, Oct 3, 11]
TearScience (Morrisville, NC; no SBIR) will announce this morning that it has raised $44.5 million in venture capital - the most by any Triangle company so far this year - to commercialize devices for diagnosing and treating dry eye disease. .. 5-year-old company has about 20 employees ... intentionally kept a low profile - it doesn't even have a Web site [David Ranii, Raleigh News & Observer, May 5, 10]
startup TearSolutions (Charlottesville, VA; no SBIR, founded 2015) is moving ever closer to commercialization after hauling in a $6.4 million funding round. The company, which launched in 2013 as a spinout of the University of Virginia, is developing a drug called Lacripep to combat dry eye. [Kieran McQuilkin, Richmond Inno, Mar 18, 19]
TechniScan Medical Systems (Millcreek, UT), with SBIR dating back to 1985 for its diagnostic technology, announced financing of $6.4M and a $2.8M SBIR from NIH.
TechniScan Medical Systems (SLC,UT) got a $2.8M Phase 2 SBIR from NIH to perfect a breast cancer screening tool. .... Without such support, promising technologies such as the USCT system might not be commercialized, said TechniScan CEO David Robinson. [Linda Fantin, Salt Lake Tribune, Dec 18] We hope that NIH had more evidence of market appeal than the company's claims and NIH scientists' hopes. Otherwise, they are just paying for a hobby that will die when the federal dollars end.
Technologies and Devices International (Silver Spring, MD) claimed a revolutionary technical breakthrough by fabricating the industry’s first 6-inch diameter GaN epitaxial materials. 6-inch diameter GaN-on-sapphire epitaxial wafers were fabricated at TDI using it’s patented hydride vapor phase epitaxial (HVPE) process and equipment. TDI has had at least 14 Phase 1s and 3 Phase 2s from MDA. [Nov 04]
Blue Laser Breakthrough. Technology and Devices International (Gaithersburg,MD) made a GaN bulk substrate, which claims to improve the performance and lifetimes of GaN-based device designs. A single crystal GaN sample boule is grown on a GaN seed layer and then sliced into 1.5 inch diameter wafers. TDI's chief executive Vladimir Dmitriev said "The crystals are grown using a 1.5 inch GaN seed crystal and are expected to scale to 3 and 4 inches in the future, TDI has had four Phase 2 SBIRs in the last two years from BMDO and Navy. This substrate advance goes with the BMDO hydride vapor phase epitaxy (HVPE) for multi-layer epitaxial structures for advanced GaN-based devices with quantum wells. But now that BMDO will probably abandon such indirect benefit work, TDI will have to mine ONR harder.
Rocket Ventures, a pre-seed, early-stage venture fund for technology-based [Ohio] companies, has awarded Ignite! grants to three Toledo firms - ADS Biotechnology, TechTol Imaging, and DoX Systems. These grants are given to help the companies develop and use technology to create new products or improve processes that have an impact on jobs and revenues in Northwest Ohio. [Toledo Free Press, Jun 13, 08] No SBIR.
The rest of DOE,'s Phase II list also shows a preference for SBIR experience: Euclid Labs (Solon, OH; $18M SBIR since 2004, all DOE including one $10M award), four new Phase IIs; Radiabeam Technologies (Santa Monica, CA, $10M SBIR since 2005 SBIR) three awards; Tech-x (Boulder, CO; something over $50M SBIR since 1994) three new awards Muons (Batavia, IL; $13M since 2002 SBIR, all DOE) three awards; Far-Tech (San Diego, CA;$9+M SBIR since 2003) two awards;Ridgetop Group (Tucson, AZ; $10M SBIR since 2002) two awards; Calabazas Creek Research (San Mateo, CA; $26M since 1994) two awards; Niowave (Lansing, MI; $5M since 2007 SBIR) two awards; Mesa Photonics (Santa Fe, NM; $0.8M since 2008 SBIR) two awards; Green Mountain Radio Research (Colchester, VT; $5.7M SBIR) two awards. Of 104 awards, 33 went to multiple winners who already had collected $378M SBIR from the federal government. Is DOE over-emphasizing contractor competence at the expense of companies and technologies with brighter futures? No one knows becasue Congress shows little interest in the question, and the agency has a bias toward making itself smarter.
The U.S. Air Force has tentatively selected over 500 companies for contracts worth $550M combined as part of an initiative launched with its AFWERX innovation arm and [SBIR]. The service said the AFVentures effort includes a strategic financing initiative where the firms will get a total of over $200M in government funding as well as $350M in private funds. [Brenda Marie Rivers, govconwire, Mar 16, 20] almost half going to the following 21 companies: Aerial Applications, Analytical Space ($3M prior SBIR), Anduril (one prior SBIR) , Applied Minds ($8M prior SBIR), Elroy Air, Sentient ($3.2M prior SBIR) , Icon, Enview ($700K prior SBIR), Edgybees ($700K prior SBIR) , Falkonry (one prior SBIR), Swarm Technologies ($1M prior SBIR) , Orbital Insight (one prior SBIR), Orbital Sidekick ($800K prior SBIR), Virtualitics (one prior SBIR) , Wickr (one prior SBIR), Tectus Corp (one prior SBIR), Valulytics, Shift.org, Pison ($1M prior SBIR), Revacomm. One other company hasn’t been named yet. These “big bet” companies are slated to receive four-year, fixed-price contracts worth a combined $550+ million through AFVentures’ Strategic Financing (STRATFI) program. This amount includes $100+ million in SBIR funds, $100+ million in Air Force funding and $350+ million in private investment. Roper said he believes future rounds of funding will be bigger. [AF Press release , Mar 13, 20]
Little more than a year after Acelity’s LifeCell Corp (San Antonio, TX; $4M SBIR) subsidiary obtained a preliminary injunction against TELA Bio (no SBIR) and two of its officers over its TELAMax hernia mesh product, the two sides are back in court [with] a new patent infringement lawsuit. [W. Scott Bailey, San Antonio Business Journal, Jul 12, 16]
Telecardia (Boston, MA; no SBIR), a MEMS-based pH sensor technology firm, has raised $1.54 million in an equity and securities offering ... intended for single, periodic and continuous pH measuring and monitoring in industrial, manufacturing and medical applications, according to the company website [Michelle Lang, Mass High Tech, Sep 28, 11]
In May, small companies focusing on security products will have the chance to show off their technologies for the chance to earn investment money and partnerships with a more established firm working with the Department of Homeland Security. It's part of the American Security Challenge which encourages universities, entrepreneurs and research labs to demonstrate their technologies. The inaugural challenge held last year awarded $100,000 to a company called TeleContinuity (Germantown, MD; no SBIR) that backs up communication networks in case of a terrorist attack. .... Chart Venture Partners of New York has agreed to pump between $200,000 and $2.5 million into a promising company. And another company will win the chance to team up with Alion Science and Technology, a McLean defense contractor. ... submit a summary of their product or company by March 31.[Kim Hart, Washington Post, Mar 23]
Ben Franklin Technology Partners of Southeastern Pennsylvania announced that nine early-stage companies have been approved to receive $1.55 million in funding. Gatherers include: Telefactor (W Conshocken, PA; $2.7M SBIR) $400K and previous $230K from Ben; AgileSwitch (Philadelphia, PA; no SBIR); Smart Structures (Southhampton, PA; no SBIR) [Peter Key, Philadelphia Business Journal, Jun 6, 13]
Telemedicine Up Close (Frisco, TX; no SBIR) which operates as DxUpClose, was awarded $280,000 [from Texas Emerging Technology Fund] of up to $1.5 million for the commercialization of a diagnostic kit designed to identify bacterial infections and determine antibiotic treatment, Gov. Rick Perry’s office announced [Christopher Calnan Austin Business Journal, Jul 25, 13]
Telik (South San Francisco, CA; $200K SBIR) got a letter from the Nasdaq Stock Market warning that its stock listing could be dropped .... stockholders' equity of just $2.44 million. That's below the Nasdaq's minimum requirement of $2.5 million. .... At the end of the quarter, it had accumulated a deficit of $552.7 million. The company, born in 1988, has been working on a treatment for myelodysplastic syndrome, a blood disorder caused by problems in bone marrow, where new blood cells are formed. [Stephen EF Brown, San Francisco Business Times, Nov 20, 13]
Telik up 30% [May 24, 12]
Telik up 16% [May 21, 12]
Telik up 21% [May 16, 12]
Telik up 15% [May 14, 12]
Telik up 12% [Apr 16, 12]
Telik up 59% [Apr 12, 12]
Telik down 19% [Apr 2, 12]
Telik up 10% [Dec 6, 07]
Telik dropped another 25% after the FDA has placed a clinical hold on the Investigational New Drug (IND) application for TELCYTA® [Jun 6, 07]
Telik dropped 21% after the FDA has placed a clinical hold on the Investigational New Drug (IND) application for TELCYTA® [Jun 4, 07]
Telik up 14% after losing less than expected. [Feb 23, 07]
Telik dropped 71% when a trial became "extremely disappointing". [Dec 26, 06] Four Phase 1 SBIRs and one Phase 2, including three awards under its original name - Terrapin.
Tempest Therapeutics (San Francisco, CA) emerged from stealth with a $70 million Series B funding round that the San Francisco company will use to advance its cancer immunotherapies to the clinic. [Frank Vinluan, xconomy.com, Mar 30, 18]
Fast Transfer on Fast Track(Aug 28) Templex Technology (Eugene, OR) won a Fast Track Phase 2 SBIR from BMDO for $1M to develop its TASM (Temporally Accessed, Spectral Multiplexing). If it works (if it already worked it wouldn't get a BMDO Phase 2), Templex's president Larry Brice expects a much higher reliability and a quarter lower cost for his terabit per fiber. Technicologically, it's a data storage application to demonstrate a new world's record for density bandwidth product -- 100,000 Terabits per square inch per second. Fast Track gives Templex $1M for $250K third party cash, presumably from the VC on the board. A Fiber Optics News story (Aug 25) quotes Ken Hill, who discovered photosensitivity in optical fiber and invented fiber Bragg gratings as It looks like a clever idea; it remains to be seen how broadly it can be applied. Isn't that always the story with new technology? See the technical stuff in a 39-slide presentation
Deca-Gigabyte Memory.(Jun 11) Tens of gigabytes memory at near semiconductor speed, orders of magnitude more than today's average, at a potential cost of half today's semiconductor memory, says Templex Technology (Eugene, OR) about its Phase 1 BMDO SBIR. (And DRAM is already so cheap that its makers are eating each other's lunch). It's the kind of SBIR that will be either a barn-burner or a burned-barn. If it works, and if it hits the market economics, it could explode into a giant market. It is will not just incrementally advance a someday-useful science (BMDO won't fund that kind of SBIR and neither will the Oregonian VC fund backer).
Tempus (Chicago, IL; no SBIR; founded 2015) announced it has raised an additional $80M ... I'm thrilled to have invested in Tempus and their team of innovators who are obsessed with developing breakthroughs in how we treat diseases.” - John Doerr, Chairman, Kleiner Perkins .... we're excited to have invested in Tempus as they seek to bring big data, artificial intelligence and advanced molecular analysis to those suffering with cancer and other life threatening diseases” - Steve Case, Chairman and CEO, Revolution [company press release, Mar 20, 18] total funding $210M [crunchbase.com]
cancer treatment startup Tempus (Chicago, IL; no SBIR) announced that it closed a $70M, Series C, round of venture funding. ... brings the two-year-old company’s total funding to $130M. ... on a mission to redefine how genomic data is used in a clinical setting. [conpamy website, Sep 25, 17] [with] Cleveland Clinic Taussig Cancer Institute will collaborate on a precision medicine initiative aimed at improving outcomes for patients diagnosed with cancer. [company press release, Sep 14, 17]
Tenax Thera down 27% [Mar 2, 18]
Tenax Therapeutics (Morrisville, NC; no SBIR, market cap $6M after reverse stock split) up 128% [Mar 1, 18] announced the publication of a positive preclinical study of levosimendan conducted by Hansen et al in the March 1, 2018, issue of Pulmonary Circulation. The study was titled "Levosimendan improves cardiac function and myocardial efficiency in rats with right ventricular failure" and found that chronic administration of levosimendan improved right heart function. [company press release, Mar 1, 18]
Tenaya Therapeutics (South San Francisco, CA; no SBIR, founded 2016) announced the successful completion of a $92 million Series B financing [to] to advance and to expand Tenaya’s pipeline and to strengthen the science, capabilities, and intellectual property that provide the foundation for Tenaya’s multi-modality product platforms – Cellular Regeneration, Gene Therapy, and Precision Medicine. ... has raised $142 million since its founding by scientists at the Gladstone Institutes and University of Texas Southwestern Medical Center. [company press release, Oct 3, 19]
Tenaya Therapeutics launched, spinning out of San Francisco-based Gladstone. The company is backed by a $50 million Series A investment from The Column Group. Gladstone says Tenaya will focus on regenerative medicine and discovering new drugs to treat heart failure. [Frank Vinluan, xconomy.com, Dec 8, 16]
Private companies to watch on electricity as picked by MIT Tech Review (Sep/Oct09): Nanosolar ($1.7M SBIR) founded 2002, raised $400M; A123 Systems IPO Sep 24; Brightsource Energy; Tendril; 1366 Technologies; Deepwater Wind; Solyndra; Silver Spring Networks; AltaRock; Stirling Energy Systems.
Abbott Laboratories announced a $250 million deal to buy heart-device maker Tendyne (Roseville MN; no SBIR, founded 2010) which features a product in the promising niche of minimally invasive mitral valve replacement. Tendyne’s Bioprosthetic mitral valve can be implanted inside a patient’s beating heart through a small tube, avoiding the need for open-heart surgery. ..... In April, the Minneapolis Heart Institute Foundation reported the first successful U.S. implant of a Tendyne valve, which was done at Abbott Northwestern Hospital. [Joe Carlson, Mommeapolis Star Tribune, Jul 30, 15] a clinical stage medical device company focused on the development of minimally invasive therapies for the treatment of mitral regurgitation. Mitral regurgitation is a condition that afflicts hundreds of thousands of individuals worldwide every year. ... raised $20M in Series C Apr 2014 [Tendyne website]
Tendyne Holdings (Roseville, MN, previously Baltimore, MD; no SBIR) startup developing technology for treating leaky heart valves has closed on $25 million in financing. ,,,, will put the funds toward clinical trials .... treats mitral valve regurgitation, a condition that causes blood to leak from the mitral heart valve and flow backward into the heart. [Katharine Grayson, Minneapolis / St. Paul Business Journal, Apr 10, 14]
There's a purchase deal for the assets of Tengion (Winston-Salem, NC; no SBIR) that began a Chapter 7 case in U.S. Bankruptcy Court in December. The offer came from RegenMedTX LLC, the Winston-Salem Journal reported ... in the $22 million range. ... Tengion had been working to commercialize some of the research of Dr. Anthony Atala and the Wake Forest Institute for Regenerative Medicine involving lab-grown organs made from a patient's own cells. [James Ritchie, Triad Business Journal, Mar 6, 15]
Cash-strapped regenerative medicine firm Tengion (East Norriton, PA; no SBIR) is raising $31.4 million to stay afloat ... Medtronic, which is one of the investors in the deal, receives a right-of-first-refusal on the Neo-Kidney Augment, the lead product candidate in Tengion's portfolio. [Minneapolis / St Paul Business Journal, Mar 1, 11]
Tengion (East Norriton, PA; no SBIR) completed a second closing of its series-C financing, receiving a total of about $21 million ... developing and commercializing human “neo-organs” and “neo-tissues” grown from a patients own cells. Its lead product in clinical testing is a neo-bladder. [Philadelphia Business Journal, Nov 19, 08]
Roche (Swiss) may have a new investment plan: Where James Bradner has been, it follows. The pharmaceutical giant announced that it has bought Tensha Therapeutics (Cambridge, MA: no SBIR) founded by Bradner, a physician-scientist who is now the president of the Novartis Institutes for Biomedical Research. Tensha is developing treatments for cancer using an epigenetic technology. Roche is paying $115 million upfront for the company and $420 million in potential clinical and regulatory milestones. .... Tensha is developing drugs that it hopes can disrupt proteins that mediate gene control and cellular memory; those proteins belong to a group called bromodomain and extra terminal domain (BET). The company’s first treatment, TEN-010, is a small-molecule BET inhibitor for cancer patients that is now in two Phase 1b studies, Tensha said in a statement. [David Holly, xconomy.com, Jan 11, 16]
Tensha Therapeutics (Cambridge, MA; no SBIR) said today that it has raised $15 million in a Series A financing to advance the development of potential cancer treatments. ... its lead program, now in preclinical development, is a small-molecule drug that could target acute myeloid leukemias, multiple myeloma, and other malignancies. In searching for new treatments, Tensha said it is using technology developed at the Dana-Farber Cancer Institute by Dr. James Bradner. Tensha said it has an exclusive license to the technology from Dana-Farber. [Chris Reidy, Boston Globe, Sep 13, 11]
biotech startup Tensha Therapeutics (Cambridge, MA; no SBIR) has taken in $500,000 of what it plans as a $15 million initial financing round, according to a federal document. reports that Tensha is working with Cold Spring Harbor Laboratory in New York on an anti-cancer compound that shows promise in treating acute myeloid leukemia, which currently is about 70 percent incurable, [says] CSHL. [Rodney Brown, Mass High Tech, Aug 9, 11]
Tepha (Lexington, MA; $2M SBIR) has raised $4.97 million of a planned $5.15 million equity financing, the company reported in a regulatory document. ... makes absorbable biomaterials that the company says adds flexibility, elasticity and biocompatibility to medical device products. [Michelle Lang, Mass High Tech, May 19, 11]
Tepha (Lexington, MA; $2M SBIR) medical devices company, has raised almost $3 million in financing, according to [SEC filing ] ... founded in 1998 as a spinoff of a collaboration between its sister company Metabolix Inc. in Cambridge and Children’s Hospital Boston to develop technologies related to cardiac tissue engineering. .. makes absorbable biomaterials, including polymers and elastomers, used in medical devices such as surgical sutures and meshes. [Mass High Tech, Feb 4, 10]
Tepha (Cambridge MA; $1M SBIR) got $10.7M private funding. The company licensed its TephaFLEX biopolymer technology, which is based on research conducted at MIT, from its Cambridge neighbor Metabolix Inc. [Mass High Tech, Jun 6]
Quiet laser startup TeraDiode (Littleton, MA; no SBIR). is ready to punch a big hole in its silence, announcing $3.2 million in a trio of [DOD] SBIR contracts. ... has taken the common diode laser — the same sort of device in your CD player or laser pointer — and figured out how to gang many of them together and combine the beams into a much more powerful single laser beam. How powerful? “Ours are a million time more powerful,” said CEO David Sossen, ... took in an initial funding round of $4 million in 2009 [Rodney Brown, Mass High Tech, Aug 23, 11]
Cloud Pharmaceuticals (formerly TeraDiscoveries, Durham, NC; at least $150K SBIR) [CEO] says he will launch a Series B round with a $10 million target. [Jason deBruyn, Triangle Business Journal, Feb 19, 16] designs and develops new drugs for a wide range of therapeutic areas including cancer, inflammation, CNS disorders, and rare diseases. [company website]
When startup FireFly LED Lighting (Austin, TX; no SBIR) was accepted into the Austin Technology Incubator two years ago, its LED bulbs were still prototypes. Since then, the company has launched its product line, signed customers including Kerbey Lane Cafe and the University of Texas and received $3.4 million from backers including the Central Texas Angel Network and the Texas Emerging Technology Fund..... Since its founding in 1989 by legendary business leader George Kozmetsky, ATI has worked with more than 200 startups, helping them raise nearly $1 billion in investment capital. [Lori Hawkins, Austin American Statesman, Jan 26, 12] Graduates: Agile Planet, Atomometrics, Axelo, Calxeda, Dorsan Biofuels, Famigo, GameSalad, Ideal Power Converters, Itzbig, Nitero, Notice Technologies, Open Algae, Qcue, RFMicron, RRE Solar, Savara Pharmaceuticals, Spredfast, Terapio ($500K SBIR), Unwired Nation, WiMax.com.
biotech startup Terapio (Austin, TX; no SBIR) plans to announce today that it has raised $5 million to continue developing a line of therapeutic applications. ... founded in 2005, is using research licensed from the University of Texas at Arlington to develop an oral medication that would treat people who are exposed to lethal doses of radiation. [Lori Hawkins. Austin American Statesman, Nov 30, 09]
Two Austin companies will share $3.7 million in grants from the Texas Emerging Technology Fund, which was created to spur commercialization of research in Texas. Receptor Logic Ltd. will receive $2 million to advance its work in the development of anti-bodies that can improve the understanding of the immune system and thus lead to better drugs and vaccines. Terapio Inc. will receive $1.7 million to develop a cream to treat hand-foot syndrome, a painful swelling and numbness of the hands and feet that can occur as a side effect of several chemotherapy drugs. Receptor was started in 2004 by Emergent Technologies Inc., an Austin-based life sciences venture capital firm, and Jon Weidanz, director of the Texas Tech University Center for Immunotherapeutic Research. The company, which has headquarters in Austin and a laboratory in Abilene, will use the investment to expand its commercialization efforts [Lori Hawkins, Austin American-Statesman, Jun 19] Neither had SBIR.
Frankly, My Dear(Mar 4) Got a hot new technology idea? Get a government grant/contract to develop it in the usual four years of SBIR. Induce Phase 3 investment interest letters to convince government it has commercial potential but cannot raise investment capital for such new and revolutionary technology. Finish development in 2001 and get set for market impact. Sorry, market was preempted by a substitute in 1998. No, government won't tell you about the last line as it blathers about SBIR as a market-driven development program. Alternatively, raise $30M from Paul Allen and friends and unveil a tenfold improvement in disk-drive storage technology, 20GB hard disk, in 14 months from company start-up. "major technical breakthrough" say analysts of TeraStor (San Jose, CA) [Wall Street Journal Mar 3, 1997] . With that, you run Gone With the Wind and/or Hamlet in a window on your PC screen while beavering away writing reports for government contracts.
Fourteen startups that received a total of more than $17 million from [Texas Emerging Technology Fund managed by Gov. Rick Perry’s office... which has backed 143 startups] have failed or gone bankrupt. .... [ MIT professor Bill Aulet, who is managing director of the Martin Trust Center for MIT Entrepreneurship] said the number of failed ETF companies would be higher if state officials took the chances they needed when investing in startups. "They really haven't taken any risk," he said. "Governments aren't good at being venture capitalists because governments aren't good at risk." .... a partial list of the ETF-backed startups in Texas that have since closed, followed by the grant amounts they received: • NanoTailor, $250,000; • Star Vision Technologies, $750,000; • Terrabon, $2.7 million; • Thrombo Vision, $1.5 million; • Nanocoolers, $3 million; • Advanced Receiver Technologies, $250,000; • Bauhaus Software, $500,000; • Net Watch Solutions, $500,000; • Sunrise Ridge Algae, $250,000; • SeprOx, $750,000; • Speer Medical, $2.5 million [Christopher Calnan, Austin Business Journal, Jan 9, 14] None of these had SBIR.
A fourth Texas high-tech startup that received taxpayer dollars through Gov. Rick Perry’s signature economic development fund has filed for bankruptcy in the $194 million portfolio’s biggest bust yet. The collapse of bioenergy producer Terrabon (no SBIR), which was awarded $2.75 million in 2010 and was backed by Perry political donors, is the second bankruptcy in the past four months for the Emerging Technology Fund, [Paul Weber, Lori Hawkins, Austin American Statesman,Oct 24, 12]
In its first round of venture funding, Terrajoule (Redwood City, CA; no SBIR, founded 2009) raised $11.5 million. .... makes efficient energy storage technology. [Stephen EF Brown, San Francisco Business Times, Nov 5, 13]
Terrajoule (Redwood City, CA; no SBIR), a startup that says its technology makes generating and storing electricity more efficient, has raised $11.5 million in Series A funding. ... Terrajoule says its energy storage technology costs five times less than today’s batteries and without degradation or cycle limitations over a 25-year system life. It says this provides continuous, on-demand solar power generation with a compelling payback compared to diesel-based off-grid and on-grid power. [Cromwell Schubarth, Silicon Valley Business Journal, Nov 5, 13] Does everyone know what "five times less" means? x-5x=-4x
TerraMetrics (Littleton CO; $1M SBIR since 1999) won an Air Force Phase 1 SBIR for a system to provide a 3D terrain model for helicopter landings in dusty, desert areas with zero visibility, such as Iraq and Afghanistan. [Denver Post, Sep 11]
Terus Technologies (Sanford, NC; nio SBIR) a small robotics company, is suing a former minority owner with allegations that he misappropriated funds and diverted potential clients to a competing company that he set up. [Chris Bagley, Triangle Business Journal, Jun 13, 13] woman-owned business with over 20 years of experience as a full-service systems integrator specializing in machine vision and robotic solutions, says the company website.
Terumo BCT
(Lakewood, CO;
no SBIR) maker of
blood-collection
devices, won a U.S. military
contract that will invest up to $29.9 million toward improving the
company’s blood pathogen reduction technologies.
.... will provide $3.46 million during the next three years to ready
Terumo BCT’s Mirasol System to be submitted to the U.S. Food &
Drug
Administration for approval for in the United States. The DoD will fund
up to $11.3 million during the next four years to cover some of the
cost of efficacy testing and clinical trials .... DoD wants the Mirasol
System to be able to screen whole blood for use in transfusions for
deployed military personnel. ....
military has
previously invested $14 million in Mirasol’s development.
[Greg Avery,
Denver Business Journal, Oct 22, 13] Military acting as an effective
owner of the business in funding its entire product development.
Tesaro (Waltham, MA; no SBIR, 430 employees) cancer drug developer whose value tripled over the course of 2016, announced that federal regulators rejected an approval application for an intravenous version of its drug for chemotherapy-induced nausea. The company, however, says it still expects approval in coming months. [Don Seiffert, Boston Business Journal, Jan 12, 17]
Tesaro, oncology-focused biopharmaceutical company (Waltham, MA; no SBIR) said that it has secured $101 million in a Series B financing to advance and expand the company’s cancer product portfolio. ... One drug candidate that Tesaro is working on is called Rolapitant; one potential use of Rolapitant is the prevention of nausea and vomiting induced by chemotherapy. [Boston Globe, Jun 22, 11]
Several former MGI Pharma (no SBIR) executives have launched a biotech startup that's raised $20 million in venture capital, reports the Boston Business Journal. The company, Tesaro (Boston, MA; no SBIR), will buy, develop and market therapies for treating cancer, taking a "personalized medicine" approach. [Katharine Grayson, Minneapolis/St Paul Business Journal, Jun 7, 10]
biopharmaceutical start-up TESARO (Boston, MA; no SBIR) said it has secured a $20 million Series A financing only weeks after its launch. ... the company's focus is finding "hidden oncology assets," [Boston Globe, May 26, 10]
Startup TeselaGen Biotechnology (San Francisco, CA; no SBIR) signed a multi-year deal with Genomatica (San Diego, CA; $6.3M SBIR) company that will license TeselaGen's software that uses synthetic biology approaches to build and modify DNA. [Ron Leuty, San Francisco Business Times, Jul 9, 13]
computer hardware developer Tessera Technologies (Columbia, MD; $200K SBIR) is spending around $850M to buy California audio technology firm DTS (Calabasas, CA; no SBIR) up 23% [Sep 20, 16]. .... it means Tessera has bought another Columbia company, iBiquity Digital (Columbia, MD; no SBIR, 120 employees), bought by DTS less than a year ago for $172M. According to the company, the plan is to meld the various technologies for use in the Internet of Things and with virtual reality. [Eric Schwartz, DCInnoBeat, Sep 20, 16]
in buying Raleigh-based RTI International (non-profit) spinoff Ziptronix (Raleigh, NC; no SBIR) for $39 million in August, Silicon Valley-based Tessera Technologies scored an innovation that’s already received solid interest from Sony, but it also inherited a lawsuit. .... Specifically, Tessera inherited pending litigation filed by Ziptronix in 2010 against Taiwan Semiconductor Manufacturing and Omnivision Technologies, alleging that the companies infringed on certain Ziptronix patents. [Lauren K. Ohnesorge Triangle Business Journal, Nov 10, 15]
Tessera Tech up 10% [Aug 4,15]
Tessera Tech up 11% [Jan 16, 15]
Tesssera Tech up 12% [Oct 31, 14] good quarter results
Tessera Tech up 10% [Feb 27, 14]
Tessera Technologies sold most of the assets of its micro-optics business [in based in Charlotte, NC] to FLIR Systems Inc. for $13 million [Stephen EF Brown,San Francisco Business Times, Aug 13, 13]
Tessera Tech (San Jose, CA; $2.4M SBIR 2003-06) that had been fighting for its life in a proxy battle has surrendered to the hedge fund that had been seeking to oust the company's board. .... "For decades, you've had situations where investors come in and realize the assets of the company are worth more than the company as a going concern," he said. "What we're seeing now is the realization that a patent portfolio can be one of those assets. Companies that seem to have a difficult road ahead of them are very susceptible." [Peter Delevett, San Jose Mercury News, May 24, 13]
Tessera Tech($1.5M SBIR) declared a special dividend.
Tessera Tech down 15% [Feb 21, 12]
Tessera Tech up 20% [Nov 16, 11] on news that the semiconductor firm renewed an agreement to license its technology to Samsung Electronics [marketwatch.com, Nov 16]
Tessera Tech down 19% [Jan 28, 11]
Tessera Tech up 13% [Jun 2, 10] raised its second-quarter revenue estimate on better-than-expected royalties from microelectronics business and increased sales of micro-optics products. [Wall Street Journal, Jun 3]
Chip-packaging technology developer Tessera Technologies' earnings slid 75% on a deep drop in revenue, but the firm's earnings excluding charges widely beat analysts' projections, sending shares up
Tessera Tech down 14% [Jan 7, 10]
Tessera Technologies dropped 6% after the International Trade Commission ruled that three of the semiconductor-packaging technology firm's patents were valid but said the firm didn't prove that rival companies had infringed on two of those patents for dynamic random access memory chips, used in computers and mobile devices. [Wall Street Journal, Dec 31, 09]
Tessera Tech down 18% [Oct 30, 09]
Tessera Technologies may just be the loneliest company in Silicon Valley. Many of the organizations that once flanked Tessera, which specializes in making the tiniest of computing devices, had assembly lines and industrial operations here. They have since withdrawn from ultra-competitive manufacturing, leaving Tessera on its own. In fact, a recent study by the United States Bureau of Labor Statistics shows that Silicon Valley lost more than a quarter of its chip, computer, instrument and communications equipment manufacturing jobs from 2001 to 2008. .... Tessera’s niche is miniaturization. The company is on a quest to make ladybug-size digital cameras and silent cooling systems, just one-fifth of an inch high, for laptops. ... Many chip makers, including giants like Intel and Samsung, have licensed Tessera’s packaging technology. ... The price of the Tessera devices should go low enough to put a camera into even the cheapest cellphones. [Ashley Vance, NY Times, Aug 16]
A director recently sold $6.7M of Tessera Tech stock. [WSJ, Jun 20, 09]
Tessera up 11% [Jun 3, 09]
Tessera up 11% [May 27, 09]
Tessera up 21% [May 21, 09]
Tessera Tech up 11% [Feb 3, 09]
Tessera Tech up 12% [Dec 12, 08]
Tessera down 46% [Dec 2, 08]
Tessera Technologies suffered a setback that rocked its share price when a U.S. International Trade Commission judge said six big chip makers didn't infringe its patents. ... shares fell 40% in after-hours trading following the news, after closing down 10% in Nasdaq trading [Wall Street Journal, Dec 2, 08] On a stock bloodbath day
An arbitration panel found that Tessera Technologies up 30%, [Oct 29,08] has valid patents on certain miniaturization technologies and is owed monetary damages for breaches of a licensing agreement by Amkor Technology.
Tessera Thera down 12% [Oct 15, 08]
Tessera Thera up 18% [Oct 13, 08]
Tessera Tech up 10% [Sep 30, 08]
Tessera Tech down 19% [Sep 29, 08]
Tessera Tech up 14% [Sep 18, 08]
Tessera Tech up 12% [Aug 1, 08]
Tessera up 33%, after the company said the International Trade Commission had overturned a judge's recent decision to stay a patent case against several wireless companies. [Wall Street Journal, Mar 29]
Tessera Technologies down 18% [Mar 19, 08]
Tessera Technologies up 10%, after saying the status of some of its patents has been mischaracterized [Wall Street Journal, Mar 7,08]
Tessera Technologies fell 39%. The Patent and Trademark Office made a preliminary ruling rejecting claims under a key patent of Tessera, a San Jose, Calif., maker of packaging technologies for chip makers. [Wall Street Journal, Mar 5]
Tessera Technologies down 34% [Feb 26, 08] The company said a judge decided to stay the company's patent-infringement action before the International Trade Commission pending completion of re-examination proceedings before the U.S. Patent and Trademark Office. [Wall Street Journal, Feb 27]
Tessera Technologies up 11% [Feb 1. 08] after saying it would acquire FotoNation, which provides imaging technologies for digitial cameras and mobile devices. [Reuters, Feb 1]
Tessera Technologies down 15% [Aug 3, 07]
Tethys BioScience (Emeryville, CA; no SBIR) is shutting down after failing to win approval for Medicaid reimbursements for its diabetes tests, Fortune's Dan Primack reported .... had raised about $100 million in funding since it was founded in 2002 [Cromwell Schubarth, Silicon Valley Business Journal, Nov 4, 13] Life is dangerous when government is the only customer.
Tetra Discovery Partners (Grand Rapids, MI; $8.7M SBIR), a biotech advanced its Fragile X Syndrome treatment, BPN14770, to Phase 2 clinical trials. (Fragile X Syndrome is the most common genetic form of autism.) The company said in a press release that its small molecule drug, BPN14770, has shown in mouse studies “the ability to improve the quality of connections between neurons and to improve multiple behavioral outcomes.” [Sarah Schmid Stevenson, xconomy.com, Jul 18, 18]
Tetra Discovery Partners (Grand Rapids, MI; no SBIR) biotech startup developing drugs to treat neurological disorders, has co-authored a study published in the Journal of Neuroscience about its experimental drug’s success in treating traumatic brain injury (TBI). Researchers from Tetra and the University of Miami treated rats with a selective phosphodiesterase 4 subtype inhibitor for three months. [Sarah Schmid, xconomy.com, Jul 18, 16]
Tetragenetics (Arlington, MA; $4M SBIR in New York) which focuses on autoimmune disease and pain targets leveraging recombinant ion channel expression, raised $1M in debt in a $2M funding round, per an SEC filing. [Rowan Walrath, BostInno, Sep 29] 20]
Pfizer closed a collaboration
deal
with
biotechnology company, Tetragenetics
(Cambridge,
MA; $1.9M SBIR in Ithaca, NY) whose
SionX technology platform
supports the discovery of antibody drugs targeted at ion channel
proteins. These proteins, which control the passage of potassium,
sodium, and other ions across cell membranes, have been implicated in
diseases ranging from schizophrenia to
kidney disorders. Tetragenetics did not disclose financial terms of the
deal, or the diseases Pfizer is targeting. Tetragenetics also announced
a deal Tuesday to license its technology to Amgen
[Berbadette
Tansey, xconomy.com, Apr 5, 13]
The Massachusetts Life Sciences Center said it has awarded $500,000 grants to three Bay State life sciences companies. "The companies receiving grants are Boston Biochem (Cambridge, MA; $900K SBIR)) Tetragenetics (Cambridge, MA and Ithaca, NY; $1.1M SBIR), and Thermedical (Somerville, MA; no SBIR) the center said in a press release. "Each company will receive $500,000 from the center to match federal small business grant funding that the companies had previously been awarded.... The three companies that are receiving awards have committed to collectively creating 40 new jobs in the Commonwealth by the end of 2011, including six jobs to be relocated from New York." The center is a quasi-public agency with the mission of helping to create jobs in the state's life sciences industry. [Boston Globe, Jun 1, 10]
TetraLogic Pharmaceuticals (Malvern, PA; no SBIR, [IPO] Dec 13) is acquiring Shape Pharmaceuticals (Cambridge, MA; no SBIR) for $13 million. [John George, Philadelphia Business Journal, Apr 8, 14]
TetraLogic Pharmaceuticals (IPO Dec 2013, no SBIR) entered into a licensing deal and research collaboration with an Australian research institute [Walter and Eliza Hall Institute of Medical Research]. .... experimental viral infection therapy birinapant, which in preclinical studies with rats conducted by the Hall Institute demonstrated effectiveness in combating the hepatitis B virus. [John George, Philadelphia Business Journal, Jan 22, 14]
Vital Therapies (San Diego, CA; no SBIR) and ’s TetraLogic Pharmaceuticals (Malvern, PA; no SBIR) both postponed their IPOs yesterday, according to the IPO research firm Renaissance Capital. [Bruce Bigelow, xconomy.com, Nov 22, 13]
TetraLogic Pharmaceuticals (Malvern, PA; no SBIR) has a $103.5 million IPO for Nov. 21 [John George, Philadelphia Business Journal, Nov 20, 13]
The biggest financing for a [Philly area] company was TetraLogic Pharmaceuticals (Malvern, PA; no SBIR) firm working on experimental cancer treatments, which raised $32 million. [Philadelphia Inquirer, Oct 18, 10]
TetraLogic Pharmaceuticals (Malvern, PA; no SBIR) completed a $32 million private stock sale, the proceeds from which will be use to advance the clinical development of the biopharmaceutical company’s experimental cancer treatments. [John George, Philadelphia Business Journal, Aug 10, 10]
Tetraphase Pharma up 16% [Oct 15, 19]
Tetraphase Pharma down 20% [Oct 2, 19]
A Tetraphase Pharmaceuticals (Watertown, MA; no SBIR) antibiotic has earned FDA approval, adding a new treatment to the effort to address drug-resistant infections. The FDA decision for the drug, eravacycline (Xerava), covers complicated intra-abdominal infections (cIAI) in adults. It’s the first drug approval for the company. [Frank Vinluan, xconomy, com, Aug 29, 18]
Tetraphase Pharma (Watertown, MA; no SBIR, founded 2006) down 60% [Feb 14, 18] announced that its IGNITE3 clinical trial evaluating the efficacy and safety of once-daily intravenous (IV) eravacycline compared to ertapenem for the treatment of patients with complicated urinary tract infections (cUTI) did not achieve statistical non-inferiority of eravacycline to ertapenem. [company press release, Feb 13, 18] has raised $530M [biocentury.com]
Tetraphase Pharmaceuticals (Watertown, MA; no SBIR, founded 2006) won a $67m contract [in February] from America’s Biomedical Advanced Research and Development Authority (BARDA) for an antibiotic that might treat both anthrax outbreaks and serious infections in hospitals. GSK also has a contract with BARDA to test an antibiotic for Gram-negative bacteria. However, the company recently suspended enrolments to its trial because of complications in some patients. Seeking new ways to kill these vicious bugs is likely to be one of the main aims of the European Commission’s new partnership. [The Economist, May 12, 12]
Tetraphase Pharmaceuticals (Watertown, MA; no SBIR) said that its lead drug candidate has been awarded a government contract worth up to $67 million. Under the contract, Tetraphase’s lead clinical compound, known as TP-434, will be developed as a potential countermeasure against bioterrorism threats. [Chris Reidy, Boston Globe, Feb 16, 12]
Tetraphase Pharmaceuticals (Watertown, MA; no SBIR) said it has closed the first tranche of its $25 million Series B financing. .. launched in 2006 to advance and commercialize the synthetic chemistry platform developed by Andrew Myers of Harvard University. [Boston Globe, Oct 7, 09]
San Diego’s free high-tech incubator, announced that it has enrolled three more startup companies: TetraVue is developing a high-resolution 3D camera and video recording system; MicroPower Technologies is developing ultra-low-power wireless video surveillance camera technologies; EcoATM plans to install self-serve kiosks for recycling mobile phones and other consumer electronics. None has SBIR.
Ziptronix (Raleigh, NC; no SBIR) announced it has sold its development lab to Tezzaron Semiconductor (Napierville, IL; $2.5M SBIR) Corp. for an undisclosed sum. The lab will be operated by Novati Technologies, a subsidiary of Tezzaron. ... to use the facility to further develop its own memory chips [David Bracken, Raleigh News & Observer, Dec 9, 13]
TFF Pharmaceuticals (Austin, TX; no SBIR) announced it has closed on $14 million [to] accelerate development of the Company's pipeline of advanced performance dry powder drugs for the treatment of pulmonary diseases and conditions such as lung transplant, severe asthma, COPD, and pulmonary infections.... licensed from UT Austin [company press release, Apr 3, 18]
&start-up TGS Knee Innovations (Plymouth, MN; no SBIR) said it secured about $1.5 million in angel investment. ....manufactures an FDA-approved medical device for tissue-guided knee surgery. ... [for] increasing distribution and hiring more employees. [Wendy Lee, Minneapolis Star Tribune, May 2, 11] established by Alexandria Research Technologies (Plymouth, MN; no SBIR) to focus on the Sales, Marketing and Clinical application of [proprietary]Tissue Guided Surgery in Unicompartmental Knee Arthroplasty. [company website]
TG Therapeutics (Brisbane, CA; no SBIR) up 33% [Dec 10, 20] announced positive topline results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab, the Company's investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide in patients with relapsing forms of multiple sclerosis (RMS). Both studies met their primary endpoint [company press release, Dec 10, 20]
TG Therapeutics (New York, NY; no SBIR)’ PI3K delta inhibitor, umbralisib, put up encouraging phase 2b data in marginal zone lymphoma, shrinking tumors in more than half of the patients followed long enough to be evaluated. Of these patients, nearly one-fifth were in complete remission. [Amirah Al Idrus, Fierce Biotech, Apr 1, 19]
TG Therapeutics (New York, no SBIR) up 31% [Feb 28, 19] announced that it intends to sell [common] shares in public offering. ...announced that it has entered into a debt financing agreement for up to $60.0 million ... also announced that the Marginal Zone Lymphoma (MZL) cohort of the UNITY-NHL Phase 2b pivotal trial evaluating umbralisib (TGR-1202), our novel, once daily, PI3K delta inhibitor, met the primary endpoint [company press release, Feb 28, 19]
TG Thera down 44% [Sep 24, 18] announced that the independent Data Safety Monitoring Board (DSMB) for the UNITY-CLL Phase 3 trial met to review ongoing data from the study and advised the Company that the interim analysis of Overall Response Rate (ORR) could not be conducted at this time as the data were not sufficiently mature to conduct the analysis. [company press release, Sep 25, 18]
TG Thera up 15% [Oct 20, 17]
TG Thera down 16% [Oct 16, 17]
TG Therapeutics up 17% [Jun 2,17]
TG Therapeutics (no SBIR) up 91% [Mar 6, 17] announced positive topline results from its Phase 3 GENUINE clinical trial of TG-1101 (ublituximab) plus ibrutinib in patients with previously treated high risk Chronic Lymphocytic Leukemia (CLL). [company press release, Mar 6, 17]
Biogen Idec drug Rituxan is the world's most prescribed treatment for NHL and rheumatoid arthritis. So analysts are aflutter with chatter about a tiny biotech named TG Therapeutics (New York City; no SBIR), that is developing a drug called Utuxin that could be a major competitor of Rituxan. [Dale Gibson, Triangle Business Journal, May 28, 13]
Four start-ups have been certified for early stage business investment tax credits by the Wisconsin Economic Development Corp. With the certification, the companies' financial backers will be eligible for a 25% tax credit on the amount they invest in the company. ... One of them, Thalchemy (Madison, WI; no SBIR) is developing an ultra low-power technology to improve the battery life of smartphones, tablets, health care and safety monitoring systems, and remote environmental sensing systems. The company says it is aiming to empower devices with the sensing capability of the human brain. [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 25, 13]
Thar Pharmaceuticals (Pittsburgh, PA; no SBIR) plans to raise as much as $3 million from investors according to a Tuesday filing with the U.S. Securities and Exchange Commission. The Pittsburgh-based life sciences company spun out of Thar Technologies (Pittsburgh, PA; no SBIR) in 2007. [Patty Tascarella, Pittsburgh Business Times, Sep 2, 14]
Thar Pharmaceuticals (Pittsburgh, PA and Tampa FL; no SBIR) raised $3.94 million toward a $5 million goal, according to [SEC] filing ... is developing oral versions of existing drugs that are only delivered to patients through an IV. It employs eight. [Patty Tascarella, Pittsburgh Business Times, Nov 20, 13] reinvents known, safe, on-the-market drugs by improving their clinical performance and economic benefits ... was spun out of Thar Technologies (no SBIR) in 2007 [company website]
Thar Pharmaceuticals (Pittsburgh, PA and Tampa, FL) raised about $1 million and is on track to begin a Phase 1 clinical trial of its lead product later this month. .... developing oral versions of existing drugs that are only delivered to patients through an IV. The company’s first product is a cancer drug that has about $2 billion in annual sales, [CEO] Houck said [Malia Spencer, Pittsburgh Business Journal, Jan 4, 13]
3D Printing Money. Shares of Voxeljet AG (Germany) more than doubled after the 3-D printing company raised $84.5 million in its initial public offering. Voxeljet's 3-D printers can make anything from vehicle parts to chairs to artwork. [AP, Oct 18]..... Stocks of 3-D printing companies have soared over the last year as 3-D printing grows in popularity. Shares of The ExOne (North Huntingdon, PA; no SBIR) have tripled since the company went public in February. Stratasys Ltd.'s (Eden Prairie, MN; no SBIR) shares have jumped 73 percent over the last year. And 3D Systems (Rock Hill, SC, no SBIR) shares have more than doubled from a year ago. [Paul Ausick, 24/7 Wall Street, Oct 18]
Cholesterol-lowering drugs known as PCSK9 blockers have been commercial busts so far, but The Medicines (Parsippany-Troy Hills, NJ; no SBIR) and Alnylam Pharmaceuticals are charging ahead into a big Phase 3 program with their own version. The two outlined the trials, which include a 14,000 patient cardiovascular “outcomes” study, this week. [Alex Lash, xconomy.com, Apr 28, 17]
Therabron Therapeutics (Rockville, MD; no SBIR) raised $2.3M of a $6M round, according to a recent SEC filing. The biopharmaceutical company builds technologies to help manage different "undertreated" respiratory conditions. [Sam Sabin, DCInnoBeat, Dec 27, 16] .... advancing a platform of novel therapeutic proteins in an effort to change how a variety of neglected and undertreated respiratory conditions are managed. We are a privately held, clinical-stage, biopharmaceutical company, developing a new class of drugs based on the naturally occurring secretoglobin family of proteins. CC10 protein, a naturally occurring secretoglobin, is a potent anti-inflammatory agent. [company website]
Theraclone Sciences (Seattle, WA; no SBIR) and the University of Texas MD Anderson Cancer Center have launched OncoResponse (Houston, TX), [after raising $9.5 million in Series A funding] dedicated to discovering new immunotherapy treatments for cancer by examining blood samples from cancer patients who have responded well to immunotherapy. ... Ultimately, clinical trials for treatments developed at OncoResponse also will be conducted at MD Anderson. Immunotherapy involves engineering a patient's blood cells and then infusing them back into the body to boost the immune system and battle cancer, or other diseases. This is a booming sector of the Puget Sound region's biotech industry right now. [Annie Zak, Puget Sound Business Journal, Oct 6, 15]
Theraclone Sciences (Seattle, WA; no SBIR, founded 2005, staff of 28) [biotech company that primarily focuses on cancer treatment] pouring money and resources into solving the problem before the next crisis hits. .... just raised a $3 million series C round to fund an effort in Ebola treatment. [Annie Zak, Puget Sound Business Journal, May 8, 15]
PharmAthene (Annapolis, MD; no SBIR) a clinical-stage bio-defense company, announced it has scrapped a planned merger with Theraclone Sciences (Seattle, WA; no SBIR) .... days after Theraclone disclosed that the Biomedical Advanced Research and Development Authority (BARDA) had declined to fund clinical trials for one of its product candidates [Bill Flook, Baltimore Business Journal, Dec 2, 13]
Theraclone Sciences (Seattle, WA; no SBIR, 34 employees) plans to combine with a publicly traded biotech PharmAthene (Annapolis, MD; no SBIR, 50 employees) in a merger of equals ... Theraclone is developing disease-specific antibodies to fight cancer and serious infectious diseases, while PharmAthene is a biodefense company focused on anthrax and chemical nerve agents. [Seattle Times, Aug 1, 13]
Theraclone Sciences (Seattle, WA; no SBIR) raised another $14 million to support its antibody drug R&D programs. ..... an extension of its Series B financing, which has now brought in $50 million .... founded in 2005 at the Seattle-based Accelerator [Luke Timmerman, xconomy,com, Mar 25, 13]
Pfizer, the world's largest drug company, has agreed to pay up to $632 million to Theraclone Sciences (Seattle, WA; no SBIR) in a research collaboration on antibody drugs for cancer and infectious disease, the companies said ... The company is led by Steven Gillis, a scientist and venture capitalist who previously co-founded Seattle biotechnology companies Immunex (Seattle, WA; three Phase I SBIRs) and Corixa (Seattle, WA; $4M SBIR). Amgen bought Immunex for about $16 billion in 2002; GlaxoSmithKline bought Corixa for about $300 million in 2005. [Duff Wilson, New York Times, Jan 19, 11] SBIR advocates should calculate the ROI to the government, and the economy, if the government had taken an appropriate equity share for its capital investment. And then insist that future SBIR be managed in such a way to push the investments to such entrepreneurs instead of the life-style companies with no taste for ROI.
Theraclone Sciences (Seattle, WA; no SBIR) developer of antibody drugs, has raised another $1.5 million in equity financing, according to a regulatory filing. The new equity comes after Theraclone received $29 million in venture capital in March 2007 [Luke Timmerman, xconomy.com/seattle, Mar 19, 10]
biotech Theradaptive (Frederick, MD; $1.2M SBIR) raised $6.2 million and is working its way toward clinical studies of its regenerative medicine technology. [Morgan Eichensehr, Baltimore Business Journal, Jan 14, 21]
Juniper Investment Company LLC completed its $68 million acquisition of Theragenics (Buford, GA; one SBIR long ago) The surgical products and cancer treatments company is now a privately held unit of an affiliate of Juniper. [Jacques Couret, Atlanta Business Chronicle, Oct 29, 13]
Theragenics (Buford, GA; one SBIR in 1987) surgical products and cancer treatments company, which reported recently it will be sold to Juniper Investment Co. for $68 million, was in the red in the second quarter [Jacques Couret, Atlanta Business Chronicle, Aug 9, 13]
Theragenics (Buford, GA; one 1987 SBIR) [surgical products and cancer treatments company ] whose bottom line has been hurt in recent quarters by shrinking demand and ObamaCare costs, has a $69.9 million to $71.4 million buy-out offer from Juniper Investment Co. LLC. [Jacques Couret, Atlanta Business Journal, May 13, 13]
Theragenics (Buford, GA; one SBIR 1987) set a revenue record in 2009 and ended up in the black. .... Research and development cost were up 69 percent to $2.2 million due to investments to support future growth in Theragenics’ surgical products segment. [Atlanta Business Chronicle, Feb 11, 10] trades on NYSE with $44M market cap, down to about 4% of its 1998 high.
specialty needle maker NeedleTech Products (Attleboro, MA; no SBIR) has been sold to Theragenics (Atlanta, GA; one Phase 1 SBIR in 1987) medical device company, for $47.8 M cash, according to Theragenics company officials. NeedleTech, a privately held company, develops coaxial needles, biopsy needles, access trocars, brachytherapy needles, guidewire introducer needles, spinal needles, disposable veress needles and other needle-based products. Its products are intended for cardiology, orthopedics, pain management, endoscopy, spine, urology and veterinary markets. [Mass High Tech, Jul 18] Theragenics sells surgical products and trades on the NYSE.
Therametric Technologies (Indianapolis, IN; $1.3M SBIR) will launch a new cavity-fighting technology this fall, creating up to 50 jobs. [Indianapolis Star, May 15]
Theranos (Palo Alto, CA; no SBIR, started by CEO Elizabeth Holmes as a Stanford University dropout 12 years ago) cleared a regulatory hurdle for its lab test system to spot a tiny virus. ... [FDA] clearance of Theranos' finger and vein blood testing technology for herpes simplex 1 is the first for a company that has come under fire from academics and established lab testing giants for not passing rigorous validation. ... Theranos' herpes simplex 1 test costs $9.07, the company said. Most other herpes tests can cost upwards of $20. [Ron Leuty, San Francisco Business Times, Jul 2, 15]
Silent, growing Theranos (Palo Alto, CA; no SBIR) is public with its big plans. In a Wall Street Journal article last weekend, the Palo Alto company, which is developing a miniature medical device that can detect hundreds of diseases with a minute amount of blood, says it is opening in-store, sample-collection centers in Walgreens...... From a business angle, too, Theranos is interesting because the device is — dare I say it — a “disruptive” technology that could blast the business models of central laboratories such as Quest Diagnostics and LabCorp [Ron Leuty, San Francisco Business Times, Sep 13, 13]
Instant Diagnosis. A Stanford dropout is bidding to make tests more accurate, less painful—and at a fraction of the current price. ... founding a life sciences company Theranos (Palo Alto, CA; no SBIR) in 2003 .... refining involves devices that automate and miniaturize more than 1,000 laboratory tests, from routine blood work to advanced genetic analyses. Theranos's processes are faster, cheaper and more accurate than the conventional methods and require only microscopic blood volumes .... launching a partnership with Walgreens for in-store sample-collection centers, .... committing to a half-off discount on Medicare fees [Joseph Rago, Wall Street Journal, Sep 7, 13] Sweeter tech is only half an innovation.
Vaccines Can Kill Business. Therion Biologics, a 15-year-old Cambridge company trying to develop a new breed of vaccines to fight cancer, will be shuttered and sold after its most promising drug candidate failed a pivotal human test .. In anticipation of succeeding with at least one of its vaccines, Therion had recently built a manufacturing facility in East Cambridge. [Stephen Heuser, Boston Globe, Jun 29] Therion had one getting-started HHS SBIR Phase 2 in 1992. From a policy viewpoint, vaccines approach the true market-failure rationale for subsidies like SBIR since they usually have too low a profit potential for Big Pharma but have a huge societal payoff when they work (which is not very often). High risk, low profit, large societal gain. True market failure should be distinguished from most of the mediocrity that SBIR is used for.
[NASA's] longstanding investment at its Glenn Research Center in heat pipes helped Thermacore (Lancaster, PA; something like $25M SBIR 1983-2010) adapt the technology to wick away dangerous heat during brain surgery. One story: When NASA needed a cryocooler to install on the Reuven Ramaty High Energy Solar Spectroscopic Imager, engineers at Goddard Space Flight Center turned to Sunpower (Athens, OH; $6M SBIR) for help. The company's cryocoolers feature just two moving parts and have a long lifespan. After 18 SBIR contracts, the company has a dozen models of cryocoolers that are aiding research in space and are employed in high-powered telescopes, multispectral and hyperspectral scanners, and superconductors on Earth. [NASA Spinoff 2017] Sounds like two cases of a federal mission agency using SBIR for straightforward engineering that uses proven technology for useful products. But then, SBIR allows both the agency and the company to proclaim innovation for whatever they're doing. No watchdogs are watching.
Modine Manufacturing has completed the sale of its Thermacore division, which makes cooling equipment for electronics, for $13.25 million. The buyer, FSBO Ventures, is owned by current and former members of Thermacore's management. The company based in Lancaster, Pa., has 179 employees, and had $32 million in sales in 2007. Modine acquired Thermacore in 2001. Based in Racine, Modine had $1.7 billion in sales in 2007. [Milwaukee Journal-Sentinel, May 2, 08] Thermacore had $20M SBIR 1984-1995.
Thermal Gradient (Pittsford, NY; $3M SBIR in one $2.9M Phase II) recently signed an agreement with Axela Inc. of Toronto, Canada to integrate its “Ultra Fast PCR” technology with Axela’s products for creation of a new, simplified and rapid molecular diagnostic system. The company is in discussions with other firms desiring access ..... graduated from its status as an incubation-phase startup business resident at High Tech Rochester Inc.’s Rochester BioVenture Center, officials said [Andrea Deckert, Rochester Business Journal, Sep 12, 13]
Many of the people laid off by the large companies [Kodak, Xerox, GM, Bausch & Lomb] in Rochester [NY] are highly trained engineers who have started their own companies and live in the upscale neighborhoods of Pittsford, Penfield and Brighton. Some have left the engineering world behind as they made the transition from company man to entrepreneur. ... iCardiac Technologies (Rochester NY; no SBIR) which measures cardiac side effects of prescription drugs, has grown to 50 employees and receives a steady stream of resumes during these times of high unemployment nationwide, many from current and former Kodak employees. .... private-equity firm Trillium Group has helped fund a number of start-ups, including iCardiac and Thermal Gradiant (Rochester, NY; no SBIR), a molecular diagnostic company started in 2004 by two people who worked at a Kodak spinoff bought by Johnson & Johnson. [Dana Mattioli, Wall Street Journal, Dec 24, 11] If Congress really wanted a jobs engine, it would seriously re-structure SBIR to push more awards to such start-ups with economic potential and away from SBIR junkies that have a semi-permanent relationship with the large agencies.
Thermal Spray Technologies (Sun Prairie, WI; $200K SBIR, 80 employees, founded 1992) said it's creating about 200 jobs through an $11.5 million expansion. [Milwaukee Journal Sentinel, Oct 8, 14] original coating work came out of collaborative graduate work with the University of Wisconsin -Madison. [company website]
ThermalTherapeutic Systems (Pittsburgh, PA; no SBIR) developer of medical technology, said it has raised $2.75 million ... to commercialize ThermalTherapeutics’ technology, which is aimed at the medical community. ... in the final stages of developing a small, portable device to heat and circulate warm, sterile fluids in a number of medical procedures. [Pittsburgh Business Journal, Sep 30, 09]
Thermedical (Waltham, MA; $8M SBIR), which is developing a proprietary thermal ablation therapy, raised $7.9M in debt in a $9.5M funding round, according to an SEC filing. [BostInno, May 14, 20]
The Massachusetts Life Sciences Center said it has awarded $500,000 grants to three Bay State life sciences companies. "The companies receiving grants are Boston Biochem (Cambridge, MA; $900K SBIR)) Tetragenetics (Cambridge, MA and Ithaca, NY; $1.1M SBIR), and Thermedical (Somerville, MA; no SBIR) the center said in a press release. "Each company will receive $500,000 from the center to match federal small business grant funding that the companies had previously been awarded.... The three companies that are receiving awards have committed to collectively creating 40 new jobs in the Commonwealth by the end of 2011, including six jobs to be relocated from New York." The center is a quasi-public agency with the mission of helping to create jobs in the state's life sciences industry. [Boston Globe, Jun 1, 10]
The Eastern New York Angels are making a second $250,000 investment in thermoelectrics company ThermoAura (Colonie, NY; $800K SBIR). [Chelsea Diana,Albany Business Review, Jan 15, 16]
ThermoAura (Colonie, NY; no SBIR) is preparing to move from pilot to full-scale production of its thermoelectric materials, said Rutvik Mehta, the scientist-turned-CEO. ... spun the company out of research he did as a [RPI] Ph.D. student ... has raised about $1.8 million in a mix of federal, state and seed money [including $750K from NSF] [Chelsea Diana, Albany Business Review, Sep 29, 15]
Rutvik Mehta, the entrepreneur-scientist behind the nanomaterials startup ThermoAura (Colonie, NY; no SBIR), anticipates turning the company's first profit in the beginning of 2015. ... manufactures thermo-electric materials for applications in smart cooling and heating. Mehta, a co-founder and CEO, will start scaling up the manufacturing for a second product next year. He is raising $1 million to facilitate that growth. Mehta spun the company out of research he did as a doctoral student at Rensselaer Polytechnic Institute. [Megan Rogers, Albany Business Review, Dec 5, 14]
The Eastern New
York Angels will
fund
more companies, this time focusing on later stage companies instead of
startups.
The goal is to raise
$2.5 million by
the end of the year. ... recently has invested $1.5
million
into six early-stage companies with a seventh pending .... Companies
funded in the first round include Paper Battery (Troy,
NY; no
SBIR), Ener-G-Rotors
(Troy, NY; no SBIR), Vital
Vio (Troy,
NY; no SBIR),ThermoAura
(Troy,
NY; no SBIR) (a manufacturer of high performing thermo-electric
material, will open a new production plant in suburban Albany this
summer as it moves into commercialization), and Free Form Fibers
(Saratoga Springs,
NY; one SBIR). [Keshia Clukey, Albany Business
Review, Jun
30, 14]
ThermoAura (Troy, NY; no SBIR) has won $750,000 [from NSF] that will ensure the company will be making its first product in the first quarter of next year. ... uses a conventional kitchen microwave to produce microscopic crystals that are able to harvest electricity from heat .... spawned out of Rensselaer Polytechnic Institute [Adam Sichko, Albany Business Review, Nov 1, 13]
ThermoAura (Troy, NY; no SBIR) a startup, has won more venture funding to commercialize something a mere one-thousandth of the width of a human hair. .... Using a $40 conventional microwave, ThermoAura produces incredibly small crystals. .... [CEO Rutvik] Mehta, born and raised in India, came to the US five-and-a-half years ago to earn a doctorate at Rensselaer Polytechnic Institute, in Troy. He created ThermoAura along with two Rensselaer [Poly] professors [Adan Sichko, The Business Review (Albany), May 23, 13]
ThermoAura (Troy, NY; no SBIR, founded 2011) was awarded $393,000 [from the state’s Energy Research and Development Authority] to aide in the commercialization of its heat-to-electricity technology ... have built a solid-state thermoelectric material which creates electricity from heat in a process more efficient than comparable products currently on the market. The company is poised to partner with Ceralink (Troy, NY; $300K SBIR) in order to scale up production to a commercial level. [Troy Record, Feb 15, 13]
ThermoCeramix (Boston,MA; no SBIR) raised $469,000 of a 1.5 million equity financing round, according to federal filings. The venture-backed engineering company develops patented, spray-on heating technology used in a variety of household items such as hot water and space heaters; high efficiency electric grill and radiant heat for homes. The thermal spray is a proven coating technology used in aerospace, according to the company. [Maureen McCarthy, Mass High Tech, Oct 8, 12]
ThermoCeramiX (Shirley, MA; no SBIR) which describes itself as the “smart” heating technology firm based in Shirley, has pulled in a $100,000 first tranche of a $2.5 million equity financing round, according to a regulatory filing today. The company develops a spray-on coating designed to heat to temperatures of more than 240 degrees Celsius -- almost instantly. [Mass High Tech, Sep 14, 09]
ThermoGenesis Holdings (Rancho Cordova CA; $800K SBIR) up 43% [Mar 16, 2023]announced that it has entered into definitive agreements for the purchase and sale of 1,071,429 shares of its common stock [worth $3M]
ThermoGenesis Holdings (Rancho Cordova CA; $800K SBIR) up 99% [Mar 15, 2023] announced that the Company is rolling out a new facility in the Sacramento metro area, containing a total of 12, class-7, ReadyStart cGMP Suites available for lease by early-stage life science and cell gene therapy (“CGT”) companies. [company press release, Mar 15, 2023]
ThermoGenesis Holdings (Rancho Cordova, CA; $500K SBIR) said it is expanding its cellular manufacturing capabilities with a new, 35,500-square-foot manufacturing facility ... develops cell and gene therapies and products that isolate cells and different components of blood. [Emily Hamann, Sacramento Inno, March 28, 2022]
ThermoGenesis Holdings up 58% [Apr 30, 20]
ThermoGenesis Holdings (Rancho Cordova, CA; $500K SBIR market cap $38M, 50 employees) up 44% [Apr 16, 20] a market leader in automated cell processing tools and services in the cell and gene therapy field, announced the Company has received the necessary acknowledgement letter which provided confirmation that the ThermoGenesis' SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection Kit has been appropriately validated during the Public Health Emergency," issued by FDA on March 16, 2020. The required registrations and listings with FDA have been completed, which now allow the diagnostic kit to be distributed. [company press release, Apr 16, 20]
Cesca Therapeutics (Rancho Cordova, CA; no SBIR), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, announced that its wholly-owned subsidiary, ThermoGenesis ($500K SBIR), has entered into an asset acquisition agreement with SynGen (Sacramento, CA; no SBIR) technology company active in the cellular processing field. [company press release, Jul 9, 17]
ThermoGenesis (Rancho Cordova, CA; $500K SBIR) announced Monday it has agreements to raise $6.7 million through a private placement of common stock to institutional investors. .... develops and manufactures automated blood and bone marrow processing systems and related disposable products for separating, processing and preserving blood, cell and tissue therapy products. [Mark Anderson, Sacramento Business Journal, Jan 27, 14] signed a five-year agreement to supply its AXP AutoXpress system directly to Cord Blood Registry, which is the world’s largest newborn stem cell company. [Mark Anderson, Sacramento Business Journal, Jan 8, 14]
ThermoGenesis (Rancho Cordova, CA; $500K SBIR) announced it is reorganizing its business, and part of that includes shedding 11 employees. In its last annual report, the company said it had 66 employees. .... develops and manufactures automated blood and bone marrow processing systems and related disposable products for separating, processing and preserving blood, cell and tissue therapy products. .... will take on a new name, Cesca Therapeutics [Mark Anderson, Sacramento Business Journal, Oct 30, 13]
ThermoGenesis (Rancho Cordova, CA; $500K SBIR) is paying $18.6 million to buy TotipotentRx (Los Angeles, CA; no SBIR) that specializes in cell-based therapy. ... Totipotent is the exclusive provider of cell-based product and services to Fortis Healthcare System, which is an integrated healthcare system that operates in 11 countries. ... ThermoGenesis develops and sells technologies for processing and storing stem cells and tissue. ... The combined company will take on a new name, Cesca Therapeutics [Mark Anderson, Sacramento Business Journal, Jul 16, 13]
ThermoGenesis (Rancho Cordova, CA; $500K SBIR) announced that its AutoXpress System was chosen by the United Kingdom’s National Health Service Blood and Transplant, and that the five-year deal will begin to bring revenue to the company within weeks.[Mark Anderson, Sacramento Business Journal, Jun 12, 13]
AesRx (Newton, MA; no SBIR) has boosted its latest financing round by about $125,000 to $1.5 million, according to a federal document. [Mass High Tech, Jil 1, 11] one of Central Texas' least-known business success stories.Thermon (Austin, TX; no SBIR) — which creates, manufactures and services heat tracing technologies for some of the world's biggest oil and chemical companies ... for decades, Thermon has consistently churned out profits and has become one of the biggest players in the worldwide heat tracing market, ... a long way from Thermon's 1954 birth, when founder Richard Burdick created the company with a borrowed $40 ... "Thermon is a really interesting play or investment in a high-growth, niche industrial technology space," [Industry analyst Brian] Drab said. "I'm always looking for high-growth industrial technology companies [Barry Harrell, Austin American Statesman, Jul 4, 11]
Infarct Reduction Technologies (Waldwick, NJ; no SBIR, founded 2010) is developing a device, the LifeCuff, to deliver an ischemic pre-conditioning protocol. Ischemic pre-conditioning has been found to improve outcomes in heart attack, stroke, sepsis and other conditions. The only other method of providing this protocol is manually by intensive care, surgical or emergency medical staff [Lauren Hertzler, Philadelphia Business Journal, Jan 16, 15] $400 Thousand in 1 Round, Aug 2014 [www.crunchbase.com] A competitor in infarct reduction is TherOx (Irvine, CA; $500K SBIR), [which] seeks $25 million for the final push to bring its treatment to increase the quality of life for heart attack patients. [http://medcitynews.com, Nov 29, 13]
Thesan Pharmaceuticals (Carlsbad, CA; no SBIR) a developer of treatments for dermatological disorders, said it has raised $49 million in venture capital financing..... had previously raised $16 million in October 2012. The company's first treatment targets include acne and atopic dermatitis, often called eczema. [Bradley Fikes, utsandiego.com, Feb 25, 14]
| Megahertz, shmegahertz. A few iconoclasts are building computer chips that dispense with the traditional clock. But they face big barriers in bringing their idea into the mainstream. Digital anarchist: Karl Fant of Theseus Logic [who] wants to take chip technology in a radical direction, [says] "Eventually every chip will be designed this way," he declares. "It's inevitable!" ... So what of Karl Fant's flamboyantly predicted revolution? In an industry as mature as chip making, there's no replacing dictatorship with anarchy overnight. But over time, the balance will probably shift toward clockless design; enough articles will be written, enough tools built, enough engineers educated that it will no longer be unrealistic to imagine marketing such a chip even outside of specialized niches. ... The switch will come when synchronous is no longer good enough." The winners in this next wave of innovation will be the companies that choose the right time to jump off the curve. Clockless chips have the promise of revolutionizing the industry, of rapidly accelerating the relentless drive toward faster and cheaper chips that we've come to expect from Moore's Law. Who is to say what might be possible? Why not an all-asynchronous chip compatible with Intel products? "If someone does that, they will have a serious competitive advantage for a number of years," says Intel's Stevens. Translation? "So yeah, we're worried." [Claire Tristram, It's Time for Clockless Chips, MIT Technology Review, Oct01] | Asynchronous logic replacing clocked chips? Never? Never is a long time. Fant's story goes back to the early 90s when he and fellow founder Ken Wagner convinced BMDO's SBIR to do a Phase 2 with a crazy idea. Fant and Wagner had convinced their employer Honeywell to let them have the idea. Fant ran the technical work and ex-AF pilot Wagner energetically marketed the idea. An idea that would probably have no chance in the new BMDO scheme of predictable advances by sane contractors. It's the sort of innovation that IF IT CATCHES ON, would shift an entire industry. The economics are daunting because the industry has so much invested in clocked chips. Only a huge cost-effectiveness advantage (or an airliner into the Pentagon and each WTC tower) could change the gorundrules. Fant tells his story to MIT TEch Review from the company's thinking section in Silicon Valley among the mathematicians. Meanwhile the development team beavers away, always with just enough funding to keep going, in Maitland FL. BMDO's Phase 2 ended long ago and did its job of getting a wholly new idea seeded. |
The idea of asynchronous logic goes back to the dawn of digital computers. Some of the earliest machines (built in the 1950s) were based on clockless designs. But the synchronous approach predominated, largely because it is easier to design chips in which things happen only when the clock ticks. In recent years, however, clockless designs have started to look more appealing. ... Wireless devices based on asynchronous chips would run for longer between recharges, and their circuitry would cause less radio interference. Dr Furber is developing asynchronous chips for such devices in conjunction with ARM, a British company whose processors appear in many handheld computers and mobile phones. Philips, a Dutch electronics firm, has already built a pager that uses asynchronous logic, and Theseus Logic of Orlando, Florida, is also pursuing low-power wireless applications. ... There is, of course, a catch. Both SMT and asynchronous logic undermine the use of a chip’s clock speed as a proxy for its performance. And that might make things tricky for the marketing men, who have long insisted that the more MHz, the merrier.
A company that got its start with BMDO SBIR shows up in the portfolio of a commercializer. Theseus Logic (Orlando, FL), which is developing a non-Boolean asynchronous logic for chips shows up in the portfolio of Milcom, a company that specializes in commercializing military technology by getting a start-up going and doing the initial management but infusing no capital. Read about Milcom (but no details on Theseus in Digital South, N/D00.
Meanwhile, while NASA snubs commercialization, a BMDO 1994 start-up cut a deal with Motorola. Theseus Logic (now Orlando, FL) formed a strategic technology alliance for its NULL Convention Logic, a clockless self-synchronizing chip design. NCL is one of those paradigm shifts that could spread into computers big-time in a way that asynchronous logic never could before. It has attracted a nice flow of capital as BMDO envisioned to carry it through the rather long gestation period for disruptive innovation. Eventually, even safety conscious NASA will adopt it for at least some of its computing. More chip designers will probably shift to it when their shrinking feature size runs into quantum effects limits. Unless, of course, some new completely innovative approach comes along.
What SBIR Should Do. The clockless company has no need to keep time in its chips which respond to events not to clock cycles. Theseus Logic (Orlando, FL) got a BMDO Phase 2 SBIR to get started developing a wholly new asynchronous design style invented by Karl Fant, an award-winning Honeywell researcher who founded a small company. Theseus's Null Convention Logic asynchronous approach differs from all other design styles which depend on Boolean logic combinatorial circuits that then have timing analysis even harder than clock logic. Clocks in computers are like metronomes. BMDO insisted on some third-party validation after some early proof - a simple 3-bit adder - and Theseus hit the financial street with its story. Now, four years later, it has 25 employees, incoming capital, a second BMDO Phase 2 SBIR, and a drive to market revenue by 2001, and profit by 2002. Ambitious, as are all market-driven start-ups. The researcher-founder realized that a Theseus CEO needed gray hairs and business scars with business experience in new technology introduction, and put himself where he could do the most good for the company as the technical leader, in Silicon Valley where the tools are being developed. No one remains in the company's Minneapolis birthplace. The new CEO, Mike Graff, an ex-large semiconductor company executive with 34 years in industry, a leader in market introduction for 30 years, saw Theseus as a CMOS analog which he rode into 99% market share in dozen years. He has fought this battle before. The board includes the CEO of a defense-conversion company MilCom, a founder of Nichols Research, another ex-VP of the large semiconductor company, and a founder of Taiwan Semiconductor. Theseus is on a success-or-die course. Disdaining dependence on government succor, except as contributing to commercial goals, it cast its lot with commercial chips. The first expression is likely to be a DSP, but that depends on the specific strategic partner it picks. The technology is generic and will require and ultimately cause a complete re-write of chip design for all the industries where asynchronous beats Boolean logic. It could conceivably eventually destroy the present chip architecture and the capital investment therein. The Semiconductor Industry Association predicts a design crisis approaching intractability by 2003 for clock-driven computing. As soon as it proves so advantageous that new chip designers shift to asynchronous's advantage of low power and no clock timing design heartaches. As chips descend into smaller and smaller feature size, the clock timing problems grow almost exponentially. Theseus is the kind of situation that SBIR's idealists envisioned when they invented SBIR. So far, only BMDO has recognized the potential as worthy of a well designed Phase 2. Theseus likes the BMDO approach to SBIR because just when the companies need flexibility and about $5M, most government programs have inflexibility and only $1M. Although Theseus has NOT yet got $5M from BMDO SBIR, it is so far the kind of story that BMDO would consider investing $5M if things go right and the private sector transitions into driving the train. Government support in Theseus-like situation needs that fine balance between support and independence like teaching a child to ride a bicycle - enough money to let the founder keep enough equity to be an incentive to others but not enough to let it be dependent on government. Stay tuned, but don't listen for a clock or a metronome.
Theseus Logic (St Paul, MN) notes that the industry cannot help but move its way. Indeed, a crisis is approaching, says the Semiconductor Industry Association. Unlike money and prosperity that expand unbounded, shrinking the scale of a chip eventually runs into a natural barrier, overcrowding of the lane. Tinier and tinier and faster and faster crashes into a wall that will demand a complete new organization of the chip. Welcome, NULL Convention Logic, an asynchronous logic invented by Honeywell mathematician Karl Fant who made a startup seeded by BMDO's SBIR. Theseus had had two Phase 2 SBIRs and is actively raising the private sector investment needed to make a real company.
More Recognition for DataFlow, aka Null Convention Logic(Jul 15) Jesse Scanlon concludes with it's clear that the industry has decided to go with the dataflow [Wired, Aug 97] From an academic idea of the 60s through an inconclusive test in the IBM 360 to two present competitors for the replacement of Intel's clock in a not-too-distant-future chip as features keep shrinking. Sharp's New Media Processor is competing alongside Theseus Logic's Null Convention Logic started with a BMDO SBIR from an invention by Honeywell mathematician Karl Fant who started Theseus.
A Clockless Web Site(Jun 25) New Website for the clockless company Theseus Logic (St Paul, MN). Discover how the clock in your computer's CPU would go away (though not the nagging reminder clock on the screen). Theseus has BMDO SBIR money and is raising its second Private Placement.
Raising Money to Raze a Tradition(Apr 22) Theseus Logic (St Paul, MN) is offering accredited investors a shot at a new industry - computing without a clock. Not the Y2K kind of clock, but the kind that Intel measures in MHz. With a new asynchronous logic supported first by a BMDO SBIR, Theseus is raising more capital in a second Private Placement to expand Karl Fant's idea into a working processor that wipes out about half the design cost of a new chip and 40% of the power demand. With a new Phase 1 SBIR for a Cascade Processor (TM) the new capital could be matched two-for-one by BMDO's Fast Track if all goes right. Accredited (wealthy) investors can get a prospectus by calling Georgene Riegel at 612-699-6171. (Note: Carl Nelson Consulting has a financial relationship with Theseus Logic.)
The Clockless ChipThe half page story in Wired Feb 97 on Theseus Logic (St Paul,MN) speculated that the asynchronous logic would get clocks out of chips and with them half the chip design cost and 40% of the power drain. Money came from a Private Placement of $1.9M and a DARPA $2.3M contract (of which Theseus will get a lot less than half). Unspoken was the BMDO SBIR contract of $750K to get the development started. The picture of Theseus's founders Fant and Wagner shows Wagner in a gesticulating pose one would expect of an A-10 jockey and Honeywell marketeer while inventor, former Honeywell mathematician, Fant sits quietly.
Connecticut Innovations has made a $500,000 investment in Thetis Pharmaceuticals (Southport, CT; no SBIR) that is developing a treatment for Type 2 diabetes that is designed to help control both blood sugar and cholesterol. The state's quasi-public agency makes investments in technology and innovation, such as the TP101 diabetes treatment now in the works by Thetis ... The new pharmaceutical company, formed earlier this year and employing six people, is combining omega-3 polyunsaturated fatty acids from fish oil with metformin, a standard blood-sugar treatment for people with Type 2 diabetes. The hope is that the fish oil ingredient will reduce the potential for stroke or heart attack [Matthew Sturdivant, Hartford Courant, Aug 22, 11]
ThingMagic, (Cambridge, MA; no SBIR) a radio frequency technology maker, announced its investment and technology development agreement with In-Q-Tel, the CIA’s venture arm. ... to develop further its RFID reader and sensor technology for industrial, government and consumer applications. ... Founded in 2000, ThingMagic has brought in more than $30 million in private funding. [Mass High Tech, Nov 24, 08]
ThingMagic (Cambridge, MA; no SBIR) closed a $9.5 million round of funding with which the RFID company has raised nearly $30 M since its inception in 2000. .... The 40-person company will use the new financing to expand its product development and penetrate new vertical markets [Mass High Tech, Jul 11, 08]
Hologic will pay $580 M to acquire Third Wave Technologies (Madison, WI; $9M SBIR) in a deal pairing two developers of medical diagnostics technology. [Boston Globe, Jun 9, 08]
Third Wave Technologies rose 40% in heavy after-hours trading [Mar 11, 08], after the company said a clinical trial for a new test achieved its primary goal. The test - which Third Wave has been developing for the last two years - is for human papillomavirus, or HPV, a cause of genital infections that might lead to cervical cancer. The company had devoted 80% of its research-and-development budget to creating the test. [Kathleen Gallagher, Milwaukee Journal-Sentinel, Mar 12]
Third Wave Technologies up 13% [Feb 26, 08]
Third Wave Technologies reported progress in its efforts to sell products in the biggest potential market it has ever tackled. The Madison maker of genetic analysis products said it has signed up enough people to proceed with clinical trials for its human papillomavirus, or HPV, tests. [Kathleen Gallagher, Milwaukee Journal-Sentinel, Jan 1]
Third Wave Technologies (Madison, WI; $4M SBIR) got a $25 million, five-year line of credit from Deerfield Management of New York. The money will be used to further Third Wave's business of developing tests for the human papillomavirus. [Milwaukee Journal-Sentinel, Dec 10]
Third Wave Technologies up 11% [Dec 6, 07]
Third Wave Technologies up 25% after winning a patent court case. [Jul 24, 07]
Third Wave Technologies agreed a private placement of about $14.9 M of debt with an unidentified institutional investor. [Milwaukee Journal-Sentinel, Dec 20] It has had $4M in SBIR over a decade for its molecular diagnostics. Its stock price sits in the middle of its five-year range.
St. Jude Medical lost share price after a device made by [heart-pump maker Thoratec ($100K SBIR)] that it plans to buy [for $3.4 billion] was the subject of safety alert from the government. ... the FDA’s “safety communication” cited recent evidence that the pump develops more dangerous blood clots than was initially known. [Joe Carlson, Minneapolis Star Tribune, Aug 6, 15]
Thoratec (Pleasanton CA; $100K SBIR) up 10% [Jul 22,15] agreed to be acquired by St Jude Medical for $3.4 B but legal sharks are circling alleging possible breaches of fiduciary duty and other violations of law by failing to adequately shop Thoratec to maximize shareholder value before agreeing to be acquired by St. Jude [Rosen Law Firm press release]
Thoratec (Pleasanton CA; $100K SBIR) up 18% [Jul 21,15] Talks reportedly ongoing for acquisition by St Jude Medical. [Minneapolis Star Tribune]
Thoratec down 30% [Aug 7, 14]
Thoratec (small SBIR long ago) said four patients using the company's heart pump device died after struggling to switch to a backup system controller that monitors the device's performance. In addition, five patients either lost consciousness or experienced decreased blood flow because of difficulty switching controllers. [Joseph Walker, Wall Street Journal, Mar 4, 14]
Thoratech (Pleasanton, CA; two SBIRs 25 years time ago) down 10% [May 3, 13]
Thoratec up 12% [Feb 9, 12]
Thoratec down 11 [Jan 28, 11]
Thoratec> down 20% [Nov 15, 10]
Thoratec up 23% [Apr 30, 10]
medical devices company Thoratec up 13% [Aug 6, 09] second-quarter revenue topped Wall Street expectations with help from a heart pump for patients awaiting transplants [Wall Street Journal, Aug 7]
Thoratech down 13% [Oct 27, 08] said there was a wear-and-tear problem with its "HeartMate II" blood-pumping device. [WSJ, Oct 28, 08]
Thoratech up 22% [Aug 1, 08]
Innovation Works and the Pittsburgh Life Sciences Greenhouse have spent the past decade as a tag-team source for fledgling companies — ideas even — to find the financial support needed to grow into viable, productive and profitable companies. .... Looking at the 2001-2005 period, firms funded by the two groups during this period include Aethon (no SBIR), Vivisimo ($700K SBIR), ALung Technologies (no SBIR), Plextronics ($300K SBIR), Inc., RedZone Robotics ($1.6M SBIR) and Thorley Industries (no SBIR) (4moms). Other than Vivisimo, which was bought by IBM in 2012, all of those companies are core firms in the portfolios of local venture capital firms [Ethan Lott, Pittsburgh Business Times, Jul 8, 13]
Innovation Works, Hazelwood (PA) VC fund, in 2007 invested $6.1 M in technology companies, including its 100th investment. The specializes in giving a leg up to young technology companies cites three [no SBIR] success stories: Knopp Neurosciences, which is working on a drug therapy to slow the advance ALS ("Lou Gehrig's disease"). ... granted "orphan drug" status by the FDA ; Printed electronics manufacturer Plextronics, which attracted more than $20 M in new investment last year and set an efficiency record with its solar cells; Thorley Industries signed a $215 M deal with Hasbro for that company to manufacture and sell a new line of Thorley products [Elwin Greene, Pittsburgh Post-Gazette, May 2].
A number of Pittsburgh companies, including ExOne (no SBIR) and [Start-Up Entrepreneur Awards to] Cohera Medical (Pittsburgh, PA; $1.7M SBIR) and ThreeRivers 3D (no SBIR), were honored with 2013 Carnegie Science Awards. [Paul Gough, Pittsburgh Business Times, Jan 31, 13]
Threshold Pharmaceuticals (SOUTH SAN FRANCISCO, CA; no SBIR) lost more than 80 percent of its value Monday after announcing poor results from two late-stage studies of its headliner drug against two types of cancer. [Ron Leuty,San Francisco Business Times, Dec 7, 15] announced the outcomes of two Phase 3 cancer studies (MAESTRO and TH-CR-406/SARC021) of evofosfamide (previously known as TH-302), an investigational hypoxia-activated prodrug, which is being evaluated for first-line treatment of advanced pancreatic adenocarcinoma and advanced soft tissue sarcoma, in combination with chemotherapy. The Phase 3 studies are being conducted under Threshold's collaboration with Merck KGaA, Darmstadt, Germany. [company press release, Dec 7, 15]
Rolling Big Dice. Threshold Pharmaceuticals plunged 75% after the Food and Drug Administration halted clinical trials for the Redwood City, Calif., pharmaceutical company's enlarged-prostate drug, TH-070, because of cases of liver toxicity.
Thrive Earlier Detection (Cambridge, MA; no SBIR) dedicated to extending and saving lives by incorporating earlier cancer detection into routine medical care, announced that it has raised $257 million in a Series B financing. [company press release, Jul 29, 20]
Thrive Earlier Detection (Baltimore, MD; no SBIR, founded 2019) has raised $110 million to commercialize a cancer-detecting blood test, developed by Johns Hopkins researchers, that doctors would give patients during routine physicals. [Lorraine Mirabella, Baltimore Sun, May 30, 19]
Fourteen startups that received a total of more than $17 million from [Texas Emerging Technology Fund managed by Gov. Rick Perry’s office... which has backed 143 startups] have failed or gone bankrupt. .... [ MIT professor Bill Aulet, who is managing director of the Martin Trust Center for MIT Entrepreneurship] said the number of failed ETF companies would be higher if state officials took the chances they needed when investing in startups. "They really haven't taken any risk," he said. "Governments aren't good at being venture capitalists because governments aren't good at risk." .... a partial list of the ETF-backed startups in Texas that have since closed, followed by the grant amounts they received: • NanoTailor, $250,000; • Star Vision Technologies, $750,000; • Terrabon, $2.7 million; • Thrombo Vision, $1.5 million; • Nanocoolers, $3 million; • Advanced Receiver Technologies, $250,000; • Bauhaus Software, $500,000; • Net Watch Solutions, $500,000; • Sunrise Ridge Algae, $250,000; • SeprOx, $750,000; • Speer Medical, $2.5 million [Christopher Calnan, Austin Business Journal, Jan 9, 14] None of these had SBIR.
The other two bankruptcies in the [Texas Emerging Technology Fund] portfolio happened in 2010. Thrombovision (no SBIR). was awarded $1.5 million, and StarVision Technologies (State College , TX; $3.6m SBIR) received $750,000. A state auditor's report in 2011 found that neither company had submitted required annual reports for three years and that the fund managers didn't even know Thrombovision had filed for bankruptcy until it was reported in the media. The auditor's report went on to fault the fund for having a decision-making process that is "not open to the public" and for not keeping up with how awardees are performing and spending their money. [Paul Weber, AP, Jun 14, 12]
Investing in ... a governor. The[Texas Emerging Tech] fund has made grants to companies operated by several prominent Perry donors, and at least one company receiving grant money went bankrupt — an uncanny similarity to the Solyndra scandal. In 2007 Perry’s office approved a $1.5 million award to ThromboVision(no SBIR) , a biomedical diagnostics company. When it declared bankruptcy in September 2010, ThromboVision revealed that businessmen Charles W. Tate and Charles Millerowne had hundreds of thousands of preferred shares in the company.Tate was involved in the initial vetting process for the company’s Texas Emerging Technology Fund grant, a step before the request was evaluated by a statewide board and then approved by the governor, lieutenant governor and House speaker. The Dallas Morning News reported that Tate made two investments in the company between the April 2007 grant approval and the October 2007 public announcement of the grant. Tate donated roughly $424,000 to Perry’s campaigns between 2000 and 2010, while Miller donated $125,000 during that time. [Steven Nelson, AP, Oct 13]
Avalon Ventures and UK-based drug giant GSK said they have formed another San Diego biotech startup. ... PDI Therapeutics (named for the enzyme protein disulfide isomerase, La Jolla, CA) , will develop immunotherapies for cancer. Like all other companies formed under the three-year-old partnership, PDI will be housed at Avalon's COI Pharmaceuticals, an incubator that provides shared facilities and management. Meanwhile, Avalon said the first two companies created under the collaboration, Sitari Pharmaceuticals and Silarus Therapetics, have identified a clear path to potential drugs, thus meeting their first milestones, said Jay Lichter, an Avalon managing director and also COI's president and CEO. Sitari and Silarus are respectively developing drugs for celiac disease and iron overload disorders. ... GSK and Avalon established their partnership in April 2013, with up to $465 million from GSK and up to $30 million from Avalon to form up to 10 companies in San Diego. Up to $10 million in Series A funding is to be invested in each company to get it off the ground. ... The five other companies founded by the Avalon/GSK collaboration are Thyritope Biosciences, Adrenergics, CadheRx Therapeutics, Calporta Therapeutics, and Iron Horse Therapeutics. [Bradley Fikes, San Diego Union Tribune, May 20, 16]
Crossing the halfway point in their alliance to form up to 10 biotech companies in San Diego, La Jolla's Avalon Ventures and UK-based GlaxoSmithKline they have added three new companies to their portfolio. Adrenergics (no SBIR), CadheRx Therapeutics (La Jolla, CA; no SBIR), and Calporta Therapeutics (no SBIR), will each receive up to $10 million, along with research and development support from the partners. Previously announced companies include Sitari Pharmaceuticals (San Diego, CA; no SBIR) , Silarus Therapeutics (La Jolla, CA; no SBIR) , and Thyritope Biosciences (San Diego, CA; no SBIR). [Bradley Fikes, utsandiego.com, Jun 15, 15]
Big pharma does startups. San Diego firm Avalon Ventures has rolled out two more biotech startups in its unique partnerhip with GlaxoSmithKline, according to a new statement. The new companies, Silarus Therapeutics (no SBIR) [therapy for anemia and iron overload disorders] and Thyritope Biosciences, [focus on Graves’ Orbitopathy, which causes thyroid-related bulging of the eyes] will each receive $10 million in Series A funding from this Avalon-GSK partnership. ... Announced more than a year ago, the venture firm and its big pharma partner will create and bankroll 10 new San Diego drug companies with $495 million in joint funding. It announced the first, Sitari Pharmaceuticals, with a $10 million Series A financing round last November to develop a treatment for celiac disease. [Meghana Keshavan , medcitynews.org, Sep 22, 14]
Kenan Sahin best known for selling his billing software company, Kenan Systems, for $1.5 billion to Lucent in 1999, without having taken a dollar of outside investment. ... he has spent much of his time and fortune quietly working to push battery technologies forward, launching Tiax in 2002 [jump-starting the company by acquiring the technology division of the once-prominent consulting firm Arthur D. Little for $16.5 million] to produce and foster promising advances before turning them over to a marketplace ... this spring it announced that a spinout, CAMX Power, was emerging from stealth mode. ... CAMX lined up deals with two of the world’s largest chemical manufacturers, U.K.-based Johnson Matthey and Germany’s BASF, to produce and sell the [lithium-nickel-cobalt] material to battery makers. ... Johnson Matthey said the CAMX material delivered as much as a 25 percent improvement in energy density over the nickel-manganese-cobalt cathode materials used in many electric vehicles today, and about a 5 percent gain over an advanced chemistry going into upcoming models. [James Temple, technologyreview.com, November 14, 2017] Sahin was an immigrant from Turkey at age 16.
Tiax (Cambridge, MA)reports it has granted an exclusive license covering its high-energy, high-performance cathode material to Canadian metal company CVRD Inco Ltd. for use in portable power applications. [MHT, Jul 11]
Tiax (Cambridge, MA; $10M SBIR) has been issued one patent and received one notice of allowance for its Cel-X battery control technology, ... a low-cost, high-performance system designed to improve the safety, capacity and pack life of lithium-ion batteries through a nondissipative approach to regulating battery charge in lithium-ion batteries, [Mass High-Tech, Jun 21]
Tibbetts Industries (Camden ME; one SBIR) is being bought by IntriCon , a Minnesota-based developer of miniature and microminiature medical and electronics products, for $4.5M. [Mass High Tech, Apr 20]
Tibion (Sunnyvale, CA; no SBIR) said it raised $10.175 million and named a new chairman and board of directors. ... its bionic leg "provides the assistance and resistance required by a stroke survivor’s weakened leg, enabling the repetitive sit-to-stand, overground walking and stair-climbing exercises to promote the 'brain re-wiring' believed necessary for gait recovery." [Elizabeth Kim, Silicon Valley / San Jose Business Journal, Mar 2, 11]
Biotech startup creator Cydan (Cambridge, MA) announced the launch of Tiburio Therapeutics, a private biopharmaceutical company focused on developing treatments for rare neuroendocrine tumors and rare endocrine diseases. Tiburio will advance two compounds licensed from Ipsen for the treatment of non-functioning pituitary adenoma (NFPA) (TBR-760) and for additional rare endocrine diseases (TBR-065). As part of the launch, Tiburio raised a $31M Series A financing that will fund the company’s lead compound, TBR-760, through human proof-of-concept for the treatment of NFPA and further clinical assessment of TBR-065 as a treatment for rare endocrine diseases. ... Cydan is an orphan drug accelerator dedicated to delivering therapies that will significantly improve the lives of people living with rare genetic diseases [Cydan press release, Jan 3, 19]
Tilera (Santa Clara, CA; no SBIR) has begun to ship a 64-core processor, promising dramatic advances in powering devices for the networking and multimedia industries. ... "It's a real disruptive technology," [founder MIT professor] Agarwal said last week. "We pretty much took a clean sheet of paper at MIT and said we're going to deliver a whole new architecture for chips." [Robt Weisman, Boston Globe, Aug 20]The technology got tens of millions of dollars from NSF and DARPA and then $40M VC for the company.
Interstate competition. Ottobock, a German prosthetics manufacturer, is closing its Minnesota operations and shifting hundreds of headquarters jobs to Utah and Texas. ... in Salt Lake City, adding about 80 jobs there with the help of a $390,000 tax credit provided by that state [Sam Black, Minneapolis / St Paul Business Journal, Jan 14, 14] president and CEO of the Economic Development Corp. of Utah, added that Ottobock’s decision to expand here reflects well on the state’s promotion of its array of life-science firms."It is important to companies like Ottobock that Utah has a well-established cluster where deep and mature talent pools increase their efficiency," he added. [Mike Gorrell, Salt Lake Tribune, Jan 14, 14] Meanwhile, Tillges Certified Orthotic Prosthetic (Maplewood, MN; no SBIR, 43 employees) will expand into the west metro and boost its trauma business after buying Metropolitan Orthotic Laboratory (Minneapolis, MN; no SBIR) near Hennepin County Medical Center. .... Tillges didn’t disclose terms of its deal. .... Tillges recently spun off a startup, Tillges Technologies, that developed a mobile app and electronic sensor designed to help diabetic ulcers heal. [Katherine Grayson, Minneapolis / St Paul Business Journal, Jan 13, 14]. What is the net effect on the US of such tax-inspired shifts except profits for the moving industry? Local tax revenue will go down in both places as corporate costs decline and profits increase (maybe).
PressureGuardian, an electronic sensor and accompanying app designed to help diabetic ulcers heal. The sensor detects how much pressure a foot brace places on a patient’s ulcer. Practitioners can then ensure a brace relieves the appropriate amount of pressure. Tillges Technologies (Maplewood, MN; no SBIR), a startup spun out of Tillges Certified Orthotic Prosthetic Inc. (TCOP), a family-owned prosthetics and orthotics firm [Katherine Grayson, Minneapolis / St Paul Business Journal, Jul 12, 13]
Cancer immunotherapy leader Merck continued to roll up oncology assets with a deal this morning to acquire Tilos Therapeutics (Lexington, MA; no SBIR, founded 2016). Merck didn’t disclose how much it will pay up front for Tilos, a startup developing drugs for cancer, fibrosis, and autoimmune diseases. But the overall payout could reach $773 million for Tilos shareholders [Frank Vinluan, xconomy.com, Jun 10, 19] prior funding $3M [crunchbase.com]
Tioma Therapeutics (St. Louis, MO; $400K SBIR as Vasculox) pharmaceutical discovery startup raised an $86 million Series A [Brian Feldt, St. Louis Business Journal, Aug 19, 16]
With $86 million Series A, and a new corporate office in the Bay Area, Tioma Therapeutics (formerly Vasculox, founded 2006 in St. Louis, MO, Brisbane, CA; $400K SBIR) is pushing forward in its effort to bring an immuno-oncology drug into human clinical trials. ... to fund a trial that could start as soon as 2017 for its lead candidate, a checkpoint inhibitor that targets a protein called CD47. The $86 million will be used for investigations into several cancers, as well as to potentially fund development of other antibodies Tioma has in its portfolio, [CEO] Donovan wrote. ... is focused on both solid and blood-based cancers. ... Donovan was co-founder and chief business officer of Alios BioPharma (no SBIR). Alios, an antiviral drug developer, sold to Johnson & Johnson for $1.75 billion in 2014. [David Holley, xconomy.com, Aug 16, 16]
TissueGene (Rockville, MD; no SBIR, founded 1999) was one of 29 entities to be awarded state funding through Maryland Technology Development Corp. to support research and development of stem cell therapies. was one of 29 entities to be awarded state funding through Maryland Technology Development Corp. to support research and development of stem cell... using $750,000 to move toward commercialization, IPO therapies. [Baltimore Business Journal, Sep 18, 17] was awarded a $750,000 clinical grant from the Maryland Technology Development Corporation (TEDCO) via the MSCRF. The clinical grant is to be used for conducting clinical trials in Maryland using cell therapy. [company press release, Jun 30, 17] Note: the primary recipient of the fund's 2017 awards is Johns Hopkins University. [fund press release]
Maryland Technology Development Corp approved awards of $8.5 million to 29 new stem cell research projects. The for-profit firms each receiving over $1M are: TissueGene (Rockville, MD; $100K SBIR), Longeveron LLC (Miami, FL; no SBIR), MaxCyte (Gaithersburg, MD; $1M SBIR), Propagenix (Rockville, MD; no SBIR), Seraxis (Germantown, MD; no SBIR), and 3Dnamics (Germantown, MD; no SBIR). [Morgan Eichensehr, Baltimore Business Journal, May 16, 17]
Salient Surgical Technologies (Portsmouth, NH; no SBIR, founded as TissueLink in 1999) has landed $15 million in new funding, according to federal documents. The company makes devices to control bleeding during surgeries. [Mass High Tech, Jan 7, 10]
Last week, Tissue Regeneration Systems (Plymouth, MI; $1M SBIR) celebrated the opening of its new lab and manufacturing center, which will help the company meet the demands of its partnership with J&J. ... [CEO Fitzsimmons] says his company was spun out of technology developed at the University of Michigan and the University of Wisconsin. TRS uses 3-D printing to fabricate individualized designs to replace injured bones based on a patient’s CT scans. ... Fitzsimmons says TRS’s long-term goal is an acquisition by one of its corporate partners [Sarah Schmid, xconomy.com, Aug 21, 14]
the Michigan Economic Development Corporation announced its new Michigan Venture Match Fund, a $5 million pot of money from the Michigan Strategic Fund for early-stage companies in the state that have already gotten funding commitments from at least one venture firm. The fund just invested $2.76 million in six companies across a variety of sectors: Stik (social networking website, no SBIR), Livio (internet car radios, no SBIR), Amplifinity (manage advocacy programs; no SBIR), Gema Diagnostics (Ann Arbor, MI; no SBIR, human embryo screening), nanoRETE (Lansing, MI; no SBIR, real-time detection of pathogens), and Tissue Regeneration Systems (Ann Arbor, MI; no SBIR, bone reconstruction). [Sarah Schmid, xconomy.com, Mar 12, 13]
Titan Pharmaceuticals (South San Francisco, CA; $500K SBIR) and partner Braeburn Pharmaceuticals (Princeton, NJ; no SBIR) received FDA approval Thursday for an under-the-skin implant that treats opioid addiction. The implant, branded Probuphine, delivers the drug buprenorphine for up to six months, according to Titan. [Ben Fidler, xconomy.com, May 27, 16]
Titan Pharmaceuticals (South San Francisco, CA; $500K SBIR) plunged the most in 17 years [of public listing] after the company failed to win U.S. regulatory approval for an implant to treat addiction to heroin and prescription painkillers. [Anna Edney, Bloomberg, May 1, 13]
Titan Spine (Mequon, WI; no SBIR, founded 2006) announced that Medtronic will acquire it. Terms not disclosed. .... makes interbody implants that serve as spacers inserted between the vertebrae during spinal fusion procedures. The implants help to relieve nerve pressure and hold the vertebrae in place while fusion takes place. .... has raised more than $50M in funding. [Katherine Davis, Wisconsin Inno, May 14, 19]
Titan Spine (Mequon, WI; no SBIR), a medical device surface technology company focused on developing innovative spinal interbody fusion implants, announced that it has expanded the distribution of its line of Endoskeleton® titanium implants featuring the company’s new proprietary nanoLOCK® surface technology nationwide. The full U.S launch follows the successful alpha introduction of the nanoLOCK® technology initiated recently in a limited number of sites. [company press release, Oct 13, 16] said it has raised $7.5 million of equity funding from one investor. [Milwaukee Journal Sentinel, Oct 13, 16]
Danish biotech firm Novozymes which maintains its North American headquarters in Franklinton [NC], has acquired TJ Technologies (Watertown, SD; no SBIR, founded 1978) to further its position in bioagriculture. .... annual revenue close to $15 million and provides farmers with biological solutions to enhance plant growth and improve yields. [Lauren Ohnesorge, Triangle Business Journal, Jun 25, 13] Headquarters in Buffalo, SD, in the northwest corner of South Dakota; owns and operates [R&D]laboratory in Brookings, SD.
If there's a single element of the classic entrepreneur story missing from Tim Childs' seven-year battle to build his small, high-tech company, I've been unable to find it. There were the sacrifices. ... There were the lean times. ... ... And the numbing work schedule. ... Childs, 38, is founder and president of TLC Precision Wafer Technology , a north Minneapolis company that is one of just six firms worldwide capable of supplying gallium arsenide and indium phosphide wafers to the semiconductor industry. ... a steadily growing business that should post sales of nearly $2 million this year, up more than 20 percent from $1.6 million in 1997. The company, which has 18 employees, has been profitable for the past four years ... All of which leaves an intriguing question: How come a poor kid from Miami, the last of eight children in a family headed by a part-time preacher and intermittent mechanic, truck driver and small businessman, wind up with a career in physics? More curious, how does an above-average athlete -- Childs, a linebacker who was defensive captain of his Florida A&M football team -- end up in such an arcane field? "My dad was always giving me thinking problems," Childs said. "He'd say, 'Use your brain, figure things out.' I found that physics gave me the tools to understand how the world around me works. "I just love the science." [Minneapolis Star Tribune, Aug 16] Black jocks do have a life after football. SBIR barely helped with about $1.5M since 1993: 10 Phase 1s and 1 NASA Phase 2.
Tmunity Therapeutics (Philadelphia, PA; no SBIR), in pursuit of its vision to save and improve lives by delivering the full potential of next-generation T-cell immunotherapy, closed a $75 million Series B financing. [conpany press release, Oct 31, 19]
Tmunity (Philadelphia, PA; no SBIR) announced an additional $35 million Series A investment [which] brings the total Series A financing to $135 million. Tmunity is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body. [company press release, Apr 19, 18]
Tmunity (Philadelphia, PA; no SBIR) focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced the closing of a $100 million Series A financing. Syndicate investors include Ping An Ventures (Chin) ... developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body. ... to advance and expand the business and operational structure of Tmunity to support the rapid translation, development and manufacture of its portfolio of novel T cell based immunotherapies, first for the treatment of cancer [company press release, Jan 23, 18] .. ... $10 Million in equity financing from Penn Medicine, the academic medical center of the University of Pennsylvania (Penn), and Lilly Asia Ventures [company press release, Jan 12, 16]
Tobira Therapeutics (South San Francisco CA; no SBIR) up 720% [Sep 20, 16] Allergan PLC said it agreed to acquire Tobira Therapeutics, a biopharmaceutical company that develops therapies for liver diseases, in a deal worth as much as $1.7 billion, or 19 times Tobira’s previous market value. [Tess Stynes, Wall Street Journal, Sep 20, 16]
Tmunity Therapeutics (Philadelphia, PA; no SBIR) developer of “products to unleash the immunological potential of T cells to treat a wide range of disease indications,” has raised $10 million in new equity funding from Penn Medicine (academic medical center of the University of Pennsylvania) and Lilly Asia Ventures. [philadelphiapact.com/, Jan 19, 16]
Tobira Thera down 60% [Jul 25, 16] after the company said a Phase 2b trial of its liver disease treatment missed its primary endpoint. [Dow Jones Newswire, Jul 25, 16]
Tobira Thera down 12% [Aug 31, 15]
Tobira Therapeutics (South San Francisco, CA; no SBIR) which last summer pulled out of a planned $74 million IPO, will merge with Regado Biosciences (Basking Ridge, NJ; one SBIR) with the combined company working out of South San Francisco on the fatty liver disease known as NASH (non-alcoholic steatohepatitis). [Ron Leuty, San Francisco Business Times, Jan 14, 15]
The IPO window is still open, sort of, but life sciences companies are not getting through unscathed. Tobira Therapeutics (San Francisco, CA; no SBIR) and Microlin Bio (New York, NY; no SBIR) postponed their offerings after T2 Biosystems (Lexington, MA; no SBIR) and Switzerland’s Auris Medical slashed the terms of their Nasdaq IPOs this week. [Bruce Bigelow, xconomy.com, Aug 7, 14]
A trio of Bay Area life sciences companies — Tobira Therapeutics (South San Francisco, CA; no SBIR, founded 2006, backed by Danish drug developer Novo A/S ), Zosano Pharma (formerly Macroflux, Fremont, CA; no SBIR, founded 2006) and IntersectENT (Menlo Park, CA; no SBIR) — will seek more than $200 million in upcoming IPOs. [Ron Leuty, San Francisco Business Times, Jun 24, 14]
Tocagen [San Diego, CA; $500K SBIR, and Forte Biosciences (Torrance, CA; np SBIR), a clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced today that they have entered into a definitive agreement under which Tocagen will merge with Forte in an all-stock transaction. The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis. [joint companies press release, Feb 19, 20]
Tocagen (San Diego, CA; $500K SBIR) announced a restructuring to focus its resources on the clinical development of Toca 511 and Toca FC ... will reduce its workforce by approximately 65% [company press release, Oct 3, 19]
Tocagen (San Diego, CA; $500K SBIR) down 77% [Sep 12, 19] announced that the Toca 5 Phase 3, randomized, multi-center clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma (HGG) undergoing resection missed the primary endpoint of overall survival compared to standard of care treatment (11.1 months median compared to 12.2 months, HR=1.06, p=0.6154). In addition, all secondary endpoints showed no meaningful difference between the arms of the trial. The safety, tolerability and adverse event profile of Toca 511 & Toca FC was as expected for this patient population. [company press release, Sep 12, 19]
Tocagen up 16% [Jun 12, 19]
Tocagen up 21% [May 30, 19]
Tocagen down 39% [May 22, 19] announced the Toca 5 Phase 3 clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma (HGG) continues without modification following a planned interim analysis of data conducted by an Independent Data Monitoring Committee (IDMC). [company press release, May 21, 19]
Tocagen up 11% [Oct 9, 18]
Tocagen down 14% [Oct 3, 18]
Tocagen (San Diego, CA; $500K SBIR) up 11% [Sep 10, 18]
Tocagen (San Diego, CA; $500K SBIR, founded 2007) reported a deal that gives Beijing-based ApolloBio an exclusive license to its gene therapy treatment for a deadly type of brain cancer. ApolloBio agreed to make a $16 million upfront payment to Tocagen, with another $4 million to come in “near-term” milestone payments. Tocagen has granted ApolloBio rights to commercialize its two-part treatment in mainland China, Hong Kong, Macao, and Taiwan. The experimental treatment is currently being tested in a global late-stage clinical trial. Tocagen said it also would be eligible under its deal with ApolloBio for additional future payments totaling $111 million, which depend on meeting unspecified development and commercial milestones. [Bruce Bigelow, xconomy.com, Apr 20, 18] total funding $268M [crunchbase.com]
Tocagen up 10% [Jan 19, 18]
Tocagen up 12% [Nov 27, 17]
Tocagen down 12% [Oct 6, 17]
Tocagen up 11% [May 1, 17]
Tocagen (San Diego, CA; no SBIR) up 25% [Apr 13, 17] raised $85 million in its stock market debut ... Tocagen’s gene therapy uses two components that come together in the brain and work to get cancer cells to produce anti-cancer compounds. [Frank Vinluan, xconomy.com, Apr 13, 17]
Tocagen (San Diego, CA; no SBIR) biotech developing gene therapy treatments for gliomas and other terminal cancers, has raised about $8.5 million of a planned $15.7 million investment round, according to a regulatory filing [Alex Lash, xconomy.com, Jul 10, 14]
Several life sciences startups in the San Diego area have received funding in recent weeks. Auspex Pharmaceuticals raised $3 million, Aethlon Medical raised $600,000, and Tocagen got $3 million. [Bruce Bigelow, signonsandiego.com, Mar 12, 10]
Tokai Pharmaceuticals (Cambridge, MA; no SBIR) said that the [FDA] has granted fast-track status for its lead drug candidate, a potential treatment of metastatic castration-resistant prostate cancer. [Chris Reidy, Boston Globe, Jun 12] focused on developing new treatments for prostate cancer. ... has now raised a total of $57 million since its founding in 2004 [company website]
Tokai Pharmaceuticals (Cambridge, MA; no SBIR) has raised an additional $23 million in financing ... to support the ongoing clinical development of galeterone, the company’s lead drug candidate, a potential treatment for patients with castration resistant prostate cancer, Tokai said. [Chris Reidy, Boston Globe, Sep 20, 11]
Tokai Pharmaceuticals (Cambridge, MA; no SBIR) has raised $12 million in an equity finance round, according to official documents. ... founded by Cambridge-based venture capital firm Apple Tree Partners, seeks to in-license and develop endocrine-based drugs to treat diseases such as cancer. Now, according to recent U.S. Securities Exchange & Commission documents, the firm has raised $12 million of a $22 million equity-financing round. [Mass High Tech, May 8, 09]
Tolerx (Cambridge, MA; no SBIR) biopharmaceutical company that looks to develop drugs by modulating T cell activity, announced the start of a confirmatory Phase 3 clinical trial to further evaluate the drug candidate otelixizumab as a potential treatment for autoimmune new-onset type 1 diabetes. [Boston Globe, Jun 28, 10]
AeroVironment (Arlington, VA; $20M SBIR) has agreed to buy Tomahawk Robotics (Melbourne, FL; $1.1M SBIR) , a developer of artificial intelligence-based command and control systems, for $120 million in cash and stock. [Naomi Cooper, govconwire, Aug 23, 2023]
Accuray (Sunnyvale, CA; $1.2M SBIR) said it will buy TomoTherapy (Madison, WI; $1M SBIR) for $277 million ( a 30% premium) in a deal that unites two companies that make radiation therapy systems. [Marley Seaman, AP, Mar 7, 11] Tomo rose 25%; Accuray fell 10%
TomoTherapy up 11% [Nov 16, 09]
Tomo Therapy down 11% [Oct 28, 09]
TomoTherapy up 12% [Aug 11, 09]
Tomo Therapy up 11% [Jul 31, 09]
Tomo Therapy down 10% [May 13, 09]
TomoTherapy said that it is restating its financial statements for 2008 and that its previously reported results should not be relied upon because of errors relating to the accounting for income taxes. [Milwaukee Journal-Sentinel, Apr 21, 09]
TomoTherapy reported a net loss on lower sales for 2008 and expects to post a loss on lower or flat sales this year. [Milwaukee Journal Sentinel, Feb 12, 09]
TomoTherapy up 10% [Feb 3, 09]
TomoTherapy down 11% [Jan 27, 09] >
Tomo Therapy up 12% [Jan 23, 09]
TomoTherapy up 12% [Jan 21, 09]
Tomo Therapy up 15% [Dec 12, 08]
Tomo Therapy down 15% [Dec 11, 08]
Tomo Therapy up 20% [Dec 3, 08]
Tomo Therapy up 19% [Dec 2, 08]
An investor in TomoTherapy is publicly urging the company's board to actively consider strategic options for the company, even a possible sale, in the wake of the firm's plunging stock price. .. from a high of about $26 in September 2007 to Monday's closing price of $2.56 a share. ... the niche nature of the company's single product and limited installed customer base. Avalon is pushing the board to instead focus on boosting shareholder value via the outright sale of the company, a joint venture or a licensing deal. [Business Journal of Milwaukee, Nov 18, 08]
TomoTherapy up 11% [Oct 30, 08]
TomoTherapy down 11% [Oct 24, 08]
TomoTherapy down 14% [Oct 22, 08]
TomoTherapy up 34% [Oct 20, 08]
TomoTherapy up 14% [Oct 16, 08]
TomoTherapy down 10% [Oct 15, 08]
Tomotherapy down 11% [Oct 8, 08]
Tomotherapy down 11% [Oct 8, 08]
TomoTherapy rose as much as 12% after it said the U.S. Food and Drug Administration approved its TomoDirect technology, a complement to its Hi-Art radiation therapy system. [Milwaukee Journal-Sentinel, Aug 28]
TomoTherapy down 49% [Aug 1, 08] after it reported a net loss of $6.9 million in the second quarter, a sharp increase from comparative results a year ago, and said it was removing $53 million in orders from its backlog. [Business Journal of Milwaukee]
TomoTherapy surprised Wall Street by lowering its guidance for results in the first quarter and for the year. The Madison maker of radiation therapy systems said longer-than-expected timeframes on certain installations and sluggish European sales have it anticipating revenue of $255 million to $290 million and earnings per share in the range of 14 cents to 33 cents for the year. [Milwaukee Journal-Sentinel, Apr 18, 08] down 32%
Cashing In. Existing shareholders of TomoTherapy will sell $180M worth of their shares next week which is about 15% above the IPO price. [Milwaukee Journal-Sentinel, Oct 12]
TomoTherapy (Madison WI; one Phase 2 SBIR) shares closed down 8% after it announced plans to sell another 10M shares to the public. [Milwaukee Journal-Sentinel, Sep 22]
Tomotherapy which IPO'd May 9,07 is trading about 20% above the IPO price.
Tomotherapy (Middleton WI; one Phase 2 SBIR) might raise as much as $200 million for the 10-year-old maker of what some have called a revolutionary system for delivering radiation to cancer patients ... had nearly 500 employees in December, and it expects to report $50 million to $52 million of revenue for the first quarter, [Kathleen Gallagher, Milwaukee Journal-Sentinel, May 7]
TomoTherapy (Madison WI, one Phase 2 SBIR) filed to go public to raise $200M. It makes a highly precise system (sub-millimeter accuracy) for treating cancer with radiation [Rick Rommel, Milwaukee Journal-Sentinel, Feb 13]
Moving to the assets. Tone Tree (Troy, NY; no SBIR) startup that can make a musical instrument out of any surface started its first week at an Intel accelerator for education technology startups [joining eight companies] in Redwood City, CA. , founded by four Rensselaer Polytechnic Institute students, develops a laser and camera sensor device that turns any table into a musical instrument. ... The accelerator will put Tone Tree in front of major investors and will earn the company up to $100,000 from Intel Capital. [Chelsea Diana, Albany Business Review, Aug 4, 15]
Topia Technology (Tacoma, WA; $800K SBIR, founded 1999, 22 employees)’s chief product, Secrata, was developed in government environments to become an ultra-secure file-encryption system ... Secrata is a data-security platform that “shreds” a file into numerous smaller pieces, uniquely encrypts each piece and transfers it along networks to devices, cloud storage or other locations. Secrata provides the encryption keys to the enterprise alone. ... About 18 months ago, Topia decided to commercialize a standardized yet flexible version of its [government] technology. ... recently raised $5.5 million in a Series B round of funding, bringing the total raised to $15 million [Jason Axelrod, Seattle Times, Jun 30, 15]
Topical Remedy LLC [Lake Oswego, OR; SBIR) raised $500,000 from angel investors as it prepares for another clinical trial to test its treatment for cold sores, according to [SEC] filing ... expects it will be another four years before the over-the-counter product is on pharmacy shelves. [Elizabeth Hayes, Portland Business Journal, Jul 22, 16]
startup Topokine Therapeutics (Boston, MA; no SBIR) is announcing that it is starting Phase 2 clinical trials of a topical gel that could combat the dreaded double chin. Topokine hopes its gel will be an alternative to cosmetic surgery for some people — if it can win FDA approval. .... will likely compete with [publicly-traded] Kythera Biopharmaceuticals (Calabasas, CA; no SBIR) that is developing a drug for submental fat. But Kythera's drug is delivered via injection. [Scott Kirsner, Boston Globe, Nov 20, 13]
ninth round for Torax Medical (Shoreview, MN; no SBIR) which makes treatments for digestive, incontinence and obesity disorders, attracted $25 million. [Patrick Kennedy, Minneapolis Star Tribune, Oct 14, 16]
Long-time Mayo Clinic Ventures portfolio company Torax Medical (Shoreview, MN; no SBIR, founded 2002) completed its biggest equity financing round yet [$25 million Series E] led by Johnson & Johnson], with the VC arm of the Rochester health care giant again taking part. .... Both the fecal incontinence device and Torax’s device for GERD, called LINX, are based on its technology of small bands of interlinked magnetic titanium beads that use their attraction to mimic the functions of the anal sphincter in the case of fecal incontinence, and of the esophageal sphincter in GERD patients. [Don Jacobson, Twin Cities Business, Aug 10, 16]
Acid-reflux fighting startup Torax Medical (Shoreview, MN; no SBIR) raises $25M [Katharine Grayson, Minneapolis / St. Paul Business Journal, Jul 25, 16] a small flexible band of interlinked titanium beads with magnetic cores [laproscopically inserted around esophagus]. The magnetic attraction between the beads is intended to help the LES resist opening to gastric pressures, preventing reflux from the stomach into the esophagus. LINX is designed so that swallowing forces temporarily break the magnetic bond, allowing food and liquid to pass normally into the stomach. ... developing a similar ring for the rectum. [company website]
Venture-capital investment in Minnesota companies rebounded in the third quarter, with med-tech firms leading the way. The state’s startups raised at least $100 million during the quarter, though that figure includes a $20 million round for Mainstay Medical (no SBIR) — a device firm that plans to move its from the Twin Cities to Dublin, Ireland. .... Torax Medical (Shoreview, MN; no SBIR) announced it pulled in $30 million,plans to use the funds to boost marketing of its device for treating acid reflux disease. and Segetis (Golden Valley, MN; no SBIR) “green” chemistry company. raised a $25 million round led by the venture-capital arm of Saudi Arabia-based manufacturing giant Saudi Basic Industries Corp.[Katherine Grayson, Minneapolis /St Paul Business Journal, Oct 12, 12]
Torque Therapeutics (Cambridge, MA; no SBIR) biotech startup developing immunotherapies for cancers, raised $38.3M in a funding round, according to an SEC filing. [Sri Kalyanaraman, BostInno, Jul 17, 19] earlier announced that [FDA] granted Fast Track designation for Torque’s first Deep-Primed™ T cell immunotherapy program, TRQ-1501 (Deep IL-15 Primed T cells) [company press release, Jun 19, 19]
Flagship Pioneering’s quiet oncology upstart Torque Therapeutics (Cambridge, MA; no SBIR) has filed a $21 million raise. .... According to its SEC form picked up by the Boston Business Journal, the company has raised just shy of $21 million, with $35 million in total on the cards. [Ben Adams, Fierce Biotech, Aug 30, 17] Torque is developing approaches to overcome these barriers [a host of immunosuppressive signals coming from the tumor microenvironment] to effective and durable cancer immunotherapy. Our Deep-Priming platform is based on more than 10 years of research and development focused on taking very potent immunomodulatory drugs—cytokines, antibodies, and small molecules—that have the ability to activate and protect T cells from this “hostile” tumor microenvironment. [company website]
Total Immersion [Los Angeles, CA $1M SBIR) got $5.5M new funding ... has been focusing on developing the most scalable and reliable Augmented Reality platform and industrialised it for massive rollouts in the Tier 1 consumer market. [xconomy.com, Mar 24, 11]
[small biz] Total Technology (Baltimore, MD; no SBIR), Pioneering Decisive Solutions (California, MD; $4.5M SBIR in management software) and Logisys Technical Services (Huntsville, AL; no SBIR) have landed spots to compete for task orders under a potential five-year, $125 million U.S. Army contract for test and support services. [Nichols Martin, GovConWire, May 22, 18]
ThermoGenesis (Rancho Cordova, CA; $500K SBIR) is paying $18.6 million to buy TotipotentRx (Los Angeles, CA; no SBIR) that specializes in cell-based therapy. ... Totipotent is the exclusive provider of cell-based product and services to Fortis Healthcare System, which is an integrated healthcare system that operates in 11 countries. ... ThermoGenesis develops and sells technologies for processing and storing stem cells and tissue. ... The combined company will take on a new name, Cesca Therapeutics [Mark Anderson, Sacramento Business Journal, Jul 16, 13]
Totus Solutions (Austin, TX; no SBIR) reported raising $7.8 million of a planned $10.4 million financing. according to [SEC[ filing .... founded in 2009 as Totus Lighting Inc., develops products that appear to be outdoor lighting but also include surveillance technology. It employed 25 workers more than a year ago. [Christopher Calnan, Austin Business Journal, Oct 14, 13]
Toyon Research (Goleta, CA; 424 SBIR awards for about $130M from DOD 1986-2018) was one of Four companies have received five-year, cost-plus-fixed-fee contracts worth $49.8M combined to help the U.S. Navy develop, test and deploy intelligence, surveillance, reconnaissance and targeting platforms. [Jane Edwards, GovConWire, Jun 26, 19] latest listed award Person-Centered Planning ToolKit: Development of an Application to Improve Workforce Participation Through Team Collaboration and Customized Employment Discovery Technology. In nature and government, every new species triggers the rise of species specializing in feeding on it.
TP Therapeutics (San Diego, CA; no SBIR, founded 2013) precision oncology company developing novel drugs that address treatment resistance, announced its completion of an $80 million round of mezzanine financing [to] to advance its lead product candidate, Repotrectinib (TPX-0005), into a Phase 2 potential registration study in early 2019 for ROS1-positive non-small cell lung cancer (NSCLC) and NTRK-positive solid tumors ... founded by Dr. J. Jean Cui, the lead inventor of Pfizer’s oncology drugs crizotinib and lorlatinib [company press release, Oct 19, 18] prior funding $64M [crunchbase.com]
Genomics startups are increasing in number and quality, so much so that three-year-old Illumina Accelerator has expanded with its latest class to accommodate five of them. ... provides genomics-focused startups with capital, lab space at Illumina Accelerator’s offices in San Francisco, access to Illumina’s sequencing equipment and expertise, and advice on developing a business from legal experts, recruiting professionals, and Illumina executives and scientists, says Amanda Cashin, co-founder and head of the accelerator. ..... takes an 8 percent equity stake .. Checkerspot: designing advanced physical materials that can be used in industrial applications; Chimera Bioengineering: aims to improve the efficacy and reduce the side effects of engineered cell therapies for oncology; Encompass Bioscience: wants to integrate genetic information into the healthcare system; Mantra Bio: studies exosomes, small lipid vesicles that are excreted from cells and deliver information, aiming to discover new drug targets and therapies; Solarea Bio: The only company not from the Bay Area, Boston-based Solarea is developing probiotic treatments that are derived from natural sources .... Of the previous 13 startups that have completed the program since 2014, a few have already made some funding splashes. Xcell Biosciences (San Francisco, CA; no SBIR) develops a type of cell culture that can be used in certain types of cell propagation and gene editing, raised a $12 million Series A round of funding in February. EpiBiome (South San Francisco, Ca) raised a $6 million seed Series A round of funding for its process of engineering microbiomes that might be used against drug-resistant bacteria in early 2016. Trace Genomics (New York) raised a $4 million seed round in mid-2016 for its work sequencing and analyzing the genomes of soil. [David Holley, xconomy.com, Jul 26, 17]
Tracon Pharmaceuticals (San Diego, CA; no SBIR; TCON, founded 2008), to develop new drugs for cancer, age-related macular degeneration and fibrotic diseases, raised $36 million through an IPO. Tracon’s lead product candidate is an antibody aimed at treating various solid tumors. [Alex Lash, xconomy.com, Feb 6, 15]
Tracon Pharmaceuticals (San Diego, CA; no SBIR) says today it has raised $14 million of a planned $22 million round of venture capital needed to advance development of TRC105, a promising therapeutic that inhibits the growth of new blood vessels that supply tumors. The National Cancer Institute also is supporting the company’s research and development, which includes ongoing trials in prostate, bladder, and liver cancer. [Bruce Bigelow, xconomy.com, Apr 20, 11]
Trailhead Biosystems (Beachwood, Ohio; one SBIR) has completed a $10 million fundraise to accelerate its growth as a maker of specialized human cells used in medical research. [Mary Vanac, Cleveland Inno, October 11, 2022]
Tranquis Therapeutics (San Mateo, CA; no SBIR) launched with $30 million in Series A funding committed to the discoveryand development of innovative medicines with the potential to revolutionizethe management of neurodegenerative and aging-related diseases [conpany press release, Jul 9, 20]
<1 END TRANQUIS THERA -->TranS1 (Wilmington NC; no SBIR) did an $82M IPO after which the shares jumped 60%. ... focused on developing innovative, minimally invasive surgical procedures for treatment of low back pain (LBP). [company website]
NASA Mimics SBIR. Invests in 18 Potentially Revolutionary Space Tech Concepts. Phase I $125K; Phase II $500K All projects are still in the early stages of development, most requiring a decade or more of concept maturation and technology development. A few awards to small biz: among new selections 3DeWitt LLC, Ancramdale, NY, no SBIR; TransAstra Corporation, , no SBIR; Howe Industries LLC, Tempe, AZ, no SBIR [NASA press release, Apr 10, 19]
Transatomic Power, an MIT spinout that drew wide attention and millions in funding, has announced it's winding down today. High hopes: Transatomic, founded in 2011, once claimed its technology could generate electricity 75 times more efficiently than conventional light-water reactors, and run on their spent nuclear fuel. But in a white paper published in late 2016, Transatomic backed off the latter claim entirely and revised that 75 times figure to “more than twice,” a development first reported by MIT Technology Review. [James Temple, MIT Tech Rvw, Sep 25, 18]
Money for science, again. Vestaron (Kalamazoo, MI; no SBIR, founded 2001) makes an eco-friendly pesticide derived from spider venom. Bagaveev (San Mateo, CA; no SBIR) uses 3-D printers to make rocket engines for nanosatellites. ... raised just $535,000 in seed funding in April from a group of investors to develop reusable launchers that can send a satellite weighing up to 22 pounds into space ... Transatomic Power (Cambridge, MA; no SBIR,founded in 2011 by [MIT] nuclear scientists ) is developing a next-generation [small-scale molten-salt reactors] that could generate reliable, clean energy without creating nuclear waste.reactor. [All] have one money from Silicon Valley [VCs]. .... After years of shying away from science, engineering and clean-technology start-ups, investors are beginning to take an interest in them again, [with] a sense that the field of consumer Internet companies has become impossibly crowded. [HIROKO TABUCHI , New York Times, OCT. 12, 2014]
Transcend Medical (Menlo Park, CA; no SBIR) has raised $22 million in Series C funding as it develops devices used to treat glaucoma. .... said the money came from an undisclosed "global pharmaceutical and medical device company" ... will support completion of a trial for its stent that is implanted in glaucoma [affects 65 million people worldwide] patient's eyes using micro-surgery. [Cromwell Schubarth, Silicon Valley Business Journal, Apr 2, 14]
[Minnesota] venture capital firm Split Rock Partners participated in a $51 million investment round for a California medical device firm. Transcend Medical (Menlo Park, CA; no SBIR) said it will use the money for the U.S. pivotal study of its CyPass Micro-Stent, a device inserted into the eye that may reduce or eliminate the need for glaucoma medications. The investment will also go toward international clinical trials and product development. [Wendy Lee, Minneapolis Star Tribune, Jul 15, 11]
Paratek Pharma (Boston, MA; $3.8M SBIR) up 29% [Oct 31, 14] completed merger with Transcept Pharmaceuticals (Point Richmond CA; no SBIR)
Transcept Pharmaceuticals (Richmond, CA; no SBIR) would use some of the $37.6 million it hopes to net from a public stock offering to sell its FDA-approved middle-of-the-night sleep drug and to move forward with a drug for obsessive compulsive disorder. [Ron Leuty, San Francisco Business Times, Apr 26, 12]
TransCorp (Byron Center,MI; no SBIR) has raised $755,958 from the sale of equity, according to SEC documents. Overall, the medical device startup is seeking $4 million. ... Founded by an orthopedic surgeon, TransCorp makes devices that help treat the compression of the cervical spine. The company has already received approval from the Food and Drug Administration for its Anterior Cervical Fusion Plate System and PEEK Cervical Interbody Fusion implants. [Thomas Lee, xconomy/com/detroit, May 16, 11]]
Many of Transcriptic (Menlo Park, CA; no SBIR, founded 2012) [biofoundry] customers are small, newly founded firms that cannot afford their own test facilities. One such, Pliant Therapeutics (Redwood City, CA; no SBIR, founded 2016, total funding $45M [crunchbase.com]), is using Transcriptic to test treatments for fibrotic disease—the formation of scar tissue in places like the lungs and the heart. Large, established firms use its facilities, too, though. It is often cheaper for them to do so than to carry out tests in house. ... Similar biofoundries are being set up around the world, from the Broad Institute in Cambridge, Massachusetts, via Silicon Valley, to the National University of Singapore. [The Economist, Mar 3, 18]
TransEnterix up 38% [Feb 10, 21]
TransEnterix (Research Triangle Park, NC; no SBIR)up 62% [Jan 19, 21] a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced the Company received CE Mark approval for the Intelligent Surgical Unit(TM) (ISU(TM) ) that enables machine vision capabilities on the Senhance Surgical System. This approval will provide Senhance digital laparoscopic programs in Europe access to this new technology, ushering them to the forefront of surgical innovation utilizing augmented intelligence. [company press release, Jan 19, 21]
TransEnterix received FDA clearance for its “digital surgical assistant,” which it describes as the first machine vision system for robotic surgery. [Conor Hale, Fierce Biotech, Mar 13, 2020]
TransEnterix down 39% [May 10, 19] reported financial results
TransEnterix down 22% [Oct 24, 18]
TransEnterix down 10% [Oct 10, 18]
TransEnterix received a CE mark to add ultrasonic instruments to its Senhance digital robotic surgery platform, broadening the system’s use to different minimally invasive procedures. [Conor Hale, Fierce Biotech, Oct 1, 18]
TransEnterix that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, announced that it has acquired substantially all of the assets of MST Medical Surgery Technologies Ltd. (Israel) in a cash and stock transaction [for] approximately $5.8 million in cash and 3,150,000 shares of TransEnterix common stock. The second tranche of $6.6 million, payable in cash or stock, is to be paid within one year. [company press release, Sep 26, 18]
TransEnterix down 12% [Aug 7, 18]
TransEnterix down 11% [Jun 29, 18]
TransEnterix down 16% [Jun 28, 18]
TransEnterix up 10% [Jun 27, 18]
TransEnterix up 23% [Jun 22, 18]
TransEnterix down 10% [Jun 4, 18]
Surgical robot maker TransEnterix (Research Triangle Park, NC; no SBIR) announced that it has received FDA 510(k) clearance for expanded indications of its Senhance Surgical System. [company press release, May 29, 18] earlier announced that it has entered into a debt financing agreement to provide up to $40.0 million in term loans.[company press release, May 23, 18]
TransEnterix Announces Global SurgiBot System Agreement .... sells SurgiBot assets to advance commercialization Company retains option to distribute SurgiBot outside of China Company expected to receive at least $29 million [company press release, Dec 18, 17]
TransEnterix, pioneering robotics to improve minimally invasive surgery, announced that Florida Hospital entered into an agreement to purchase the Company's Senhance™ Surgical Robotic System. ... the first commercial unit of the Senhance Surgical System tobe installed in the United States. [company press release, Nov 13, 17]
TransEnterix – which received [FDA] clearance for its Senhance surgical robot just last month – is expecting its first sale in the U.S. by the end of 2017. [Jennifer Henderson, Triangle Business Journal, Nov 9, 2017]
TransEnterix up 11%[Nov 13, 17]
TransEnterix up 13%[Oct 20, 17]
Transenterix up 42% [Oct 17, 17]
Transenterix
up 93% [Oct 16, 17] after
the company gained FDA clearance for its Senhance surgical robot. The
company was
previously denied clearance from the FDA for its SurgiBot System back
in April 2016. According to the company, Senhance is now the
first new market entrant in abdominal surgical robotics since 2000,
when Intuitive Surgical, gained clearance for its
da Vinci Surgical System. [Wayne Duggan
Benzinga, Yahoo
Finance, Oct 16, 17] Meanwhile, Intuitive
Surgical purchased a 60,000-square-foot building in the Triangle
Business Center in Durham [NC] for just shy of $6 million.
[Jennifer Henderson, Triangle Business Journal, Oct 16, 17]
TransEnterix announced it applied for U.S. approval of its Senhance surgical robot and that it raised enough cash to get it through the year, but its shares plummeted as investors apparently focused on the negatives that come with the company’s latest public offering. [Raleigh News & Observer, Apr 28, 17]
surgical robotics maker TransEnterix (Morrisville, NC; no SBIR) reported a small revenue stream [$53K] in the fourth quarter as the company looks to sell a third surgical robot in Europe. ... sold its second robot, called the Senhance, to a German hospital in February [John Murawski, Raleigh News & Observer, Mar 6, 17]
TransEnterix plans to focus on getting its ALF-X robot approved in the United States, but the company has not given up on its goal of winning regulatory approval for its SurgiBot robot. [Raleigh News & Observer, Aug 5, 16]
TransEnterix (Morrrisville, NC; no SBIR), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced the first global sale of its ALF-XⓇ Surgical Robotic System to Humanitas Hospital in Milan, Italy. [company press release, Aug 2, 16]
TransEnterix laid off a third of its staff in the aftermath of the [FDA] rejection of the company’s SurgiBot robotics technology, the company reported [John Murawski, Raleigh News & Observer, May 11, 16]
TransEnterix down 15% [Apr 22, 16]
TransEnterix down 52% [Apr 21, 16]
robotics developer TransEnterix said that federal regulators rejected the company’s application to manufacture and sell a surgical robot it has been developing for the U.S. market. .... The surgical robot industry has been dominated by a single surgical robot, called the [Intuit Surgical's] da Vinci system, for about 15 years. [John Murawski, Raleigh News & Observer, Apr, 20, 16]
TransEnterix down 10% [Apr 18, 16]
TransEnterix up 10% [Apr 6, 16]
Transenterix up 10% [Apr 5, 16]
TransEnterix up 10% [Mar 9,16]
surgical robot developer TransEnterix (Research Triangle Park, NC; no SBIR) will look to raise as much as $44 million from the public markets in the coming months. [Jason deBruyn, Triangle Business Journal, Feb 12, 16] secured $55 million in a second round of institutional financing in 2009 and $15M in 2011 and $50M IPO [company press releases]
surgical device manufacturer TransEnterix (Morrisville, NC; no SBIR) acquired the surgical robotics division of Sofar S.p.A., an Italian health care company, in a deal that could be worth $100 million. Sofar developed the Telelap ALF-X robotic system for minimally invasive surgery, which TransEnterix will combine with SurgiBot, the surgical robot it developed. ... In June, TransEnterix raised $50 million from public markets to help launch a sales effort. The company reported having $71 million in cash and equivalents as of June 30. As it has been primarily a research and development stage company, TransEnterix has not generated significant revenue. ... Since inception, TransEnterix has accumulated deficit of $155 million [Jason deBruyn,Triangle Business Journal, Sep 21, 15]
TransEnterix (Research Triangle Park, NC; no SBIR) surgical robot developer, plans to go back to the public markets to raise money in anticipation of a new product launch. ... The SurgiBot System is a patient-side, robotically enhanced laparoscopy platform, assisting surgeons who perform minimally invasive surgeries. [Jason deBruyn, Triangle Business Journal, Jun 9, 15]
surgical device developer TransEnterix ( Research Triangle Park, NC; no SBIR) extended an agreement with Oxford Finance and Silicon Valley Bank to borrow up to $25 million. ... lead product is called the SurgiBot system, a minimally invasive surgical robotic system that allows the surgeon to be patient-side within the sterile field. [Jason deBruyn, Triangle Business Journal, Sep 30, 14]
TransEnterix (Research Triangle Park, NC; no SBIR, founded 2006) will not have to test its surgical robot in humans before filing for approval with FDA, meaning it hopes to sell the medical device as early as 2015. ... says the $53 million raised through a public offering in April will be enough to complete development and begin commercialization of the SurgiBot system. ... [Jason deBruyn, Triangle Business Journal, Aug 7, 14] founded under the auspices of Synecor, a privately held business accelerator .... raised $21M in 2007 [company website]
surgical
robotics developer TransEnterix
(Morrisville, NC; no
SBIR) raised $52 [by
IPO]
.... for research and development, sales and marketing, and
commercialization related to its SurgiBot system [which] builds on the
Spider surgical robot [Jason deBruyn, Triangle Business
Journal,
May 5, 14]
TransEnterix (Morrisville, NC; no SBIR) took a step out of the shadows this week and now set its sights on FDA approval and a commercial launch of a new medical device its CEO says will expand the robotic surgery market. ... moved off the OTC Bulliten Board and to the New York Stock Exchange .... founded in 2007 and developed the Spider surgical robot. TransEnterix sold 3,500 of the single-use devices .... will charge $500,000 for the SurgiBot, well below the $1.2 million to $2 million the da Vinci costs [Jason deBruyn, Triangle Business Journal, Apr 17, 14] priced its public offering [to] meaning net roughly $46 million. [Apr 15, 14]
Transenterix (Research Triangle Park, NC; no SBIR) the surgical technology company that last week closed on a $2 million debt round, is merging with SafeStitch Medical (Miami, FL; no SBIR, founded 2006). ... [to] "enhance our ability to bring our innovative robotic surgery platform to market,” [Lauren Ohnesorge, Triangle Business Journal, Aug 14, 13]
TransEnterix (Research Triangle Park, NC; no SBIR) is developing what it’s calling “SurgiBot,” and it is officially in preclinical testing. .... a robotic single-site surgical platform that is mobile, provides high-definition 3D vision and also allows a human surgeon to stay at the patient’s side. ..... has more than $75 million in total funding, hopes to nab market clearance from the FDA in 2014. [Lauren Ohnesorge, Triangle Business Journal, Jun 24, 13]
TransEnterix (Morrisville, NC; no SBIR) says its innovative system for minimally invasive surgeries has won regulatory approval for sale in the European Union ... founded in 2006 and has raised $75 million in venture capital [David Ranii, Raleigh News & Observer, Oct 20, 10]
TransEnterix (Durham, NC; no SBIR) is poised to begin selling its first products after obtaining all of the necessary regulatory approvals for its new surgical system and finding new space to assemble them. ... leased 37,000 square feet of space in Morrisville's Keystone Technology Park ... founded in 2006, is being fueled by the $55 million it raised in October [David Ranii, Raleigh News & Observer, Jan 19, 10]
Medical device maker TransEnterix (Durham, NC; no SBIR) landed $55M in a second round of venture-capital funding ... to bring its surgery technology to market next quarter and hire some 50 new employees over the next 14 months. [Triangle Business Journal, Oct 7, 09]
A young, fast-growing medical device company has raised $55 million in venture-capital financing, TransEnterix (Durham, NC; no SBIR) will use the money to manufacture and market a device that promises scar-free abdominal surgery to repair hernias or remove gall bladders, ovaries and appendixes. [Raleigh News & Observer, Oct 8, 09]
TransEnterix (Durham, NC; no SBIR) raised $21M in VC to chase every surgeon's dream: to cure without cutting.... is a brain child of Synecor, a business incubator that spun out of Duke University seven years ago to turn medical device ideas into money makers. [Sabine Vollmer, Raleigh News&Observer, Jan 8, 08]
Transgenomic (Omaha NE; $200K SBIR) up 13% [Feb 11, 15]
Transgenomic (Omaha NE; two SBIRs, market cap $25M, 171 employees) up 10% [Jan 28, 15]
Qualcomm reduced its outlook for fiscal 2015, saying it expects its newest Snapdragon mobile chip will not be used in a major customer's flagship smartphone. [Noel Randewich, Reuters, Jan 28, 15]
Biotechnology company Clinical Data (no SBIR) said Monday that it has agreed to sell its diagnostic business to Transgenomic (Omaha, NE; $200K SBIR) for at least $15.4 million. [Boston Globe, Nov 30, 10]
Translate Bio down 21% [Jun 26, 20]
Translate Bio up 47% [Jun 23, 20] Sanofi Pasteur (France) and Translate Bio (Lexingon, MA; no SBIR), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to expand their existing 2018 collaboration and license agreement to develop mRNA vaccines for infectious diseases. Translate Bio will receive a total upfront payment of $425 million, ... Translate Bio will also be eligible for potential future milestones and other payments up to $1.9 billion, including $450 million of milestones under the 2018 agreement. Of these potential milestones and other payments, approximately $360 million are anticipated over the next several years, inclusive of COVID-19 vaccine development milestones. [joint companies press release, Jun 23, 20]
Translate Bio down 19% [Jun 3, 20]
Translate Bio up 23% [May 18, 20]
Translate Bio down 19% [Mar 8, 19]
Translate Bio up 27% [Feb 15, 19]
Translate Bio (Lexington, MA; no SBIR), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, announced that the Company has received verbal notification from [FDA] that the Agency has completed its review of the Company’s Investigational New Drug Application (IND) submission for MRT5201 for the treatment of ornithine transcarbamylase (OTC) deficiency and has additional clinical and nonclinical questions. ... The FDA is placing the IND on clinical hold until [certain] questions are resolved.[company press release, Jan 23, 19]
Translate Bio up 24% [Nov 15, 18]
Translate Bio down 10% [Aug 16, 18]
Translate Bio down 12% [Aug 6, 18]
Translate Bio down 10% [Jul 31, 18]
Sanofi paid Translate Bio (Lexington, MA; no SBIR, founded 2011, 58 employees) , a clinical - stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, announced a multi-year R&D collaboration and exclusive licensing agreement [for $805M] with Sanofi to develop mRNA vaccines for up to five undisclosed infectious disease pathogens. [company press release, Jun 14, 18] Its auditor for 2017 gave an unqualified opinion expressing doubt that the company can continue as a going concern. [Bloomberg, Jun 1, 18]
Translattice, (Santa Clara, CA; SBIR) a startup with "geographic database technology" that provides data only where and when it is needed, disclosed that it has raised $10.3 million .... claims its technology cuts costs and simplifies deployment while making database systems more reliable, scalable and faster. [Cromwell Schubarth, Silicon Valley Business Journal, Jun 7, 13] Data and software innovations are almost all inappropriate for SBIR since they are technically easy and pose only a business uncertainty - a role that government should not be funding as a market-failure program. Private finance has the money, the flexibility, and the knowledge of markets. Government intelligence, a big user of data, is excused from SBIR.
United
Therapeutics
(Silver
Spring, MD; no SBIR) has
ambitions
to build an unlimited supply of certain transplantable
organs.
... said the company's new multiyear collaboration —
specifically
with United Therapeutics' transplantation-focused subsidiary, Lung
Biotechnology
PBC — will use patient-specific
biological material, including re-differentiated stem cells, to create
materials for the transplants. The project will be based out of 3D Systems (San
Diego, CA; no SBIR) new
bioprinting lab. ... United
Therapeutics additionally invested $100 million in two rounds, in 2014
and 2016, in Synthetic
Genomics
(La Jolla, CA), a
company started by
scientist J. Craig Venter, to further its own research and development
in its North Carolina facility. The local company also invested $41.8
million in TransMedics
(Andover, MA; no SBIR) that
develops
ex vivo perfusion systems for donor lungs, hearts and kidneys.
[Tina Reed, Washington Business Journal, May 2, 17]
TransMedics (Andover, MA; no SBIR) focused on organ preservation technology, announced the closing of a $36 million financing round ... According to the company, its portable preservation technology maintains donor organs in a near-physiologic and functioning condition from donor to transplant recipient. [Chris Reidy, Boston Globe, Nov 27, 12]
TransMedics (Andover, MA; no SBIR) medical device firm, has raised $2.5 million in a debt offering ... launched in 1998 to provide more effective organ transplant support technologies .... Last December, pulled its [$86M IPO] registration ... has raised more than $90 million in venture capital from 10 different firms [Mass High Tech, Jul 16, 09]
TransMedics (Andover, MA; no SBIR), a medical device company that filed plans to go public in September 2007, has yanked its initial public offering, citing unfavorable market conditions ... So far, there have been 43 IPOs priced this year - including just one since the end of August - compared with 272 last year, according to Renaissance Capital's IPOhome.com. [Todd Wallack, Boston Globe, Dec 17, 08]
Transmeta up 19% [Sep 25, 08] as the maker of software-based microprocessors reached new licensing deals with computer-chip and microprocessor manufacturer Intel. [Wall Street Journal]
Transmeta reviewed a range of strategic options over the past few months and concluded that finding a buyer was the best thing for shareholders, according to a statement today. Separately, Transmeta said it signed agreements to license its patents to Intel for $91.5 million, speeding up payments from an earlier deal. ... once backed by billionaires George Soros and Paul Allen, set out originally to make low-power computer processors chips in competition with Intel, the world's largest semiconductor maker. After failing to win enough market share, the company focused on just licensing its chip designs. [San Jose Mercury News, Sep 24]
Transmeta gained, however. The shares jumped 9.75 to 13.93 after the computer-chip developer struck a licensing deal with Intel, settling all outstanding patent disputes. [WSJ, Oct 25]
Transmeta (Santa Clara, CA; no SBIR (too secret)) fell 18% after the semiconductor company launched a plan for a $12.8 M follow-on share and warrants offering. [Wall Street Journal, Sep 22]
TransMolecular (Cambridge, MA; $1M SBIR) said that the FDA has granted orphan drug designation for a drug candidate that aims to treat Stage IIb-IV melanoma, the deadliest form of skin cancer. [Chris Reidy, Boston Globe, Dec 23, 08] Founded in 1996 on technology originating from the University of Alabama at Birmingham and currently located in Cambridge, MA, TransMolecular is privately held and funded by venture capital, raising $42.8M to date through three private placements[company website]
The FDA granted TransMolecular (Cambridge, MA, originally Birmingham AL; $1M SBIR) its "orphan drug" designation for the non-radiolabeled version of TransMolecular's anti-cancer compound TM601, which is entering clinical trials for the treatment of the brain cancer known as malignant glioma, company officials say. [Mass High Tech, Jan 7, 08]
For 11 years, TransMolecular (Cambridge, MA; $1M SBIR in Alabama) has been working on a promising brain cancer treatment from a substance found in scorpion venom. ... already raised $43 M VC, hopes to raise additional funding as it embarks on pivotal clinical trials. ... one of about three dozen local biotech companies slated to speak at the Massachusetts Biotechnology Council's annual investor conference in Boston ... And ready money is available: According to Ernst & Young, the US biotech industry raised $14B in financing through the first half of the year, putting it on pace to beat the 2006 total by 40%. [Todd Wallack, Boston Globe, Nov 5]
Transphorm (Goleta, CA; $3M SBIR) down 26% Jun 9, 22]
Gallium in the future again. KKR is using its own money to lead a $70 million funding round for the startup Transphorm (Goleta, CA; $600K SBIR) ... developing electronic components using gallium nitride rather than silicon, hoping to save energy ... Yaskawa Electric Corp. in February announced plans to use Transphorm’s components in a solar-power converter that it said is half the size of competing products. ... Meanwhile several other firms are pursuing another gallium future also. Among them, startup Efficient Power Conversion (EPC) (El Segundo, CA; no SBIR) is targeting broader, low-voltage applications for its gallium-nitride transistors. [Don Clark, Wall Street Journal, Jun 22, 15]
TransTech (Schenectady, NY; $2.8M SBIR) will receive the largest part of a $99,976 federal grant to design and test sensors to detect land mines and unexploded ordnance for the U.S. Army. ... Its collaborator on the project, Applied Research Associates (Randolph, VT), will receive $6,450. Trans Tech develops and sells devices that measure the density of soil and pavement. "This is a new use of our current technology," said David Apkarian, TransTech CEO. [Richard D'Errico, The Business Review (Albany), Jun 12, 12] Old stuff in anew place. Of course it's innovation; the DOD says so, and Congress gave the agency unilateral authority to say what SBIR innovation is.
A promising drug targeting Alzheimer's disease and developed by [vTv Therapeutics, formerly TransTech Pharma (High Point, NC; $1.8M SBIR)] is heading into a final phase of clinical trials. The move into Phase 3 testing of azeliragon comes nearly two years after the successful completion of Phase 2 trials during which the drug showed results in slowing cognitive decline among patients with mild or moderate Alzheimer's disease. [Owen Covington, Triad Business Journal, May 20, 15]
A new licensing agreement by TransTech Pharma (High Point, NC; $1.8M SBIR) for one of its cancer treatment programs could mean an infusion of more than $100 million. ... TransTech Pharma and High Point Pharmaceuticals (no SBIR), the sister company spun off from TransTech in 2008, will partner with Calithera Biosciences, a San Francisco-area clinical stage pharmaceutical company, under the new agreement. ... Along with an initial license fee of $600,000 from Calithera, the High Point companies will receive up to $30.5 million for the first licensed product generated by their research and up to $77 million in sales-based milestones and royalty payments once the product hits the market [Owen Covington, Triad Business Journal, Mar 6, 15]
Jobs. A clinical-stage pharmaceutical company and its spinoff company will invest $23M in High Point with plans to create 205 jobs within five years. The majority of the jobs will come from TransTech Pharma (High Point, NC; $1.4M SBIR), and PharmaCore will bring about 50 positions. If TransTech creates all its jobs and sustains them for 12 years, it could receive up to $6.57 M in benefits under the state Job Development Investment Grants program. [Raleigh News&Observer, Dec 21]
Tranzyme (Birmingham, AL; three SBIRs) down 76% [Nov 15, 12]
Evoke Pharma (Solana Beach, CA; no SBIR) down 15% [Jul 19, 16] after announcing a Phase 3 trial on a gastroinetestinal drug for diabetes patients failed to meet its goals. ... Others have had trouble developing a treatment for diabetic gastroparesis, too. In 2012, then-Research Triangle Park, NC-based Tranzyme Pharma (Research Triangle Park, NC; no SBIR), which was acquired by Ocera Therapeutics in a reverse merger in 2013, stopped work on its experimental treatment for the condition after the company’s pill was outperformed by a placebo in a mid-stage clinical trial. [David Holly, xconomy.com, Jul 18, 16]
Drug developer Ocera Therapeutics (Palo Alto, CA, formerly Tranzyme; $400K SBIR in Alabama, 11 employees) could borrow up to $20 million, extending the company’s cash runway into at least mid-2017. ... In 2003, Tranzyme Pharma received $150,000 from the N.C. Biotechnology Center and had raised $146 million, including $54 through an IPO, before this loan. [Jason deBruyn, Triangle Business Journal, Jul 31, 15]
Tranzyme down 10% [Oct 10, 12]
Investors bailed out (down 45%) on Tranzyme Pharma (Durham, NC; no SBIR) after the drug-development company said new test results demonstrated that its most advanced drug candidate performed no better than a placebo. [David Ranii, Raleigh News & Observer, Mar 12, 12] Went public in 2011 to raise $50M.
Tranzyme (Durham, NC; $400K SBIR in Alabama) drug-development company raised nearly $50 million Friday on Wall Street after cutting the size of its proposed IPO to get the deal done. ... is testing a drug that helps restart the body's digestive functions after bowel or abdominal surgeries. Another promising medicine treats a stomach condition that afflicts diabetics. Both represent large potential markets, and Tranzyme has attracted larger pharmaceutical companies as partners, including Bristol-Myers Squibb. But those drugs still require years of expensive clinical trials [Alan Wolf, Raleigh News & Observer, Apr 2, 11]
Three deep-pocketed investors are betting $20M on Transzyme Pharma (Durham NC; no SBIR; 44 employees) that is working on treatments for serious constipation. It's the trio's second large investment in Transzyme in three years. ... targeting gastrointestinal treatments was a calculated decision, Garg said. Few competitors exist for innovative gastrointestinal medicines. [Raleigh News&Observer, Nov 1]
Travecta Therapeutics (New York and Singapore, no SBIR), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier, announces today it has secured US$15 million in its Series A round of financing ... Travecta's mVECTATM proprietary platform is built upon a deep understanding of the Mfs2da transporter protein and its function at the blood-brain-barrier as well as in other key physio-pathological conditions discovered by Dr. David Silver, Professor at Duke-NUS and Scientific Founder of Travecta. [company press release, May 12, 20]
After a few years fine-tuning its investment strategy, Accelerate Long Island has seeded its first group of startups. The nonprofit organization and the Long Island Emerging Technologies Fund announced plans to put $500,000 into five Long Island, NY-based biotech and cleantech startups: Goddard Labs, Green Sulfcrete, PolyNova, SynchroPET, and Traverse Biosciences. [Ben Fidler, xconomy.com, Jun 9, 14] None had SBIR.
Traycer Diagnostic Systems (Columbus, OH; $900K SBIR) closed a $5 million investment round led by a Silicon Valley VC firm to complete the commercial launch of its imaging system using non-harmful terahertz frequencies. ..... technology was developed by physicist Lee Mosbacker while completing his doctoral degree at Ohio State University. The company’s website bills it as “the first real-time, broadband, cost-effective terahertz (THz) camera.” [Carrie Ghose, Columbus Business First, Sep 6, 13]
Trefoil Therapeutics (San Diego, CA; no SBIR, one $500K NIH grant) announced it raised $28 million in an oversubscribed Series A financing. ... is developing novel engineered fibroblast growth factor-1 proteins (eFGF-1) as a regenerative pharmacologic therapy to treat serious corneal endothelial diseases and epithelial disorders. [company press release, Jun 16, 19] prior funding $5M [crunchbase.com]
The Research Institute at Nationwide Children's Hospital in Columbus, Ohio, is accusing biotech Trellis Bioscience LLC (Menlo Park, CA; $500K SBIR) of violating Ohio's trade secrets law by using Children's technology – shared under a confidentiality agreement while discussing a potential partnership – to develop its own treatments. The federal lawsuit's argument is heavy on the biochemistry, but think of the allegation this way: It's as if Children's was trying to hire a ship's crew to help find buried treasure, and instead the crew took a copy of the map to go digging on their own. [Carrie Ghose, Columbus First Business Journal, Dec 8, 15]
Trellis Bioscience (South San Francisco CA, $0.5M SBIR) that monitors cells at the individual level to assess what sort of treatments to give people, said it has raised $10M in a second round of financing. ... Novartis Bioventures led the round [Venture Beat, Feb 14]
Bioplastics company Trellis Earth Products (Wilsonville, OR; no SBIR) [said] it will move part of its overseas manufacturing to its Wilsonville headquarters next year, spending $7 million to make the move. ... has outsourced all of its manufacturing to China in the past. Even under current plans, the company's bag production will remain overseas. But high tariffs and shipping costs... [Molly Young, The Oregonian, Aug 31, 11]
Trethera (Los Angeles, CA; no SBIR), a biotechnology firm raised up to $8 million from investors, according to a securities filing posted March 11. [Dana Bartholomew, LA Business Journal, Mar 11, 19] a preclinical-stage biopharmaceutical company developing cancer treatments for a range of cancers with unmet needs. [company website]
Trevena (Chesterbrook, PA; no SBIR, IPO2014) announced that it has recently submitted its New Drug Application (NDA) for OLINVO™ (oliceridine injection) to [FDA]. [company press release, Nov 2, 17] In October 2009, the company was awarded a $7.65 million Grand Opportunities (GO) grant by the NIH Office of the Director to apply high throughput screening technologies to the search for biased ligands across a set of GPCR targets [company press release, Aug 18, 11]
Trevena (Chesterbrook, PA; no SBIR) announced an update to its strategy to focus its resources on the potential approval and commercialization of OLINVO™ (oliceridine injection) in the United States. With this strategic re-positioning, the Company is halting its investment in early stage research. [conmpany press release, Oct 11, 17]
The CEO of a biotech just released some good news about a pain relief product it’s developing from late-stage clinical trials. Maxine Gowen of Trevena (King of Prussia, PA; no SBIR) told the Philadelphia Business Journal that Olinvo, an opioid that doesn’t have side effects to similar drugs. Investors and analysts are worried that the drug isn’t a significantly different product, causing a stock slide for the company after the trial results were released [Staff, The Business Journals, Feb 23, 2017]
Trevena (King of Prussia, PA; no SBIR, founded 2007) focused on the discovery and development of biased ligands targeting G protein coupled receptors,announced that the company’s TRV027 failed to meet either the primary or secondary endpoints in the Phase 2b BLAST-AHF study in acute heart failure (AHF). The company expects to focus its efforts on its lead Phase 3 oliceridine pain program and its earlier stage programs. [company press release, May 16, 16]
Trevena (King of Prussia, PA; no SBIR, founded 2008) biopharmaceutical company, hopes to raise $63.4 million in a public stock sale this week. ... to complete late-stage testing, submit a new drug application and begin launch preparations for its lead new drug candidate. The drug, called TRV130, in the phase-III clinical testing as a potential treatment for moderate-to-severe pain. [John George, Philadelphia Business Journal, Sep 14, 15]
Trevena (King of Prussia, PA; no SBIR, founded 2008) [biopharmaceutical company] raised $47.7 million in net proceeds from a public stock offering that closed this week. ... for the continued clinical development of its new drug candidates and for preclinical research and development activities. ... lead new drug candidate is a potential treatment for acute heart failure and moderate-to-severe pain. ... went public earlier this year through a $64.75 million [IPO] [John George, Philadelphia Business Journal, Dec 11, 14]
Trevena (King of Prussia, PA; no SBIR, founded 2007) raised about $64.8 million [in IPO] ... developing the next generation of medicines that target G-protein coupled receptors (GPCRs) [for acute pain and heart failure]. [John George, Philadelphia Business Journal, Jan 31, 14]
Trevena (King of Prussia, PA; no SBIR) scrapped plans for a $92.9 million initial public stock offering because of unfavorable market conditions. [John George, Philadelphia Business Journal, Nov 20, 13] clinical stage biopharmaceutical company dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. [company website]
Trevena (King of Prussia, PA; no SBIR) signed a collaborative licensing option agreement valued at up to $430 million for the development of its experimental acute heart failure treatment, TRV027, with Forest Laboratories Holding Ltd. .... One of Trevena’s founders, Robert Lefkowitz, a professor of medicine and biochemistry at Duke University in North Carolina, won last year’s Nobel Chemistry Prize for his works with GPCR. [John George, Philadelphia Business Journal, May 9, 13]
Trevena (King of Prussia, PA; no SBIR) start-up pursuing a treatment for acute heart failure, as having raised $17.5 million. (For its part, Trevena said in July that it had completed a $35 million financing.) [Philadelphia Inquirer, Oct 18, 10]
Trevi Therapeutics (New Haven, CT; no SBIR, founded 2012, ten employees) received a $15 million loan that will allow it to finish clinical trials on a treatment for chronic itching associated with kidney dialysis and, separately, a rare skin condition marked by hard, crusty bumps. ... is in late-stage development of its drug, Nalbuphine ER. In total the company has raised $55 million to develop its drug, including the $15 million loan from Solar Capital Ltd. [Matthew Sturdevant, Hartford Courant, Jan 8, 15]
Efficient Ears. On average, companies generated roughly $28 in earmark revenue for every dollar they spent lobbying. By any standard, that's a hefty ratio: The companies in the Standard & Poor's 500-stock index brought in just $17.52 in revenues for every dollar of capital expenditure in 2006. ... Says Keith Ashdown, chief investigator for the watchdog group Taxpayers for Common Sense: "The lion's share of these projects is about politics and jobs, rather than real needs." [Business Week, Sep 17] The earmark efficiency champ is an SBIR company, Scientific Research (Atlanta GA and others; about $15M SBIR), that got $344 in earmarked funds per dollar of political "investment".Other SBIR investors: Isothermal Systems (KY and WA; $2M SBIR) at $221 per lobbying dollar; Prologic (Fairmont WV; $2M SBIR) at $133 per dollar; Trex Enterprises (San Diego CA; $7M SBIR) at $116 per dollar. From an efficiency viewpoint, politicians make a good investment. You just have to learn how to kiss frogs.
Triad Semiconductor (Winston-Salem, NC; $1.1M SBIR) raising $10M in equity [Katie Arcieri, Triad Business Journal, Feb 10, 17]
Harvard Bioscience (no SBIR) paid a total of $11 million in cash to acquire two companies — Multi-Channel Systems MCS GmbH, a German subsidiary of the UK-based Biochrom Limited for $9.5M, and Triangle BioSystems (Durham, NC; $600K SBIR) for $1.6M — which make equipment to study the electrical properties of cells. [Don Seiffert, Boston Business Journal, Oct 1, 14]
Startups trying fusion energy. Jeffrey P. Bezos, founder of Amazon.com has invested in General Fusion, a start-up in British Columbia. ... Paul Allen, a co-founder of Microsoft, is betting on another fusion company, Tri Alpha Energy (Foothill Ranch, CA; no SBIR) ... Peter Thiel — the co-founder of PayPal, has invested in Helion Energy (Redmond, WA; no SBIR) [ DINO GRANDONI, New York Times, Oct 25, 15] Helion also has $5M from DOE. [company website] TriAlpha has raised tens of millions of dollars from private investors who range from some of Silicon Valley’s foremost venture capitalists to Hollywood actor Harry Hamlin. [Orange County Register, Sep 8, 15]
LANL and Tribogenics (Marina del Ray, CA; no SBIR) an X-ray technology company, have partnered to create a small, lightweight, low-cost X-ray system based on the MiniMAX camera. The MiniMAX (which stands for miniature, mobile, agile) X-ray camera can provide real-time inspection of sealed containers, ... based on a DARPA-funded initiative that originated at the University of California, Los Angeles, and the company is venture-backed. [Dan Mayfield, Albuquerque Business First, Jun 26, 13]
Tribologix (Dayton, OH; $2.7M SBIR, 4 employees) high-tech coating company has relocated its headquarters to Golden [CO] . [Denver Business Journal, Aug 30, 12]
Trice Medical (Malvern, PA; no SBIR) announced that it is acquiring S.E.G-WAY™ Orthopaedics (Carlsbad, CA; no SBIR), a leader in solutions for minimally invasive orthopedic procedures. SegWAY is best known for its Endoscopic Carpal Tunnel Release (ECTR), a device that supports minimally invasive carpal tunnel surgeries. Trice Medical addresses the growing need for accurate, cost-effective orthopedic diagnostic solutions with its mi-eye™, a fully disposable arthroscopy camera. [Trice press release, Feb 7, 19]
Trice Medical (King of Prussia, PA; no SBIR) announced that it closed a $19.3 million Series C and will use the proceeds to accelerate and expand the company’s U.S. market penetration for mi-eye2™, R&D, sales, marketing and key international regulatory approvals. ... received FDA 510(K) clearance during the fourth quarter of 2016, has captured the attention of medical professionals who are embracing the technology as a replacement to the MRI [company press release, Jun 6, 17]
Trice Medical (King of Prussia, PA; no SBIR) received [FDA] clearance for its lead product, the mi-eye ... a fully disposable, single-use, streamlined visualization device that uses a standard 14-gauge needle with an integrated camera and light source that will allow doctors to perform diagnostic arthroscopies in their office .... received the balance of the cash related to its $11.6 million Series B financing in July, which was led by Safeguard Scientifics [John George, Philadelphia Business Journal, Sep 3, 14]
Trice Orthopedics (King of Prussia, PA; no SBIR) raised $3 million in startup capital .... to pioneer needle-based technologies that integrate miniaturized opto-electronics into diagnostic and therapeutic technologies for orthopedics. [John George, Philadelphia Business Journal, May 10, 13]
Tricida (South San Francisco, CA: no SBIR) pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced that it received a [FDA] Complete Response Letter (CRL) for its New Drug Application (NDA) for veverimer on August 21, 2020. the FDA is seeking additional data beyond the TRCA-301 and TRCA-301E trials regarding the magnitude and durability of the treatment effect of veverimer on the surrogate marker of serum bicarbonate and the applicability of the treatment effect to the U.S. population. FDA also expressed concern as to whether the demonstrated effect size would be reasonably likely to predict clinical benefit. [company press release, Aug 24, 20]
Tricida (South San Francisco, CA; no SBIR, founded 2013) up 57% [Mar 28, 19] Announces Positive Results From Long-Term Clinical Trial of TRC101 in Patients With CKD and Metabolic Acidosis [company press release, Mar 28, 19] total funding $257M [crunchbase.com]
Tricida down 15% [Oct 24, 18]
Tricida down 11% [Sep 11, 18]
Tricida up 16% [Sep 5, 18]
Tricida down 10% [Jul 6, 18]
Tricida up 10% [Jul 3, 18]
Tricida up 15% [Jun 29, 18]
Tricida (South San Francisco, CA; no SBIR) up 37% [Jun 28, 18] a late-stage biotech targeting conditions associated with chronic kidney disease, raised $222 million [by IPO] [nasdaq.com, Jun 28, 18]
Tricida (South San Francisco, CA; no SBIR, $267M raised), a late-stage biotech developing therapies for conditions associated with CKD, filed to raise up to $150 million [IPO] [nasdaq.com, Jun 4, 18]. They built and sold Ilypsa and Relypsa[Ron Leuty, San Francisco Business Times, Jun 5, 18]
Biotech startup Tricida (South San Francisco, CA; no SBIR, founded 2013) clinical stage, biopharmaceutical company focused on the discovery and development of first-in-class chronic therapies for patients with chronic kidney disease (CKD), announced that it has raised a $55M Series C round, bringing the company’s total financing to $95M. [company press release. Jul 25, 16]
On May 10, 2006, Team Submarine (Team Sub) awarded Trident Systems a contract worth $50M for the delivery of Shipboard Mobile Computing Engineering Model under the SBIR program. This award represents the billionth dollar that Team Sub has awarded under the SBIR program, in Phase IIIs alone, since it began more than a decade ago. Says the Navy's Summer 2006 Transitions, now on the Navy SBIR website. Trident knows how to play the game with at least 109 Phase 1s since 1989 and 33 Phase 2s, several over $1M. The Navy SBIR puts great weight on the companies' connecting with and serving Navy programs. How much is innovation and how much is plain vanilla R&D service is left for the Navy programs to decide. Which seems to work just fine for the goal of spending SBIR on things the Navy wants while the Navy sees no other worthwhile goals for its SBIR.
The US Army selected four companies for positions on a potential $93.4 million contract for [RDT&E] services focused on aerial target systems over a five-year period. Griffon Aerospace (Madison, AL; no SBIR), Kord Technologies (Huntsville, AL; $2.2M SBIR), Kratos Defense and Security Solutions (San Diego, CA; no SBIR) and Trideum (Huntsville, AL; $200K SBIR) may bid for orders under the cost-plus-fixed-fee contract. [GovConWire, May 22, 18]
Trilumina (Albuquerque, NM; no SBIR, founded 2010) announced this week it was expanding its Albuquerque footprint [Collin Krabbe, Albuquerque Business Journal, May 25, 18] delivers a VCSEL technology platform capable of low-cost, small form facto and high power illumination for laser radar (LiDAR) and 3D-Sensing. [company website] Sounds like an outgrowth of VCSEL developed by Jack Jewell's 1980s team at Bell Labs, then funded with some SBIR to Jewell's firms Photonics Research (became Vixel), and Picolight. Jewell is now a consultant claiming 72 issued US patents and 150 publications [https://www.linkedin.com/in/jack-jewell-a1149410]
TriLumina (Albuquerque, NM; no SBIR) which provides illumination solutions based on vertical-cavity surface-emitting laser (VCSEL) arrays for automotive laser radar (LiDAR) and sensing platforms, has closed an $8.5m Series A round of funding ... to support active and future customer integration projects [company press release, Mar 4, 15]
During the first quarter of 2014, four venture capital deals with a combined value of $4.8 million closed in New Mexico, according to the new MoneyTree Report from PricewaterhouseCoopers and the National Venture Capital Association: XF Technologies (Albuquerque, NM; no SBIR) $2 million, formerly known as Incitor, working to develop a new type of biofuel; Masterson Industries (Albuquerque, NM; no SBIR) $1.5 million, developing new specialty materials; Trilumina (Albuquerque, NM; no SBIR), $250,000, developing and manufacturing high-speed lasers.
Trimble Navigation (Sunnyvale, CA; $500K SBIR) reckons that as an established geographical-information company it is well placed to move into the smart-farming market, with a system called Connected Farms. It has bought in outside expertise in the shape of AGRI-TREND, a Canadian agricultural consultancy, which it acquired last year. [The Economist, Jun 11, 16]
Trimble Navigation up 21% [Oct 30, 15]
Trimble Navigation (Sunnyvale, CA' $500K SBIR) in Huber Heights [OH] landed a $12.8 million order from the military. ... The advanced manufacturing company [of drafting, surveying and mapping instruments]— which has about 400 people on its local campus — was awarded a deal to make more than 270 laser leveling systems for the U.S. Army and Marine Corps. [Joe Cogliano, Dayton Business Journal, Sep 14, 15]
Trimble Navigation (Huber Heights, OH and Sunnyvale, CA; $500K SBIR in the 1980s, 400 empoloyees) manufacturing plant has snagged $12.8 million in work from the U.S. Marine Corps. ... to supply 33 laser leveling systems, along with training and support, the Department of Defense announced late Thursday. The work will be performed through April 2018 [Joe Cogliano, Dayton Business Journal, Nov 8, 13]
Trimeris down 17% [Dec 29, 09] after South Korean medical equipment maker Arigene ended its $80.3 million acquisition offer for the Durham, N.C., biopharmaceutical maker because it was unable to secure sufficient financing. [Wall Street Journal, Dec 30]
Trimeris down 18% [Nov 12, 09] The proposed $81 million acquisition of AIDS drug company Trimeris is in jeopardy. The Durham-based company announced that the South Korean company that wants to buy it has asked for more time because it currently lacks the money and financing to complete the deal [David Ranii, Raleigh News & Observer, Nov 12, 09]
Trimeris up 37% [Oct 2, 09]
Trimeris,a once-promising biotech company that failed to reach its potential, is being acquired by a South Korean medical equipment company. [Raleigh News & Observer, Oct 3, 09]
For the first time since Trimeris won approval to sell Fuzeon in spring 2003, annual global sales of the HIV/AIDS drug decreased. ... Demand for Fuzeon has waned since powerful new AIDS drugs started coming to market in 2007 ... has closed its research lab in Morrisville [Sabine Vollmer, Raleigh News & Observer, Feb 4, 09]
Trimeris up 15% [Dec 10, 08]
Trimeris up 12% [Oct 23, 08]
Trimeris down 12% [Oct 3, 08]
Trimeris down 12% [Oct 3, 08]
Trimeris up 16% [Sep 18, 08]
Trimeris down 13% [Sep 17, 08]
Trimeris down 12% [Jun 23, 08]
The quarterly earnings report Thursday from Trimeris -- once among the Triangle's most promising biotechnology companies -- could be one of its last. After laying off all but 10 employees, winding down research and development and putting the company's Morrisville laboratory up for lease, the money managers and investment firms that make up Trimeris' board have decided to begin disbursing one of the company's remaining assets -- $80 million in cash and cash equivalents. .... At its peak, Trimeris employed about 150 people, before Fuzeon failed to meet expectations [Raleigh News & Observer, May 9, 08]
Too Much Competition. Trimeris down after reporting that first-quarter sales of its Fuzeon AIDS drug dropped 34%. ... Other drugs to treat HIV and AIDS have eclipsed Fuzeon, including new products from Pfizer and Merck that became available last year. ... The stock began trading publicly in 1997 and soared above $70 in 2000, largely on the potential of the company's revolutionary medicine to treat AIDS. But patients and physicians balked at the drug's high cost and painful daily injections. ... down from 150 workers to 10 [Alan Wolf, Raleigh News & Observer, Apr 18, 08]
After being loved and left several times in the past decade, a sizable Morrisville (NC) building is on the rebound, in search of someone who will appreciate it for what it is on the inside: a lab. Trimeris, a once-promising drug developer, is trying to sub-sublease its 61,000-square-foot research facility ... The Triangle is teeming with hungry lab hunters at a time when other sectors are expanding cautiously, if at all. [Jack Hagel, Raleigh News & Observer, Apr 14]
Dani Bolognesi will take another run at developing a novel, blockbuster drug, an accomplishment that eluded him when he led Trimeris. As chief executive and chairman of B3Bio, a startup, Bolognesi is looking for a new class of medicines that promises to better treat cancer, inflammation and infection. At Trimeris, a troubled Morrisville drug development company, Bolognesi had a similar goal with AIDS drug Fuzeon. [Sabine Vollmer, Raleigh News&Observer, Mar 12, 08]
Price Too Dear. AIDS drug company Trimeris (Morrisville NC) plans to halt its research and development efforts and lay off its R&D staffers next year. The new strategy announced after the markets closed Monday follows last month's appointment of a new CEO -- the company's fourth chief executive in the past year -- and a steady stream of turmoil. ...Trimeris' AIDS drug Fuzeon has racked up disappointing sales, partially as a result of its steep price tag of about $20,000 a year [David Ranii, Raleigh News&Observer, Dec 11]
Trimeris generated third-quarter earnings that trounced analysts' estimates. The company mostly credited higher overseas sales of its HIV/AIDS drug Fuzeon for a 61%earnings increase from the same period a year ago. [Raleigh News&Observer, Nov 9, 07]
The short-time CEO and CFO at Trimeris are departing as allegedly planned after they did their six-month job of creating a blueprint for developing a new AIDS drug, TRI-1144. Meanwhile, HealthCor -- now the company's largest shareholder with a stake of nearly 18% -- has urged the company to halt development of a new drug and consider putting itself up for sale. [Raleigh News&Observer, Oct 12]
Trimeris and its Swiss partner Roche said that they will withdraw an application to sell HIV/AIDS drug Fuzeon in a needle-free device. ...the FDA, concerned that the device could cause nerve pain and bruising, delayed approval and asked for additional data. [Raleigh News& Observer, Oct 4]
Over the past two months, a New York investment firm has bought more than 9 percent of Trimeris shares, filings with the Securities and Exchange Commission show. HealthCor Management, which has more than $1.8 billion under management, isn't saying what it plans to do with its stake in the struggling Morrisville drug company. Trimeris executives aren't returning calls. [Raleigh News & Observer, Aug 10]
CEO by the Hour. Two top executive positions [filled by outside consultants] at Trimeris, the struggling Morrisville NC company that specializes in AIDS treatments, will be paid on an hourly basis for as long as another 16 months ... Company officials did not return phone calls, and an analyst who follows Trimeris said it isn't clear what strategy the firm is trying to pursue. [Raleigh News & Observer, Aug 8, 07]
Trimeris up 11% [Aug 8, 07]
Less Acceleration. Trimeris, the troubled Durham company that markets the AIDS treatment Fuzeon with its Swiss partner Roche, reported that worldwide sales increases for Fuzeon slowed in the first quarter. [Raleigh News & Observer, Apr 18] Trees don't grow to the sky.
Trimeris up 15% on hot quarter revenue. [Apr 18, 07]
Trimeris plunged 29% on the the resignation of CEO/CSO and CFO and termination of an R&D deal with Roche. [Mar 16, 07]
Trimeris up 20% on news of reshuffling of emphasis and some people. [Nov 15, 06]
Trimeris shot up 23% on news of greatly improved profits fueled by the growth in sale of its HIV drug Fuzeon [Nov 8, 06]
Trimeris shares dove 13% after the company lowered sales projections for its AIDS drug Fuzeon. Even so, it expects to post yearly profit for the first time since beginning operations 13 years ago. [David Ranii, Raleigh News and Observer, Oct 12] Trimeris had one Phase 2 SBIR in 1997.
TriQuint Semi up 10% [Oct 29, 14]
TriQuint up 26% [Feb 24, 14] Radio frequency chipmaker RF Micro Devices Inc will buy peer TriQuint Semiconductor for about $1.6 billion in an all-stock deal to create a company that could better compete in selling chips to mobile-handset makers. [Reuters, Feb 25, 14]
TriQuint Semi up 11% [Feb 11, 14]
TriQuint down
15%
TriQuint Semiconductor has its eyes set on a bigger chunk of a growing market. ... announced a deal last week to acquire CAP Wireless (Newbury Park, CA; $800K SBIR). Terms of the deal were not disclosed. TriQuint makes chips for mobile phones. [Matthew Kish, Portland Business Journal, Aug 16, 13]
TriQuint up 18% [Jul 25, 13]
TriQuint up 10% [Apr 25, 13]
Triquint Semiconductor down 13% [Feb 7, 13]
TriQuint down 13% [Oct 25, 12]
Triquint down 13% [Apr 26, 12]
Shares of TriQuint Semiconductor plunged in extended trading on Wednesday as investors balked at the semiconductor specialist's weak guidance. [James Rogers, San Jose Mercury News, Apr 25, 12]
Triquint down 26% [Oct 27, 11]
Triquint up 25% [Oct 13, 11]
TriQuint down 27% [Jul 28, 11]
TriQuint Semiconductor (Hillsboro, OR; $300K SBIR in mid 1990s) missed out on the Verizon iPhone, but continues to do enormous business with Apple. ... company still expects to top $1 billion in revenue this year [Mike Rogoway, The Oregonian, Feb 24, 11]
Triquint up 10% [Sep 22, 10]
TriQuint Semiconductor said it has been awarded a $16.2 million [DARPA] contract to conduct advanced semiconductor research. [Portland Business Journal, Oct 23, 09]
TriQuint Semiconductor down 28% [Oct 22, 09] third-quarter revenue fell below estimates and it said a key customer was cutting orders. [AP]
Triquint up 10% [Jul 23, 09]
TriQuint down 10% [Jun 16, 09]
TriQuint up 17% [Jun 1, 09]
Triquint up 10% [Apr 23, 09]
Triquint up 12% [Apr 6, 09]
Triquint up 11% [Feb 6, 09]
Triquint down 14% [Jan 7, 09]
Triquint up 10% [Jan 5, 09]
TriQuint up 18% [Dec 30, 08]
TriQuint up 18% [Dec 17, 08]
TriQuint up 12% [Dec 8, 08]
TriQuint down 11% [Dec 1, 08] On a stock bloodbath day
Triquint down 10% [Nov 6, 08]
Triquint up 14% [Oct 28, 08]
Triquint up 11% [Oct 16, 08]
Triquint down 14% [Oct 15, 08]
Triquint up 11% [Oct 13, 08]
TriQuint down 18% [Oct 7, 08]
TriQuint down 18% [Oct 7, 08]
TriQuint up 11% [Feb 25, 08]
Triquint up 11% [Oct 31, 07]
Triquint Semiconductor up 15% [Oct 25, 07] after the company reported a 19 percent jump in third-quarter revenue
Triton Systems (Chelmsford, MA) got Israeli VC financing to spin off three new companies, Elecon, Sensera, and Tribond. Elecon will sell TOR-CPä conductive polymers for the electronics marketplace. Sensera will sell electronic sensors to monitor and detect chemical and bio-contamination in fluids with Triton’s conductive polymer film technology. TriBond will sell Smart-Bond, a temperature-controlled welding/sealing technology using radio frequency (RF) energy. Privately-owned Triton Systems claims to have grown 45% annually since its founding in 1992 by Ross Haighihat who left SBIR-champ Foster-Miller.
Triton Systems (Chelmsford, MA) ... is a "creative explosion." The materials product and process development firm recently launched three new spin-off companies and met with members of the Senate Small Business Committee last week to present its new products. ... the gurgling test tubes and grunting machines are churning out polymers. Triton specializes in using nanotechnology methods to create lightweight, durable plastic products for the military, aerospace and commercial industries. Its NanoTuf protective polymer coatings are used on military visors and windshields, and its materials have been used for everything from automotive parts to space suits. The company creates military food trays that can withstand a fall from a helicopter, and its durable plastic capsules are used to hold helium on Converse's line of helium running shoes. Triton also produces an award-winning space-shielding material that enables spacecrafts to survive up to 10 times longer in orbit. .. SBIR has been one of Triton's primary financial supporters since the company was founded in 1992. ... Chief Operating Officer David Model said most ideas take many years to develop into products. Some work, and some don't, he said. "But you just keep trying." Triton is also working on four other potential spinoffs currently in incubation. The company has seen 45% annual growth, Model said, and he anticipates revenues in the area of $8M this year. Triton started with three staff members and currently employs more than 50, with plans to hire 20 more by year's end. The plan is to continue to expand Triton's commercial products and eventually go public, Model said. "Our goal is to no longer need SBIR," he said. [Peter Key, Staff Writer, Lowell Sun]. Triton was founded by a former SBIR user at Foster-Miller, the going-away SBIR champ at gathering funds.
More is Less. A venture between Israeli investment group KPP Investments and Triton Systems (Chelmsford MA; 181 Phase 1s and $55M Phase 2 SBIR) has yielded a new company, FRX Polymers LLC in Chelmsford, is expected to work to commercialize a new family of flame retardant polyphosphonate homopolymers and copolymers. [Mass High Tech, Sep 28] Great fire, but after how much government kerosene? When should the government say enough, or at least keep raising the barrier to new projects? A progressive barrier makes the company reach farther for either highly disruptive new technology or for proof of market validation of the company's technical successes. Well, as long as the agencies are forced to divert a noticeable percentage of their R&D budgets into political programs, the more pressure they feel to take it back in the form of contracts to do what they would have done if the money had not been sequestered. When SBIR was only 1.25% of extramural spending, it could focus on truly inventive stuff. Raising it to 2.5% and then plumping for even more forced it into the same mold as all other R&D programs in the mission agencies. Triton Systems (Chelmsford, MA) acquired Israel-based Ceramight for an undisclosed amount, and has combined it with its extreme environmental composites group to form a new subsidiary called Ceracom Inc. [Mass High Tech, Apr 2]
Triton Systems is selling a nanoengineered plastic pouch for use as a helium-filled heel cushion in Converse Helium sneakers sold in Japan and China. Trition uses an additive of clay nanoparticles to tighten the molecular structure of the pouch, allowing it to trap the helium underfoot for a minimum of 18 months, said Ross Haghighat, Triton's CEO. [Boston Globe, Sep 10]
Triumvira Immunologics (Austin, TX and Germany; no SBIR) biopharmaceutical developing a novel platform for engineering T-cells to attack cancers, successfully completed a USD $55 million Series A financing [to] to advance multiple autologous and allogeneic programs into the clinic for solid tumors and hematologic malignancies. [company press release, Aug, 27, 20]
Triumvira Immunologics (Austin, TX & Germany; no SBIR) biopharmaceutical developing a novel platform for engineering T-cells to attack cancers, successfully completed a $55 million Series A financing round [to] advance multiple autologous and allogeneic programs into the clinic for solid tumors and hematologic malignancies. [company press release, Aug 26, 20]
Amplyx Pharmaceuticals (San Diego, CA; no SBIR, founded 2006) raised $40.5 million in [VC] the antifungal drug developer said ... is preparing to launch a Phase 1 clinical trial of APX001, which belongs to a new class of antifungals, next year. It's to be used to treat life-threatening infections. ... a spinoff of Stanford University. ... Another San Diego company developing an antifungal drug is Cidara Therapeutics (no SBIR), whose CEO, Jeff Stein, also headed Trius. ... The company is based at JLABS, Johnson & Johnson's life science incubator in La Jolla [Bradley Fikes, San Diego Union Tribune, Nov 11, 15]
The $704 million sale of Trius Therapeutics to Cubist Pharmaceuticals has been completed, Cubist said. The deal ends the antibiotic maker’s existence as a publicly traded company. Trius had developed tedizolid phosphate, which treats drug-resistant infections.; [Bradley Fikes, utsandiego.com, Sep 11, 13]
Trius Thera up 20% [Jul 31, 13] on acquisition by Cubist
Cubist Pharmaceuticals has agreed to pay up to $1.6 billion for Trius Therapeutics and Optimer Pharmaceuticals, expanding its heft in antibiotics at a time when the number of drug-resistant viruses are on the rise. The widely praised deals will give Cubist, one of the few big players in U.S. antibiotics in the United States, an additional $600 million to $1 billion in revenue on an annual basis from the companies' lead drugs. Antibiotics has often been shunned by many big pharma firms as a field of research due to poor returns. [Vrinda Manocha and Zeba Siddiqui, Reuters, Jul 30, 13]
Trius Thera up 10% [Jul 11, 13]
Trius Therapeutics said it plans to ask U.S. regulators to approve its antibiotic tedizolid phosphate for treating severe skin infections. Tedizolid is to be used against bacteria, including antibiotic-resistant "superbugs" such as methicillin resistant Staphylococcus aureus, or MRSA. [Bradley Fikes, utsandiego.com, Mar 25]
An experimental antibiotic from Trius Therapeutics (San Diego, CA; no SBIR, 88 employees) against the "superbug" MRSA has been approved by regulators for faster review and incentives to bring the drug to market.focuses on the discovery, development, and commercialization of antibiotics for life-threatening infections. [Bradley Fikes, utsandiego.com, Jan 9, 13]
Trius Thera down 11% [Jan 13, 12]
Trius Thera up 10% [Dec 20, 11] said its new antibiotic tedizolid phosphate performed well during the first of two Phase 3 clinical trials, and that the second trial will be completed late next year. [Gary Robbins, signnsandiego,com, Dec 20]
Trius Thera down 12% [Dec 19, 11]
Trius Therapeutics made headlines just over a year ago when the antibiotic developer raised $45.6 million in an [IPO]. Since then, the company has doubled in size as its lead drug candidate moved into late-stage testing in humans. ... [the opportunity] is that big pharmaceutical companies have largely abandoned antibiotic development because the drugs are typically taken for short periods of time and can quickly become obsolete when resistance develops, conditions that limit the profitability of the treatments. That has left the task of creating new infection-fighting therapies up to smaller biotechnology companies such as Trius. [Keith Darce, signonsandiego.com, Nov 1, 11]
Trius Thera down 19% [Aug 8, 11]
Trius Theradown 14% [Aug 4, 11]
Bayer Pharma will pay Trius Therapeuticsas much as $94 million for the development and commercialization of the San Diego company's lead antibiotic in China, Japan, most other Asian countries, Latin America, Africa and the Middle East, Trius said [Keith Darce, signonsandiego.com, Jul 18, 11]
Trius Thera up another 12% [May 12, 11]
Trius Thera up 12% [May 11, 11]
Trius Thera up 11% [Apr 18, 11]
Trius Thera up 12%[Feb 25, 11]
Trius Thera down 11% [Feb 24, 11]
[DOD] awarded a $29.5 million contract to Trius Therapeutics (San Diego,CA; no SBIR) biotechnology company and the Scripps Institution of Oceanography to search for treatments for biological weapons in the muck lining the bottom of the ocean, the groups said. ... expect to find several promising new antibiotics over the next four years that might work against Yersinia pestis, better known as the Black Death, and other bacterial infections that could be used by terrorists or rogue nations. [Keith Darce, signonsandiego.com, Sep 20, 10]
Trius Therapeutics is down 20% from its IPO Aug 2... developing technology for making a new class of antibiotic compounds, ended [its first trading day]—at its IPO price of $5 a share. Trius was forced to cut its price to $5 a share (from a range of $12 to $14 per share), and increased the size of its offering from 6 million to 10 million shares. [Bruce Bigelow, signonsandiego, Aug 29, 10]
Trius Therapeutics (San Diego, CA; no SBIR) which is developing technology for making a new class of antibiotic compounds, ended the day as it began this morning—at its initial public offering price of $5 a share. ... lead drug candidate targets a sometimes-fatal bacterial infection formally known as methicillin-resistant Staphylococcus aureus, or MRSA. [Bruce Bigelow, signonsandiego.com, Aug 3, 10]
Trius Therapeutics (San Diego, CA; no SBIR) developer of antibiotics, said today it has agreed with the FDA on a special protocol assessment that establishes the design for a pivotal clinical trial. The clarity from the FDA is vital to Trius and its lead drug candidate, torezolid phosphate. The company postponed its IPO plans in March after it learned of new FDA guidelines that altered its plans for a pivotal antibiotic study. [Luke Timmerman, signonsandiego.com, Jun 28, 10]
TriVascular Techup 13% [Aug 31, 15]
TriVascular Technologies (Santa Rosa, CA; no SBIR) fell short of its IPO target but raised $78 million in the latest sign of weakness in the market for new stocks. [Cromwell Schubarth, Silicon Valley Business Journal, Apr 16, 14]
TriVascular Technologies (Santa Rosa, CA; no SBIR) hopes to expand sales and marketing, fund additional research and pay off a note to Boston Scientific Corp. with a planned $100 million initial public offering. .... maker of devices that help doctors repair abdominal aortic aneurysms ... formed in January 1998 and sold to Boston Scientific in April 2005 and renamed Boston Scientific Santa Rosa Corp. But that company was acquired from Boston Scientific in March 2008 and renamed under the TriVascular banner. [Ron Leuty, San Francisco Business Times, Mar 11, 14]
Trovagene down 12% [Jun 10, 16]
I own TROV (Trovagene). Here’s the key, what if Steve Jobs peed in a cup every week to keep updates on his pancreatic cancer instead of get invasive biopsies. That’s the difference between TROV and what hospitals do now. The market for this is basically every person above the age of 40. Meanwhile TROV is doing deals with every medical facility out there to test the test. I own it and I’m not selling until $70. [jamesaltucher.com, Jun 7, 16]
Trovagene up 13% [May 16, 16]
Trovagene up 10% [May 13, 16]
Trovagene down 24% [Apr 25, 16]
Trovagene up 10% [Apr 18, 16]
Trovagene said it has fired its CEO and CFO, alleging breach of fiduciary duty. ... "Trovagene alleges that [the two] failed to present a lucrative corporate opportunity to Trovagene concerning promising new therapeutics in the field of precision medicine and instead took that opportunity for their own personal benefit," the company said in a press release. [Bradley Fikes, San Diego Union Tribune, Mar 29, 31]
TrovaGene up 12% [Mar 1,16]
Trovagene up 14% [Feb 17, 16]
Trovagene up 15% [Feb 1, 16]
Trovagene down 12% [Jan 25, 16]
Trovagene (San Diego, CA; no SBIR) down 15% [Jan 22, 16]
Trovagene(San Diego, CA; no SBIR) up 70% [Jan 21,16], a developer of cell-free molecular diagnostics, announced that it has entered into an agreement with America's Choice Provider Network (ACPN(R)) establishing health insurance access to its entire suite of circulating tumor (ct)DNA Precision Cancer MonitoringSM (PCM) tests and services. ... established as a preferred provider, and its PCM testing services will be covered by over 1,700 payers in North America. ... technology detects and quantitates oncogene mutations in cancer patients for improved disease management. [company press release, Jan 21, 16]
Peter Thompson, a biotechnology investor and a University of Washington affiliate professor, is launching a biotech startup Silverback (Bellevue, WA) while netting $10 M. [Seattle Times, Apr 12, 16] Thompson also co-founder of Corvus Pharma, Cleave Biosciences, and Trubion Pharma. [LinkedIn.com]
In Washington state’s biotech cluster, 83 local biotech companies were awarded grants worth a combined $34 million, Adaptive TCR, AVI Biopharma, Omeros, Proteotech, and Trubion Pharmaceuticals and 78 others. [Luke Timmerman, Seattle Times, Nov 3] Most were $245K, a little money for almost everyone. Too little money to make a big swing in effect. Just politics.
Trubion Pharmaceuticals ($100K SBIR in 2004) up 50% [Aug 13, 10] after Emergent BioSolutions agreed to acquire the Seattle company for at least $96.8 million in a deal that diversifies Emergent's oncology and autoimmunity pipeline. [Wall Street Journal, Aug 14]
Trubion Pharma down11% [Jul 23, 10]
Trubion Pharma up 11% [Jul 22, 10]
Trubion Pharma up 10% [May 24, 10]
Trubion Pharma up 15% [May 12, 10]
Trubion Pharma up 20% [Jan 25, 10]led all NASDAQ risers
Trubion Pharma up 10% [Dec 14, 09]
Trubion Pharma down 10% [Sep 2, 09]
Trubion Pharma up 13% [Aug 31, 09]
Trubion Pharma up 45% [Aug 28, 09] Facet Biotech Corp. will pay Trubion Pharmaceuticals Inc. as much as $196.5 million and make a $10 million investment in the company in return for the marketing rights for an experimental leukemia drug, the companies said [AP, Aug 28]
Trubion Pharma up 30% [Jul 27, 09] drug giant Wyeth is extending its collaboration with Trubion for an additional year, through December 2010 [Puget Sound Business Journal, Jul 27]
Trubion Pharma up 11% [May 29, 09]
Trubion down 19% [May 21, 09]
Trubion Pharma up 18% [May 18, 09]
Trubion Pharma up 31% [May 15, 09]
Trubion Pharma down 16% [Oct 8, 08]
Trubion Pharma down 16% [Oct 8, 08]
Trubion Pharmaceuticals said that it’s won a preliminary patent skirmish in Europe. .... the Opposition Division of the European Patent Office has revoked a Genentech Inc. and Biogen Idec Inc. patent for a rheumatoid arthritis treatment antibody. [Puget Sound Business Journal, Sep 11]
Trubion Pharma up 13% [Sep 18, 08]
Trubion Pharma down 14% [Sep 8, 08]
Trubion Pharma up 11% [Sep 5, 08]
Trubion Pharma up 15% [Jul 11,08]
Trubion Pharma down 10% [Jun 23, 08]
Trubion Pharmaceuticals up 13%said that Wyeth has exercised its option under the terms of its collaboration agreement with Trubion to extend the research period for an additional one-year period. > [press release, Jun 19, 08]
Trubion Pharmaceuticals down 14% [Jun 6, 08]
Trubion Pharmaceuticals up 10% [May 27, 08]
Trubion Pharmaceuticals down 20% [Apr 22, 08] after it launched a new clinical trial of a rheumatoid arthritis drug with partner Wyeth
Trubion Pharmaceuticals up 13% [Apr 18, 08]
Trubion Pharma up 12% [Apr 16, 08]
Trubion Pharmaceuticals up 14% [Apr 10, 08]
Trubion Pharmaceuticals up 10% [Mar 31, 08] after a downgrade recommendation.
Trubion Pharmaceuticals down 15% [Mar 28, 08] and down 47% over 52 weeks.
Trubion Pharmaceuticals up 22% [Mar 20, 08]
Trubion Pharmaceuticals down 19% [Mar 17, 08]
Trubion up 22% [Mar 11, 08]
Trubion Pharmaceuticals down 10% [Feb 14, 08]
Trubion Pharmaceuticals up 15% [Feb 13, 08]
Trubion Pharmaceuticals up 10% [Feb 6, 08]
Trubion Pharmaceuticals down 12% [Feb 5, 08]
Trubion Pharmaceuticals up 13% [Jan 25, 08]
Trubion Pharmaceuticals (one SBIR) up 20% [Jul 25, 07] and 54% for 52 weeks.
Biotech startup Trucode Gene Repair (South San Francisco, CA; no SBIR) announced that it is advancing its next-generation in vivo gene editing technology to correct mutations that cause sickle cell disease, cystic fibrosis, and other devastating genetic disorders. With $34 million from investors, Trucode has now emerged from stealth-mode after establishing a broad and exclusive intellectual property estate for its triplex gene editing technology, assembling a cohesive team of industry veterans, and identifying lead candidates in multiple clinical indications. [company press release, Sep 10, 19]
A County district judge has granted Xenex Disinfection Services (San Antonio, TX; no SBIR) request for a temporary restraining order against a competing biotech company from Tennessee, Tru-D SmartUVC (no SBIR), Xenex officials said. ... Xenex is seeking a permanent injunction that would prevent Tru-D from claiming that its device is six times more effective than the Alamo City company's germ-zapping robots. [W. Scott Bailey, San Antonio Business Journal, Oct 5, 15] Beware any ads that claim n times better, because the base is usually some slippery definition. There's also the fact that most ad readers don't know the difference between "n times better than x" and "n times as good as x."
True Bearing Diagnostics (Washington, DC; SBIR) biotech s seeking $20 million in new funding, according to the WBJ. The company is developing an RNA-based blood testing tool for the early detection of coronary disease [DCInno, Jan 7, 20]
biotech startup True Bearing Diagnostics (Washington, DC; no SBIR) is looking to raise $20M in a new funding round to further develop a RNA-based blood test tool for early detection of coronary artery disease, the WBJ reported [Brent Wistrom, DCInno, Dec 11, 19]
True Diagnostics (San Diego, CA; no SBIR, founded 2010) to develop immunoassay diagnostics, said it has entered into a collaboration with Darmstadt, Germany-based Merck KGaA (which operates in the U.S. as EMD Serono) to develop rapid, point-of-care screening for hypothyroidism in the People’s Republic of China. Financial terms were not disclosed. The company said its diagnostic device takes only a few minutes and requires only a small sample of whole-blood collected directly from the patient’s fingertip.[Alex Lash, xconomy.com, May 29, 14]
True Health Diagnostics, a startup that launched out of the North Texas Enterprise Center last year, has bought one of its largest competitors, Health Diagnostics Laboratories (Richmond, VA; no SBIR) for $37.1 million. ... solidified at the auction of Health Diagnostics, which filed for Chapter 11 bankruptcy. [Danielle Abril,Dallas Business Journal, Sep 14, 15]
True North Therapeutics (South San Francisco, CA; no SBIR) a clinical stage biotechnology company developing novel products that selectively inhibit the Complement system to treat certain rare diseases, announced that it has completed a $45 million Series D equity financing. ... to accelerate further development of its lead complement inhibitor, TNT009, for Cold Agglutinin Disease (CAD), as well as other rare diseases targeting the Complement system. [company press release, Oct 19, 16]
Biotech startup True North Therapeutics (South San Francisco, CA; no SBIR) raised $40 million in Series C funding to accelerate the development of treatments for rare diseases. [Gina Hall, Silicon Valley Business Journal, Dec 4, 15] has a robust product engine capable of generating a proprietary pipeline of novel monoclonal antibodies to treat rare diseases. Our most advanced product candidate, TNT009, is a first-in-class, anti-C1s antibody that selectively targets the Classical pathway of the Complement system. [company website]
True North Therapeutics (South San Francisco, CA; no SBIR) will head into its first clinical trials with $35 million in equity financing ... to take its lead drug through safety studies and into testing against a range of diseases. That list includes a type of kidney transplant rejection as well as rare blood diseases ... initially is zeroing in on antibody mediated rejection in kidney transplant and rare blood disorders, such as cold agglutinin disease, an autoimmune disease in which high levels of circulating antibodies attack red blood cells. [Ron Leuty, San Francisco Business Times, Apr 7, 15]
True North Therapeutics (South San Francisco, CA; no SBIR) nabbed its first round of funding totaling $22 million to move its flagship drug into clinical development. .... develops therapies that inhibit specific immune pathways to treat rare diseases. [Sarah Drake, Silicon Valley Business Journal, Jun 18, 14]
After using its stem cell technology to discover drugs, iPierian (South San Francisco, CA; no SBIR) and its backers are hoping that splitting into two companies (spinout company, True North Therapeutics) and infusing them with a collective $30 million will bring an Alzheimer’s disease therapy and autoimmune drug to market faster. [Ron Leuty, San Francisco Business Times, Sep 4, 13]
Future Army contracts. The Army revealed a new roster of industry partners under a potential $37.4B contract that covers knowledge-based professional engineering support services to command, control, communications, computers, intelligence, surveillance and reconnaissance programs. SBIR companies: Artel (now big, $300K); Dynetics (now big, 31 awards); Macaulay-Brown (now big, 23 awards); NetCentric (now big, $900K); Scientific Research (Now big, $16M); Array Information Technology (one SBIR); Bennett Aerospace (21 SBIR awards); Envistacom (one SBIR); Fibertek (127 SBIRs); Future Technologies ($1M); Fulcrum ($1.2M); LinQuest ($1M); Manufacturing Techniques (One SBIR); Navmar Applied Sciences (68 awards); Peerless Technologies ($2.6M); Research Innovations (one SBIR); Sonalysts (128 awards); SURVICE Engineering (50 awards); Truestone (one SBIR).[GovConWire, Oct 19, 18]
TruTouch Technologies (Sudbury, MA (formerly Albuquerque, NM; $400K SBIR) raised an additional $5.2 million. ... makes a non-invasive device that can shine light through a person's finger to detect both their blood alcohol level and verify their identity. .... has grown and raised about $14 million overall [Dan Mayfield, Albuquerque Business First, Dec 3, 14]
TruTouch Technologies (Sudbury, MA; $400K SBIR) recently raised $5.2 million in debt from a variety of investors to expand its customer base for a device that shines light through the skin to quickly detect blood-alcohol level and a person's identity in the workplace. ... founded in 2004, has raised $14 million since [David Harris, Boston Business Journal, Nov 24, 14]
TRX Systems (Greenbelt, MD; $18M SBIR) Awarded $402M Army Dismounted Assured PNT System Generation II Production Contract [Jane Edwards, govconwire.com, April 13, 2023]
Try Eco LLC (Portland, OR; no SBIR) is out to revolutionize the way agriculture uses water. ... an early commercial stage company working with researchers at Oregon State University to perfect a starch-based soil amendment that acts like a sponge, holding water until needed by growing plants. The concept is not new but Try Eco’s version is 100 percent biodegradable ... collaborating with Vince Remcho, an OSU chemistry professor to perfect the science under a $150,000 investment by Oregon BEST ... Eco’s product, AgriSorb, absorbs 200 to 1,000 times its weight in water, which is released while the plant is growing. [Wendy Culverwell, Portland Business Journal, Jul 6, 15]
Tryton Medical (Durham, NC; no SBIR), a company developing stents to treat coronary bifurcation lesions, has raised $20 million in equity from a group of investors .... to complete enrollment in its Investigational Device Exemption (IDE) Extended Access Registry, to support U.S. Food and Drug Administration (FDA) submission, said Shawn McCarthy, Tryton’s president and CEO. [Brian Feldt, St. Louis Business Journal, Sep 8, 14]
stent developer Tryton Medical (Durham, NC; no SBIR, nearly 20 employees) raised $20 million from private equity investors ... developing a stent to be used where an artery branches off into a side artery ... already sells these stents in Europe, Middle East & Africa, but is still in the investigational stage in the United States. [Jason deBruyn, Triangle Business Journal, Sep 8, 14]
Medical device company Tryton Medical (Durham, NC; no SBIR) has raised $24 million in new funding that it expects will see it through approval of its first product for the U.S. market. ... moved its headquarters from Boston to Durham in 2008 and previously raised $37 million in venture capital, [David Ranii, Raleigh News & Observer, Jan 8, 13]
Tryton Medical (Newton, MA; no SBIR, founded 2003), a developer of coronary stents, reports it has raised $14 Min a Series C VC round. [Mass High Tech, Apr 1, 08]
TScan Therapeutics (Waltham, MA; no SBIR) a biopharmaceutical company focused on the development of T cell receptor (TCR) therapies which reprogram a patient’s own T cells to recognize shared cancer targets, today announced an agreement with Novartis to discover and develop novel TCR-engineered T cell therapies. The collaboration includes an upfront technology access fee and research funding totaling $30 million, and potential milestone payments contingent on clinical, regulatory and sales success that could aggregate in the hundreds of millions of dollars. The collaboration will leverage TScan’s proprietary platform to discover novel cancer antigens that may be targeted by TCR-based therapies. [company press release, Apr 15, 20]
TScan Therapeutics (Cambridge, MA; no SBIR) dedicated to unleashing the power of the immune system through life-changing T cell therapies, announced its Series B financing, with over $48 million raised since the company’s inception. [company press release, Jul 23, 29] TScan’s research is still in the lab, but the company is mapping a course that could lead to human testing in two years. [Frank Vinluan, xconomy.com, Jul 24, 19]
The Column Group, the David Goeddel-led VC firm whose investments include up-and-coming companies like Igenica Biotherapeutics (Burlingame, CA; no SBIR) , Immune Design ( Seattle, WA; no SBIR) and NGM Biopharmaceuticals (S San Francisco, CA; no SBIR) has raised $176 million toward a projected $250 million fund. .... Goeddel was the first scientist hired by Genentech and eventually went on to cofound Tularik (S San Francisco, CA; $500K SBIR), which was sold to Amgen 10 years ago for $1.3 billion. [Ron Leuty, San Francisco Business Times, Apr 17, 14]
Air Force (USAF) selected Sierra Nevada (Sparks, NV; $1M SBIR, founded 1963, 2500 employees) and its partner Embraer (Brazil) Defense and Security for its Light Air Support (LAS) program. ... deemed the A-29 Super Tucano aircraft, and the overall solution offered by SNC, to be the superior choice for this critical mission. The initial $427.5 million delivery order is to supply the USAF with 20 A-29 Super Tucano aircraft. ... for. light air support, reconnaissance and training capabilities to the Afghanistan military. As such, it is a vital element of the United States’ Afghan withdrawal strategy .. work will be in Jacksonville, FL [company press release Feb 27, 13] over the years it has gathered up companies: Space Dev (Poway, CA; $5M SBIR) ;MicroSat Systems (Littleton, CA; $11M SBIR) ; Straight Flight (Denver, CO; no SBIR) ; Waveband (Torrance, CA; $17M SBIR); Aviation Resources Delaware (no SBIR); Inter-4 (San Francisco, CA; no SBIR); Turtle Mountain Communications (no SBIR) ; Plano Microwave (Plano, TX; no SBIR) ; Spectral Systems (Beavercreek, OH; no SBIR) ;Advanced Countermeasure Systems (Sacramento, CA; no SBIR) .
Becton, Dickinson announced it has completed the acquisition of TVA Medical (Austin, TX; no SBIR) that develops minimally invasive vascular access [FDA approved] solutions for patients with chronic kidney disease requiring hemodialysis. [BD press release, Jul 9, 18]
TVA Medical (Austin, TX; no SBIR) biomedical startup is the first company to receive funding from S3 Venture’s new investment fund. ... said that it has raised $9.5 million to continue validating its minimally invasive therapy for renal disease and conduct clinical studies. .... S3 Ventures — one of Austin’s most active venture capital firms — [said] it has raised a $75 million fund to invest in information technology and medical device companies. [Lori Hawkins, Austin American Statesman, Jun 11, 13]
TVA Medical (Austin, TX, founded 2008) has raised $2.6 million to continue developing minimally invasive therapies for renal disease. [Lori Hawkins, Austin American Statesman, Jan 10, 10]
Tvardi Therapeutics (Houston, TX; no SBIR, founded 2017), a clinical-stage private biopharmaceutical company focused on the development of STAT3 inhibitors, announced completion of a $9 million Series A financing ... to enable the completion of ongoing Phase 1 studies for Tvardi’s lead compound TTI-101 in solid tumor cancers, and the completion of IND-enabling studies of a second product for use in non-cancer indications, including cachexia. [company press release, Sep 20, 18] total funding $9M [crunchbase.com]
Medtronic PLC agreed to pay up to $458 million to acquire an obscure but promising California company called Twelve (no SBIR)... aimed at speeding up Medtronic’s progress toward a minimally invasive mitral valve by at least two years. Privately [stealthily]funded Twelve has no website, but it filed a report on www.clinicaltrials.gov in April announcing intentions to enroll 10 patients in Poland in an early clinical trial of its heart device. ... has been called the 12th spinoff company from med-tech start-up incubator the Foundry in Menlo Park, CA. Funded by several private-equity firms, Twelve announced a successful $35 million equity offering in April in securities filings. [Joe Carlson, Minneapoils Star Tribune, Aug 25, 15]
Twentyeight-Seven Therapeutics (Watertown, MA; no SBIR), which focuses on the modulation of RNA to treat cancer and other human diseases, raised $15M in a Series A extension, bringing the startup's total financing to more than $80M. [Boston Inno, May 10, 19]
Twentyeight-Seven Therapeutics (Cambridge, MA; no SBIR, founded 2016) launched with $65 million [VC] to fund its treatments for a variety of cancers, which aim to modulate noncoding strands of microRNA to increase the levels of tumor-suppressing genes. [Conor Hale, Fierce Biotech, Sep 6, 18]
start-up Twin Star Medical (St Paul, MN; $3.5M SBIR) hopes one day to [solve] the condition, known as compartment syndrome, which occurred in roughly 13,500 U.S. patients in 2008. ... launching the FDA-approved device next week as a monitoring device [Wendy Lee, Minneapolis Star Tribune, Sep 10,10]
TwinStrand Biosciences (Seattle, WA; $6.3M SBIR) raised $10.3 million [Rick Morgan, Seattle Inno, Jul 7, 2023]
DNA synthesis company Twist Bioscience (San Francisco, CA; no SBIR, founded 2013) raised $70 million from its IPO, which will fund more R&D and expansion plans that include China. [Alex Lash, xconomy.com, Nov 2, 18]
Synthetic DNA startup Twist Bioscience (San Francisco, CA; no SBIR, founded 2013) raised $37 million in Series C funding to accelerate commercialization efforts. Gene-sequencing company Illumina led the round ... synthetic DNA production for specialty chemical compounds and drug development. The company claims its platform has the potential to greatly accelerate the development of personalized medicine [Cromwell Schubarth, Silicon Valley Business Journal, Jun 11, 15]
Twist Bioscience (San Francisco, CA; no SBIR) announced a $31 million cash infusion to push its silicon-based gene synthesis system toward the market. CEO Emily LeProust told Xconomy she hopes to launch the service in 2015. The firm coupled a $26 million Series B round led by members of the Pritzker family with a $5 million grant from [DARPA]. [Alex Lash, xconomy.com, May 29, 14]
Atomwise (San Francisco, CA; no SBIR, founded 2012), which uses deep learning to shorten the process of discovering new drugs, has raised a $45 million Series A ... was founded in 2012, has now raised more than $51 million ... clients include four of the top 10 biggest pharmaceutical companies .... Now there is a roster of companies using artificial intelligence and machine learning to analyze molecules and fix bottlenecks in the drug discovery process, including Recursion Pharmaceuticals (Salt Lake City, UT, no SBIR, founded 2013), BenevolentAI (UK), TwoXAR (Palo Alto, CA; no SBIR, founded 2014), Cyclica (Canada), and Reverie Labs (Allston, MA; stealth mode). [Catherine Shu, TechCrunch, Mar 7, 18]
Tyme Technologies (New York, NY; no SBIR) up 30% [Nov 26, 18]
medical device maker Dexcom has acquired a University of Virginia software spin-off that develops algorithms for regulating and adjusting insulin delivery for people with diabetes.The purchase price for TypeZero Technologies (CHARLOTTESVILLE, VA; $200K SBIR, 15 employees) was not disclosed. But the deal is not expected to have an impact on Dexcom’s financial results in the short term. [Mike Freeman, San Diego Union Tribune, Aug 24, 18]
Tyra Biosciences (Carlsbad, CA; no SBIR) is taking aim at [tumor] rewiring, called acquired resistance, banking $50 million in its series A round [Amirah Al Idrus, Fierce Biotech, Jan 10, 20]
startup Tyrosine Pharma (Albuquerque, NM; no SBIR) is changing its name to Zocere to reflect the company’s expanding portfolio of injectable neuroprotectant drugs [from innovations licensed from technology developed from the University of New Mexico] .. .... In July, the New Mexico Angels invested $250,000 to help the company develop its technology, and last February it was awarded a $1.6 million NIH grant to research the new therapy. [Dan Mayfield, Albuquerque Business First, Jan 17, 14]
The New Mexico Angels have committed to investing $250,000 in the New Mexico biotech startup Tyrosine Pharmaceuticals (Albuquerque, NM; no SBIR) ... developing a new class of drug aimed at protecting against stroke injuries, utilizing technology developed at the University of New Mexico ... was [recently] awarded a $1.6 million [NIH] grant. [Dan Mayfield, Albuquerque Business First, Jul 18, 13]
Medtronic paid $160 million in cash for Tyrx (New Brunswick, NJ; one SBIR in 2004, founded 1998), a maker of antibacterial pouches for medical devices, the companies said ... Tyrx’s AIGISRx Antibacterial Envelopes aim to reduce the risk of infection following device-implantation procedures [Katharine Grayson, Minneapolis / St. Paul Business Journal, Jan 6, 14] In December 2010 TYRX raised $23 million in private financing [company website]
Tyrx (Monmouth Junction, NJ; one SBIR) won FDA approval of the second iteration of its AigisRX Antibacterial Envelope, a drug-device combination used to prevent infections in patients getting an implantable electronic cardiac device such as a pacemaker or defibrillator. The new version of the device dissolves completely, whereas the original system only partially does and leaves a substrate that remains with a pacemaker over the long-term [Ben Fidler, xconomy.com, Jul 12, 13]
Biotech company uBiome (San Francisco, CA; no SBIR, founded 2012) started as a “citizen science” project that collected and studied microbiome samples in order to learn how the trillions of bacteria living in and on people’s bodies affect human health. Six years and 250,000 samples later, uBiome is now moving beyond simply helping people understand their microbiomes. ... raised $83 million to expand into microbiome drug research. [Frank Vinluan, xconomy.com, Sep 21, 18] total funding $110M [crunchbase.com]
uBiome (San Francisco, CA; no SBIR, founded 2012 ) startup that goes to your other end just raised $22 million ... a rare company that is an alumnus of three of Silicon Valley's top accelerator programs — Stanford-affiliated StartX, Y Combinator and 500 Startups. .... analyses the DNA of microorganisms found in your poop with a test it calls SmartGut. [Cromwell Schubarth, Silicon Valley Business Journal, Nov 2, 16] founded with crowdfunding campaign [company website]
UbiQD (Los Alamos, NM; $2.2M SBIR) announced that it was recently awarded a new small business contract by NASA for optimization and scale up of extruded UbiGro greenhouse films for boosting crop yield in both space and terrestrial applications. The new NASA contract leverages matching funds that were provided by private investors. Additionally, the United States Patent and Trademark Office (USPTO) has granted the company a key patent on its greenhouse technology. [company press release, Dec 5, 2022]
Apparently spun out of a biotechnology company, startup UCAN (formerly GlyGenix Woodbridge, CT; no SBIR) landed $624,000 of a planned $2.5 million funding round ... focused on marketing a nutritional sports product it calls SuperStarch ... GlyGenix, however is focused on treating and curing Glycogen Storage Disease Type 1a ... GlyGenix took a $1.645 million Series A round of funding in January [Mass High Tech, Dec 28, 09]
UES {Dayton, OH; tons of SBIR) won a potential eight-year, $90.3M contract to develop a technology for the U.S. Air Force identify molecular signatures of airmen performance. The company will conduct basic, applied and advanced research on molecular assessment sensing tools and demonstrate signatures in operational environments, the Department of Defense said. [Matthew Nelson, GovConWire, Aug 26, 19]
Science and technology company UES (Beavercreek, OH; multiSBIRs) and the University of Dayton Research Institute have landed spots on a five-year, $99M contract to help the Air Force Research Laboratory conduct scientific studies. Both contractors will support AFRL research projects in the power, energy, thermal, integration and control areas as part of efforts to develop military weapon and emerging technology applications, the Department of Defense said. [Nichols Martin, GovConWire, May 14, 19]
UES (Dayton,OH, roughly $50M of SBIR, founded 1973) awarded a [$22M] contract to work with the AFRL on Advanced Characterization of Materials (ACOM) at RX’s Materials Characterization Facility (MCF). [company press release, Dec 20, 17]
UES (Beavercreek, OH; zillions of SBIR, founded 1973, including $1.5M STTR in March 2016) defense firm was awarded a $48.7 million contract with the U.S. Air Force. [Kaitlin Schroeder, Dayton Business Journal, Mar 27, 17] ] AFRL’s Materials and Manufacturing Directorate selected UES Inc. as a winner of the $43.75million, 8-year Technical OPerations Support V (TOPS-V) contract. US Air Force Research Laboratory (AFRL) awarded UES a contract to execute on the NeMO -Nanoelectronic Materials Optimization contract, which has a basic award of $42 million, over a 6 year performance period. [company website Sept 2016] US Air Force (AFRL/RXC) has awarded UES Inc. (UES) a $32.3 million, indefinite-delivery/indefinite-quantity contract under the Composites Hybrids And Metals Materials and Processes (CHAMMP) research program... US Air Force (AFRL/RQK) selected UES for a $2 million award, over a period of 2 years, to sense key biomarkers and biometrics that can help predict human performance. [company website Sept 2015] US Air Force (Space and Missile Center, El Segundo CA) selected UES for a $2.9 million award, to initiate Additive Manufacturing Technology Development. [company website Aug 2015] awarded $11M by the Air Force Research Laboratory Materials and Manufacturing Directorate to operate and maintain the Directorate’s Materials Characterization Facility II (MCF), a micro-analysis facility supporting AFRL’s research mission. [company website Mar 2014] awarded $46.2M from the Air Force Research Laboratory 711th HPW/RHXBC to develop technologies to discover, characterize, detect, and analyze complex biosignatures in order to provide tools for Intelligence, Surveillance, and Reconnaissance (ISR) and human performance assessment. [company website Mar 2013] Expecting to compete in any of these technologies for SBIR? UES will be there near the USAF flagpole with endless connections.
UES (Beavercreek, OH; tons of SBIR) was awarded a $42 million contract with the Air Force Research Laboratory. ... six-year nanoelectronic materials contract to develop nanoscale material and processing technology for future U.S. Air Force systems. ... the sixth largest Department of Defense contractor in the Dayton region, with $42.14 million in total 2015 awards, according to the DBJ Book of Lists. [Kaitlin Schroeder, Dayton Business Journal, Sep 8, 16]
UES (Beavercreek, OH; tons of SBIR, founded 1973,200 employees) said it has secured a $1.4 million development deal with the Air Force’s Air Logistic Centers for its flagship Robo-Met.3D product. That platform can speed up the evaluation of aerospace coatings, making it more consistent and repeatable. [Joe Cogliano, Dayton Business Journal, Oct 1, 15]
UES also was awarded the six-year contract for the Air Force’s Soft Organic Functional Technology program. The SOFT contract covers emerging biotechnology areas, including materials inspired by biology and advanced flexible electronic materials. ... Last week, UES won a spot on a $32.3 million AFRL contract for work on advanced materials and process development. It also has won a $2 million deal to from the Air Force to identify key biological markers to predict human performance as well as a $2.9 million contract from the Air Force Space and Missile Systems Center to advance its 3D printing capabilities. [Joe Cogliano, Dayton Business Journal, Sep 29, 15]
UES (Beavercreek, OH; mucho SBIR) says the technology behind its SilverHAWQ [Human-portable Air and Water Quality] sensor developed by UES with the U.S. Army Corps of Engineers [SBIR] for E. coli detection — will be extended to detect certain toxins released by hazardous blue-green algae blooms in water. A new product currently is in the development and commercialization stages at UES, which is looking for partners to help get it to market. [Joe Cogliano, Dayton Business Journal, Sep 9, 15] The story says "cost effective" and "lucrative" without citing any numbers that might show competitive advantage.
UES (Beavercreek, OH; gazillions of SBIR,200 employees) was awarded a $2.9 million contract [from the Air Force Rapid Innovation Fund] for work on additive manufacturing technology development. ... the 74th largest company in the Dayton region with $42.5 million in revenue last year, according to Dayton Business Journal research [Joe Cogliano, Dayton Business Journal, Aug 24, 15]
UES (Beavercreek, OH; tons of SBIR) has won a $1.5 military SBIR contract to advance an electrical system generation technology that can be added to future aerospace systems. .... to boost performance of the dual-mode electrical accumulator unit, an electrical component. ... 200 employees and is the 5th largest woman-owned business in the region, according to Dayton Business Journal research. It reported $41 million in revenue in 2013. [Joe Cogliano, Dayton Business Journal, Dec 19, 14] An all-too-typical case of product improvement engineering by highly experienced established firms for incremental improvements of existing working technology. Innovation? is whatever the agency money and local Congresscritter says it is. No one will protest that this is a waste, fraud, and abuse of tech innovation money.
UES (tons of SBIR, 170 employees, founded 1973) can earn up to $9 million during the next eight years to boost engine technology for the U.S. Air Force. .... research and development work for Air Force programs on high performance, highly efficient and adaptive turbine engines. [Joe Cogliano, Dayton Business Journal, Aug 15, 14]
UES (Beavercreek, OH; tons of SBIR, founded 1973) has landed a $240,000 U.S. Army order for its second generation portable air quality sensor system, known as SilverHAWQ. .... the fourth largest defense contractor on the Dayton region with nearly $46 million in DoD contract value in 2012, according to Dayton Business Journal research. [Joe Cogliano, Dayton Business Journal, Apr 9, 14] Lesson: the DOD loves experience and a high probability of success, even in infant R&D. And since really good new ideas with market potential can tap the ocean of private capital sloshing around the world, government programs like SBIR will only see ordinary ideas from ordinary companies. That's good news for second tier companies as the political system sets aside 3% of the agency's R&D biz for small biz, a 3% that the small biz would probabhy not win much of in open conmpetiton from all comers. No matter, politics demands that the babies be kissed.
UES (Beavercreek, OH; tons of SBIR) won an $11 million contract to run a micro-analysis facility supporting Air Force Research Laboratory. .... follows similar work done by UES under a previous contract and is a critical win because it bolsters the company during a time of tight federal budgets. .... the fourth largest defense contractor on the Dayton region with nearly $46 million in DoD contract value in 2012 [Joe Cogliano, Dayton Business Journal, Mar 4, 14] When a new life forms appears in nature, other life forms will appear or adapt to feed on it.
UES (Beavercreek, OH; lots of SBIR, something like $70M, founded 1973) landed a $46 million [seven-year contract] to help the U.S. Air Force determine threats in the field based on human “biosignatures.” .... to develop a system for intelligence workers to quickly identify human threats from long range by understanding their biosignatures: a combination of the way a person moves, their size and shape, and physiology. ..... nearly $46 million in DoD contract value in 2012, according to Dayton Business Journal research. The company has about 180 employees. , and nearly $46 million in DoD contract value in 2012, according to Dayton Business Journal research. The company has about 180 employees. [Joe Cogliano, Dayton Business Journal, Nov 15, 13] Most recent SBA recorded SBIR [which is two years behind] in 2010. Officially a small company eligible for SBIR while collecting multi-million mainline contracts. Being near the flagpole has its plusses. No doubt the SBDC lobbyists for SBIR consider this an SBIR success story as the mission agency pushes its SBIR into established firms.
UES
(Beavercreek, OH;
tons of SBIR including 19 Phase Is in 2010) earned as much as
$22.7 million in additional work for
the U.S. Air Force. .... was issued a modification
to a
research contract it
originally won in late 2009, according to the Department of Defense.
The work includes metallic and ceramic materials research.
The
contract, now worth about $45.5 million and runs through the end of
2015 [Joe Cogliano, Dayton Business Journal, Apr
8,
13]
Those 19 SBIRs in 2010 crowded out 19 awards that might have been made
to fresh ideas by fresh entrepreneurs in fresh conmpanies, as USAF uses
SBIR to buy what it wants without regard to larger federal investment
objectives. And as far as the politicians care, any money going into
their district must be good for America. Where to point fingers about
missing opportunites to start fresh industries? The mirror.
UES (Beavercreek, OH; lots of SBIR) won a U.S. Air Force research [seven year] deal that could be worth as much as $42 million..... to perform on-site work at the AFRL. It includes analysis development, experimentation and reporting. [Joe Cogliano, Dayton Business Journal, May 31, 12]
UES (Beavercreek, OH; tons of SBIR) has won a $3 million deal with the U.S. Air Force. ... will support Air Force Research Laboratory at Wright-Patterson. ... the third significant contract award for UES in the last four months. .... As of October, the company reported having 170 employees. It reported $27 million in revenue last year. [Dayton Business Journal, Apr 22] Need another heart-rending story of why SBIR needs more money for its nurturing of start-up techs while the big R&D agencies pour SBIR money into established companies with a big foot in the government door? Oh, never mind, the Congresscritters from Dayton will love the idea while they vote to cut Medicaid and funs a second-source jet fighter engine. There's no interest like a vested interest.
UES (Beavercreek, OH; about $40+M SBIR) says a U.S. Air Force deal it landed in December will be worth up to $74.5 million during the next eight years. ... the third major contract award for UES in the last five months [Dayton Business Journal, Feb 7, 11]
UES (aka Universal Energy Systems, Beavercreek, OH; something like $70M SBIR) has landed a $35 million U.S. Air Force research contract. ... UES’ fourth significant win from Wright-Patt in the past 16 months. Others include: • Sept. 2009 – a six-year, $44.5 million contract to provide research and development for the nano and biological materials branch of the Materials and Manufacturing Directorate at AFRL; • Dec. 2009 – a $22.7 million contract for work at AFRL; and • Sept. 2010 – a three-year, $5 million contract to support the 711th Human Performance Wing at Wright-Patt. The work involves using biotechnology to advance intelligence, surveillance and reconnaissance — or ISR — capabilities. As of October, UES reported having 170 employees. [Dayton Business Journal, Jan 17, 11] Living near the base's front gate helps a lot. Despite $100M mainline AF contracts, AF keeps handing it SBIRs. Just when does the AF deem a company competitive and in no need of SBIR? Never!
Helping the Neighbor. UES (once called Universal Energy Systems (Dayton); Beavercreek, OH; about $40+M SBIR) was awarded a $22.7 million [USAF-AFRL] contract [for] research, development and technology transition on advanced metallic and ceramic structure materials. In September, UES snagged a six-year, $44.5 million deal to provide research and development for the nano and biological materials. [Dayton Business Journal, Dec 31, 09] in 2009, it was still getting Phase 1 SBIR awards, its 140th Phase 1 following about 40 Phase 2s. DOD's due diligence on SBIR must not include a check on whether a firm is ready to compete for mainline DOD R&R funding and thus does not need nursery funding. Did the Congress intend such situations in SBIR? Well, the Dayton Congressional delegation will certainly not be complaining about a firm parked outside the DOD gate getting a lot of contracts. What are neighbors for anyway? I do hope that the big contracts do not include consulting work on SBIR topics and selection of winners.
Ulthera (Mesa, AZ; no SBIR, founded 2004) which had filed an $86 million [IPO]in April, instead is being purchased by Merz Pharma Group, a German pharmaceutical company with $1.5 billion in annual sales. .... deal is valued at up to $600 million in up-front cash and milestone payments [Angela Gonzales, Phoenix Business Journal, Jun 26, 14]
Guided Therapy Systems (Mesa, AZ; one SBIR, founded 1994, 20 employees), which founded Ulthera LLC, is getting into the musculoskeletal business. .... recognized as one of the world’s first companies to develop and commercialize products that combine ultrasound imaging with therapeutic ultrasound. [Angela Gonzales, Phoenix Business Journal, May 22, 14]
Ulthera (Mesa, AZ; no SBIR, 160 employees and debt free) medical device company, filed an $86 million [IPO] .... markets the Ulthera System, which is cleared by the U.S. Food and Drug Administration to use an ultrasound system to lift eyebrows and skin under the chin. [Angela Gonzales, Phoenix Business Journal, Apr 22, 14]
Army's venture venture. The Army's VC (OnPoint Tech) current investment portfolio : A123 Systems (Boston, MA; $750K SBIR, IPO 2009) advanced Lithium-Ion based cells for rechargeable battery packs; Atraverda (UK) advanced bi-polar battery electrodes for rechargeable batteries; Integrated Fuel Cell Technologies (Burlington MA; no SBIR) next generation fuel cell systems for portable devices; Nanosolar (Palo Alto, CA; $1.7M SBIR) thin-film solar technology for roll-to-roll printing of solar cells on flexible substrates, PowerGenix (San Diego, CA; no SBIR) next-generation rechargeable batteries; Power Precise (Herndon, VA; no SBIR) a fabless semiconductor company specializing in battery management devices; Ultra Cell (Livermore, CA; no SBIR) integrated fuel cell systems; Zinc Matrix Power (Santa Barbara, CA; no SBIR) high-performance rechargeable alkaline battery technology for commercial and military markets; Akermin (St Louis, MO; no SBIR) portable fuel cells based on its proprietary “Stabilized Enzyme Biofuel Cell” SEBC™ technology; Superprotonic (Pasadena CA; $200K SBIR) solid acid fuel cell. [defense-ventures.com] No surprise that a VC, even one doing it for the government, sees tech opportunity much different than does Army SBIR. I note that the three outside trustees (of five trustees) of OnPoint are a DOD political appointee, and entrepreneur/attorney, and Paul Gompers from Harvard Business School who with Josh Lerner publish a lot of venture research. Lerner did a lot of SBIR study until, I presume, he gave up on SBIR's ever being anything but a political handout.
UltraCell (Livermore,CA; $800K SBIR) will get $1 million from the state of Ohio to help move more of its manufacturing operations to the Dayton region. .. has production operations in the area, recently landed a $3 million contract [funded by stimulus dollars] with the USAF to develop portable fuel cells for use by soldiers in the field. ... raised $3.8 million in venture funding to help expand operations at its facility in Dayton. ... has raised $30 million total since it was started in 2002 [Dayton Business Journal, Dec 18, 09] launched with technology licensed from Lawrence Livermore National Laboratories ... [In 2007] it planned to invest $74M in the Dayton operation. The state has promised $15.2M in loans, grants and tax credits. [Dayton Business Journal, May 15, 07] portfolio.com lists James Kaschmitter as Chairman & CEO. Kaschmitter had a battery firm Polystor ($500K SBIR in 1996)and founded PowerStor (no SBIR) in 1997 as a spin-off from PolyStor [allbusiness.com, Dec 99].
Fuel cell maker UltraCell(Livermore, CA; $800K SBIR) raised $3.8 million in venture funding to help expand operations at its facility in Dayton OH, where it has added a handful of workers since December. [Dayton Business Journal, May 26, 09]
UltraCell (Livermore, CA; no SBIR) has developed a 25 watt fuel cell that can power the military's rugged laptops for up to eight hours on eight-and-a-half ounces of methanol. Intrigued, DARPA and the Army CERDEC have granted UltraCell a follow-on contract to refine their fuel cell tech for laptop-toting soldiers in the field. [Matt Safford, Extreme Tech, Jun 24, 08] Note that it needs an ounce of methanol per hour which has to be transported from Kuwait to the forward bases and somehow mated with the power supply.
Kaschmitter Still in Power. Energy source isn't powering cars as expected, but startups, others making progress on smaller scale. UltraCell Corp (no SBIR) plans to open its plant this week ... near Dayton OH. ... CEO Jim Kaschmitter was a researcher at the Department of Energy's Lawrence Livermore National Laboratories in California before he started UltraCell in 2002. [Austin American-Statesman, Sep 9, 07] In between, he was also CEO and President at PowerStor and PolyStor Corporations. PolyStor (Dublin, CA; one Phase 2 SBIR) was to become the first American manufacturer to mass produce rechargeable lithium-ion batteries, powering millions of wireless phones and laptop computers.... PolyStor has spun off a second company, PowerStor (no SBIR), that will focus on super capacitors that can quickly discharge far more energy than those now on the market. PolyStor has also signed a $9.5 million contract to develop and deliver batteries for hybrid electric cars, which will run on a combination of battery power and gasoline. And bicycles may be next. [East Bay Business Times, Nov 1998] The Commerce ATP Program reports that PowerStor licensed aerogel capacitor technology from Lawrence Livermore National Laboratory. PowerStor overcame financial barriers to constructing production facilities by manufacturing its aerogel ultracapacitor products by hand in Malaysia. Cooper Electronic Technologies acquired PowerStor when the parent company, PolyStor, folded [Missile Defense Agency 2003 Technology Applications Report: Electrical, Electronic, and Magnetic Devices] (Note: Unlike the other SBIR programs, MDA's Tech App program keeps up with company developments that come from its SBIR investments.) and that In 2000, PolyStor won an award from the Advanced Technology Program to help develop a safe, ultrahigh capacity next-generation rechargeable battery based on Li-ion polymer gel technology. After suffering a sharp decline in demand for its products in 2001, tied to a global decline in the demand for cell phones, PolyStor ceased operations in 2002. [Source: Steve Peng. "Mold to Fit Battery." Edgereview]
Ultragenyx Pharmaceutical (Novato, CA; no SBIR), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, announced that the U.S. Food and Drug Administration (FDA) has approved Dojolvi™ (triheptanoin) as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). LC-FAOD are a group of rare, lifelong and life-threatening genetic disorders in which the body is unable to convert long-chain fatty acids into energy. [company press release, Jun 30, 20]
Ultragenyx Pharmaceutical (Novato, CA; no SBIR), a biopharmaceutical focused on the development and commercialization of novel products for rare and ultra-rare diseases, and Kyowa Kirin (Japan), a global specialty pharmaceutical company creating innovative medical solutions using the latest biotechnology, today announced that the [FDA] has approved Crysvita® (burosumab) for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adults and pediatric patients 2 years of age and older. Crysvita is a human antibody that blocks excess activity of FGF23, a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney. [company press release, Jun 18, 20]
Dimension Therapeutics (Cambridge, MA; no SBIR) up 40% [Sep 18, 17] a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, today confirmed that it has received a non-binding, unsolicited proposal from Ultragenyx Pharmaceutical (no SBIR) to acquire Dimension for $5.50 per share in cash. But As announced on August 25, 2017, Dimension entered into a definitive merger agreement with REGENXBIO under which REGENXBIO will acquire Dimension in an all-stock transaction. [company press release, Sep 18, 17]
Ultragenyx (Novato, CA; no SBIR, founded 2010) focused on the development of novel products for rare and ultra-rare diseases, announced that a Phase 3 study evaluating aceneuramic acid extended release (Ace-ER) in patients with GNE Myopathy (GNEM) did not achieve its primary endpoint of demonstrating a statistically significant difference in the upper extremity muscle strength composite score compared to placebo. [company press release, Aug 23, 17]
Ultragenyx (Novato, CA; no SBIR), and partner Kyowa Hakko Kirin aim to file for approval of burosumab, for the rare genetic disease X-linked hypophosphatemia, after the drug hit its main goal in a Phase 3 trial. [Ben Fidler, xconomy.com, Apr 21, 17]
Wrinkle-smoothing drug developer Revance Therapeutics Pharmaceutical (Newark, CA; no SBIR) and rare drug company Ultragenyx (Novato, CA; no SBIR) raised a combined $225 million with IPOs over the past couple of weeks [Cromwell Schubarth, Silicon Valley Business Journal, Feb 19, 14]
Ultragenyx Pharmaceutical (Novato, CA; no SBIR, founded 2010) raised $121 million through an [IPO] priced well above a range the drug developer had forecast. ... developing several possible treatments for rare or extremely rare diseases. Its portfolio includes an intravenous enzyme replacement therapy for treating Sly Syndrome, a cellular and organ dysfunction that typically leads to death by the time patients become teens or reach early adulthood. [AP, Jan 31, 14] Stock price doubled in Day One trading.
Presage Biosciences (Seattle, WA; no SBIR) has been named one of FierceBiotech ’s “Fierce 15” of 2013. ... a spinoff company of the Fred Hutchinson Cancer Research Center .... patented a novel method for simultaneously analyzing multiple cancer drug candidates and drug combinations within a single tumor while that tumor is still in a patient. .... FierceBiotech evaluates hundreds of private companies from around the world each year before selecting the 15 it considers the most innovative, creative and promising. The other Fierce 14 are: Acetylon Pharmaceuticals; AnaptysBio; CytomX (Santa Barbara, CA; $500K SBIR); FibroGen (South San Francisco, CA; $1.3M SBIR); Immunocore; Jounce Therapeutics; Kala Pharmaceuticals; MacroGenics (Rockville, MD; $2.6M SBIR) ; Moderna Therapeutics; Nimbus Discovery; Scioderm; Ultragenyx; UniQure; and Visterra. [Valerie Bauman, Puget Sound Business Journal , Sep 24]
Ultralife ($300K SBIR long ago) down 20% [Oct 26, 2023]
Ultralife (Newark, NY; $300K SBIR) up 30% [Aug 22, 2023]
Ultralife up 23% [May 18, 21]
Ultralife down 19% [May 2, 19] reported lower quarterly profits
Ultralife up 10% [May 29,17]
Ultralife received an indefinite quantity contract for purchases not to exceed $21.4 million from the United States government’s Defense Logistics Agency. The contract is for the Newark firm’s lithium manganese dioxide, non-rechargeable batteries. [ANDREA DECKERT, Rochester Business Journal, Mar 3, 17]
Ultralife up 23% [Jun 8, 16]
Ultralife down 10% [Apr 28, 16]
Ultralife up 11% [Apr 18, 16]
Ultralife down 10% [Oct 9,15]
Ultralife up 10% [Mar 11, 15]
Ultralife up 10% [Feb 12, 15]
Ultralife down 12% [Dec 31, 14]
Ultralife up 20% [Dec 30, 14]
New York State Energy Research and Development Authority awarded $250K to DNV GL (Rochester, NY; no SBIR) – will develop a novel separator for lithium-ion batteries. ... to decrease the risk of fires due to Lithium-ion batteries, which – while rare – have occurred in the past. Ultralife (Newark, N.Y.) and Oak-Mitsui (Hoosick Falls, N.Y.) will participate in project reviews. The company will also investigate methods for automatically extinguishing a Lithium-ion fire should it occur. [NYSERDA, Oct 27, 14]
Ultralife up 10% [Aug 7, 14]
Ultralife up 19% [Jan 30, 14]
Ultralife up 10% [Mar 15, 13]
Ultralife down 18% [Aug 2, 12]
Ultralife down 11% [Jul 30, 12]
Ultralife agreed to pay $2.7 million, plus accrued interest, to resolve allegations it provided false pricing certifications in three federal contracts with the U.S. Army, recent filings with the Securities & Exchange Commission show. [Andrea Deckert, Rochester Business Journal, Jun 2, 11]
Ultralife up 10% [May 11, 11]
Ultralife down 14% [Dec 29, 10]
Ultralife received a military order that could total some $42 million [of batteries] over the next several years. [Rochester Business Journal, Sep 17, 10] A modern army no longer travels on its stomach; it needs zillions of batteries.
Ultralife up 11% [Jul 13, 10]
Ultralife has received orders valued at about $21 million for its satellite-communications technology from a U.S. defense contractor for use in armored vehicles. [Wall Street Journal, May 15, 10]
Ultralife will receive $2.4 million in NYSERDA funds to help integrate battery and ultra-capacitors, an electronic energy-storage device, on a common power circuit serving two renewable-energy generation sources that will allow increased renewable-energy contributions to the grid. [Andrea Deckert, Rochester Business Journal, Mar 10, 10]
Ultralife up 10% [Dec 22, 09]
Ultralife down 13% [Oct 21, 09]
Ultralife down 13% [Oct 20, 09]
Ultralife down 11% [Sep 28, 09]
Ultralife up 10% [Jun 29, 09]
Ultralife down 16% [Apr 30, 09] reported Thursday a drop in revenues and a first-quarter net loss Thursday, driven by lower shipments of some products and an increase in operating costs. [Andrea Deckert, Rochester Business Journal, Apr 30, 09]
Ultralife up 10% [Mar 31, 09]
Ultralife up 10% [Mar 23, 09]
Ultralife down 11% [Mar 20, 09]
Ultralife up 12% [Mar 10, 09]
Ultralife up 13% [Dec 5, 08]
Ultralife down 18% [Dec 1, 08] On a stock bloodbath day
Ultralife up 15% [Nov 26, 08]
Ultralife up 23% [Nov 21, 08]
Ultralife up 11% [Nov 13, 08]
Ultralife up 13% [Nov 7, 08]
Ultralife down 10% [Nov 5, 08]
Ultralife up 19% [Oct 28, 08]
Ultralife up 12% [Oct 16, 08]
Ultralife down 11% [Oct 15, 08]
Ultralife down 10% [Oct 7, 08]
Ultralife down 12% [Oct 2, 08]
Ultralife down 10% [Oct 7, 08]
Ultralife down 12% [Oct 2, 08]
Ultralife down 19% [Sep 29, 08]
Ultralife up 13% [Sep 18, 08]
A boosted outlook helped shares of Ultralife Batteries, which gained 31%. ... raised its second-quarter and full-year revenue forecasts [Wall Street Journal, May 30]
Ultralife up 16% [May 1, 08]
Ultralife down 15% [Mar 28, 08]
Ultralife up 13% [Mar 27, 08]
Ultralife down 17% [Feb 15, 08]
Ultralife down 14% [Jan 30, 08]
Ultralife down 17% [Jan 11, 08]
Ultralife Batteries (Newark, NY) up 17% on a $40M order [Dec 26, 07] after it said that revenue will soar to a record high next year.
Ultralife Batteries up 12% [Sep 27, 07]
Ultralife Batteries dipped 12% on a dipping forecast of a quarterly loss. [Oct 26. 06]
Ultramet Wins Again(Sep19) Ultramet (Pacoima, CA) won $175K develop a spin-off application for cutting-edge coatings for the drilling industry. The money comes from the Los Angeles Regional Technology Alliance to help companies compete for federal funding (love that interstate competition). Help? Hah! Ultramet should have been on the selection committee. Ultramet's $15M puts it in the top twenty SBIR winners - the premier federal money for start-up companies. This time Ultramet got a nudge from BMDO, one of Ultramet's generous suppliers of SBIR funds, in the form of a nomination to LARTA through an experiment by BMDO's Technology Applications program (one of the government's best) with the National Association of State Development Agencies (NASDA). While BMDO's motive was to help its SBIR companies succeed in real life (and get off the federal handout), I wonder if BMDO knew what reinforcement of dependency it was risking. The similar grant to Aguila (San Marcos, CA), in San Diego's competition, makes a lot more sense if the objective is to give the fledgling most-likely-to-succeed California companies a one-time hand in the federal competition. Ah well, I suppose I have to share LARTA's blame since I gave Ultramet a lot of that SBIR money over the last decade. None of the other winners is an SBIR junkie (uh, veteran).
A $1.27 million [NIH SBIR], two-year grant will move Ultradian Diagnostics (Rensselaer, NY; one SBIR) one step closer to commercialization of its glucose monitoring device. .... conducted its first clinical trial, with a $191,000 SBIR grant, in 2010 [Barbara Pinckney, The Business Review (Albany), Sep 12, 13]
After Ultraviolet Sciences (San Diego, CA; $800K SBIR) was founded in 2002, it took the cleantech startup seven years to launch its first product. It’s a water purification device that uses ultraviolet (UV) light to sterilize microbial contaminants in drinking water. ... developing a highly reflective film for the inner chamber walls, which reflects 98 percent of the UV light—instead of absorbing more than 80 percent [which turns uselessly into heat] ... the company has obtained two patents for the design.... has forecast sales of $500,000 this year, and expects to generate $1.5 million in sales next year [Bruce Bigelow, signonsandiego,com, May 11, 10]
I do believe that more flexible robots such as those from Universal Robots, Unbounded Robotics and Baxter from Rethink Robotics will have a major impact on the workplace. Estimating the global manufacturing labor costs at $6 trillion annually, McKinsey forecast that advanced robotics could have an economic impact on the manufacturing sector of between $720 billion to $1.45 trillion annually. [Colin Lewis, http://robotenomics.com, Apr 23] No SBIR in those three.
Startup Unchained Labs (Pleasanton, CA; no SBIR) pulled in $25 million in a Series A financing. ... started by Tim Harkness, who built Santa Clara protein analysis technology company ProteinSimple. That company sought to raise $86.3 million in an initial public offering last year, before its $300 million acquisition in August by Minneapolis-based Techne Corp ... Unchained Labs sees itself as a life sciences tools company. It plans to buy businesses and product lines, starting with the recent acquisition of Optim, an analytical instrument designed to help drug developers measure protein stability and, as a result, poor drug candidates early in the development process. [Ron Leuty, San Francisco Business Times, Feb 12, 15]
Konarka Technologies launched a new $45 million R&D deal with Total Gas & Power Ltd., a UK-based oil and gas company. With the deal, Total will become the leading stakeholder in Konarka, with a slightly less than 20 percent share. ... Konarka’s thin-film technology allows for the colored printing and application of a polymer material that can convert light into energy. The technology, originally developed by the late Sukant Tripathy, a materials scientist and professor at the University of Massachusetts Lowell, and Alan Heeger, a 2000 Nobel Laureate in Chemistry, has attracted a lot of attention since the company was founded in 2001, as well as more than $100 million in private funding from a number of investors. [Mass High Tech, Dec 15] Heeger did the chemistry of conductive plastics that became the bedrock of UNIAX that Heeger co-founded and got SBIR from BMDO in 1992.
Nobel Prize touches SBIR company(Oct 11) One of the Nobel laureates in chemistry was Alan Heeger, of the University of California-Santa Barbara, who did the chemistry of conductive plastics that became the bedrock of UNIAX that Heeger co-founded. Its first Phase 2 SBIR came from - you guessed it - BMDO in 1992.
Uniax bought.(Apr 24) DuPont bought UNIAX (Santa Barbara, CA) for the world’s first polymer-OLED (organic light-emitting diode) displays. Poly-OLEDs are critical to developing brighter, lower cost and lightweight displays for use in wireless devices, such as cell phones and personal digital assistants. Price unnamed. Dr. Nick Colaneri, Director of New Technology at UNIAX said, A complete OLED display is less than 2 mm thick and weighs about 1/10 oz. Current display prototypes have in excess of 25,000 pixels, suitable for wireless Internet applications. The displays are daylight readable, and capable of displaying full motion video. UNIAX Corporation started in 1990 with conducting polymer technology developed by Dr. Alan Heeger and licensed from the UCSB. UNIAX got its start as an SBIR Phase 2 from (who else?) BMDO in 1992 and has had seven Phase 2s, three from BMDO. No more SBIR, now, of course, for a subsidiary of a 94000-employee company. UNIAX got its start as a Phase 2 recipient of (who else?) BMDO.
Lighted SiliconPaint a few lines on the silicon surface and overcoat them with the magic polymer, activate the circuit in the silicon with less than 4V and Voila - The Polymer Shines. Not just any polymer though. UNIAX Corp (Santa Barbara, CA) owns the right shiny polymer with which it reported the Light Emitting Electrochemical Cell in Science 1995 after its 1994 Phase 1 BMDO SBIR. UNIAX sees this set-up pushing aside two presently pursued technologies: light emitting epitaxial layers like AlGaAs/GaAs, and porous silicon. (When will these technology advances stop obsoleting DOD's investments? Can't we halt the sledgehammer of progress and return to an orderly world?) Since then it has attracted well over $1M beyond the SBIR subsidy plus one large chemical company is putting in a new $1M. The professor-started company has now got a business type CEO, Jim Long, a sina qua non for business success.
Unica up 118% [Aug 13, 10] IBM plans to pay $21 per share for all outstanding shares of Unica (Waltham, MA; $600K NSF SBIR in the 1990s). Unica makes enterprise marketing software, and IBM said buying Unica will expand its ability to help its customers develop more targeted marketing campaigns, using Unica’s “sophisticated analytics and marketing process improvement” technologies. Unica brings to the deal more than 1,500 customers [Mass High Tech, Aug 13, 10] Which values Unica at $480M. SBIR advocates could reasonably speculate that if the $600K in the mid 1990s was, say, 10% of the company value at the time, and the government took 10% equity, SBIR has a rich ROI to help justify its existence. But the downside of doing so is raising the embarrassing question of the total ROI for all of SBIR over nearly thirty years. Some of the advocates, who believe more in handouts than capitalism, will even complain that the small company was swallowed up in another attack by big money capitalists on small business.
Unica up 10% [Jul 15, 09]
Unica down 12% [Mar 27, 09]
Unica up 19% [Mar 23, 09]
Unica up 17% [Mar 10, 09]
Unica up 10% [Mar 6, 09]
Unica down 11% [Mar 5, 09]
Unica up 11% [Mar 4, 09]
Unica down 12% [Mar 2, 09]
Unica up 11% [Feb 26, 09]
Unica up 16% [Feb 24, 09]
Unica down 11% [Jan 9, 09]
Unica up 13% [Dec 31, 08]
Unica up 25% [Dec 16, 08]
Unica up 20% [Dec 8, 08]
Unica up 16% [Dec 2, 08]
Unica down 18% [Dec 1, 08] On a stock bloodbath day
Unica up 15% [Nov 26, 08]
Unica down 11% [Nov 25, 08]
Unica down 13% [Nov 14, 08]
Unica up 26% [Nov 13, 08]
Unica down 12% [Nov 5, 08]
Unica down 13% [Oct 24, 08]
Unica down 11% [Oct 22, 08]
Unica down 11% [Oct 17, 08]
Unica up 18% [Oct 16, 08]
Unica up 10% [Oct 10, 08]
Unica down 10% [Oct 14, 08]
Unica down 11% [Oct 2, 08]
Unica down 11% [Oct 2, 08]
Unica up 12% [Sep 18, 08]
Unica down 10% [Mar 6, 08]
Unica up 10% [Feb 13, 08]
Unica
down 10% [Jan 4,
08]
Unica up 15% [Dec 6, 07]
Nano IPOs. NANOTECHNOLOGY companies, nurtured on billions of dollars in government grants and venture investments through most of this decade, are getting ready to go public. ... NanoGram (Milpitas, CA; no SBIR), Unidym(Menlo Park, CA; no SBIR), NanoDynamics (Buffalo, NY; $1M SBIR). Unidym is a subsidiary of the Arrowhead Research Corporation, a public investment company that was founded in 2003 to back small companies engaged in nanotechnology research. [James Flanigan, New York Times, Dec 20]
Energy-storage startup UniEnergy Technologies (Mukilteo, WA; no SBIR) said it has raised $25 million in funding to continue producing a huge, liquid battery meant to help utilities and large industrials companies make energy last longer.... said the investment comes from Tokyo investment firm Orix and from existing investors. [Rachel Lerman, Seattle Times, Dec 8, 15]
Unified Nexsys,(Carlsbad, CA; no SBIR, two employees) secure connection company founded last year, said it has received first round of funding from Aerojet[Mike Freeman, utsandiego.com, Mar 21]
Unilife down 11% [Aug 2, 16]
Unilife down 14% [Jul 29, 16]
Unilife up 11% [Jul 21, 16]
Unilife down 13% [Jul 19, 16]
Uni-Pixel down 10% [May 6, 16]
Uni-Pixel down 36% [Apr 28,15]
Uni-Pixel up 11% [Apr 23,15]
Uni-Pixel down 17% [Apr 20,15]
Uni-Pixel up 32% [Feb 27, 15]
Uni-Pixel up 13% [Nov 24, 14]
Uni-Pixel up 17% [Nov 7, 14]
Uni-Pixel up 11% [Sep 29, 14]
Uni-Pixel down 11% [Sep 19, 14]
Uni-Pixel up 15% [Jun 10, 14]
Uni-Pixel up 26% [Jun 5, 14]
Uni-Pixel down 19% [Nov 8, 13]
UniPixel up 15% [Sep 25, 13]
UniPixel down 10% [Jun 12, 13]
UniPixel down 23% [May 31, 13]
Uni-Pixel down 12% [Jan 8, 13]
Uni-Pixel down 18% [Dec 20, 12]
Uni-Pixel down 26% [May 17, 13]
Uni-Pixel down 10% [Dec 11, 12]
Uni-Pixel up 55% [Dec 10, 12] is collaborating with a manufacturer of personal computers to develop and introduce products that contain next-generation touch screens based on UniPixel’s UniBoss pro-cap, multi-touch sensor film. [Wall Street Cheat Sheet, Dec 9]
Presage Biosciences (Seattle, WA; no SBIR) has been named one of FierceBiotech ’s “Fierce 15” of 2013. ... a spinoff company of the Fred Hutchinson Cancer Research Center .... patented a novel method for simultaneously analyzing multiple cancer drug candidates and drug combinations within a single tumor while that tumor is still in a patient. .... FierceBiotech evaluates hundreds of private companies from around the world each year before selecting the 15 it considers the most innovative, creative and promising. The other Fierce 14 are: Acetylon Pharmaceuticals; AnaptysBio; CytomX (Santa Barbara, CA; $500K SBIR); FibroGen (South San Francisco, CA; $1.3M SBIR); Immunocore; Jounce Therapeutics; Kala Pharmaceuticals; MacroGenics (Rockville, MD; $2.6M SBIR) ; Moderna Therapeutics; Nimbus Discovery; Scioderm; Ultragenyx; UniQure; and Visterra. [Valerie Bauman, Puget Sound Business Journal , Sep 24]
United Devices (Austin TX; no SBIR) which develops software for powerful grids of individual computers, announced today that it has merged with a Chicago company, Univa, which develops related technology, No financial terms were disclosed. [Austin American-Statesman, Sep 18]
United Therapeutics buys Miromatrix (Eden Prairia, MN; $2.5M SBIR) in $91M xenotransplant deal [Conor Hale, Fierce Biotech, Oct 30, 2023]
United
Therapeutics
(Silver
Spring, MD; no SBIR) has
ambitions
to build an unlimited supply of certain transplantable
organs.
... said the company's new multiyear collaboration —
specifically
with United Therapeutics' transplantation-focused subsidiary, Lung
Biotechnology
PBC — will use patient-specific
biological material, including re-differentiated stem cells, to create
materials for the transplants. The project will be based out of 3D Systems (San
Diego, CA; no SBIR) new
bioprinting lab. ... United
Therapeutics additionally invested $100 million in two rounds, in 2014
and 2016, in Synthetic
Genomics
(La Jolla, CA), a
company started by
scientist J. Craig Venter, to further its own research and development
in its North Carolina facility. The local company also invested $41.8
million in TransMedics
(Andover, MA; no SBIR) that
develops
ex vivo perfusion systems for donor lungs, hearts and kidneys.
[Tina Reed, Washington Business Journal, May 2, 17]
United Therapeutics (Silver Spring, MD; no SBIR) unveiled unsatisfactory clinical data for its oral pulmonary hypertension drug last week, Wall Street delivered a hefty blow to the value of its stock. Shares of the biotechnology firm slipped 18% on Wednesday ....Chief executive Martine Rothblatt founded the firm in 1996 to focus on pulmonary hypertension after her daughter was diagnosed with the disease. The firm now counts 500 employees and projects it will hit $1 billion in revenue by 2013. [Steven Overly, Washington Post, Aug 28, 11]
HealthTronics (Austin, TX; one SBIR, founded 1985), a developer of mobile technology that zaps kidney stones and cancer tumors, has acquired United Therapies LLC (Chicago, IL; no SBIR). .... said the deal would broaden its national presence and includes investments in facilities that provide low-cost alternatives to hospitals. ... In early 2014, Endo International PLC sold HealthTronics to New York-based Altaris Capital Partners LLC for $130M. [Christopher Calnan, Austin Business Journal, Mar 9, 16]
Unity Biotechnology (Brisbane, CA; no SBIR) has yet to show that its drugs can treat diseases of aging in humans, but it now has $85 million [IPO] to start those tests. ... follows a $55 million Series C round of financing in March ... is developing drugs that target senescent cells— dormant cells that still secrete proteins that trigger aging or disease in tissue, the company says in its prospectus. [Frank Vinluan, xconomy.com, May 2, 18]
Three weeks after Unity Biotechnology (San Francisco, CA; no SBIR) raised $55 million in financing to bring its osteoarthritis drug candidate into human testing, the anti-aging biotechnology company is now laying out plans for [$85M IPO]. ..... In preclinical research that has been published in Nature and Science, Unity says eliminating the senescent cells extended the health and lifespan of animals. Unity now aims to show that its approach can work in humans. The company says it will use proceeds from the IPO to support two drugs, UBX0101, for osteoarthritis, and UBX1967, an experimental treatment for eye diseases. [Frank Vinluan, xconomy.com, Apr 6, 18]
UNITY Biotechnology (San Francisco, CA; no SBIR) creating therapeutics that prevent, halt, or reverse numerous diseases of aging, announced the closing of a $116 million Series B financing. .... [New CEO] Keith Leonard, 25-year biotech industry veteran brings a wealth of leadership experience, including 13 years at Amgen. Most recently, he was CEO of KYTHERA Biopharmaceuticals, a company he co-founded with Ned David that was acquired by Allergan for $2.1 billion in late 2015. [Unity press release, Oct 27, 16]
Mayo Clinic results opened the possibility of developing a whole new class of drug therapies targeting cellular senescence as an anti-aging strategy and led to the creation this year of Unity Biotechnology San Francisco, CA; no SBIR) co-founded by Van Deursen and backed by Mayo Clinic Ventures. [Don Jacobson, Twin Cities Business, Aug 24, 16]
Unity Biotechnology (Novato, CA; no SBIR needed) has been working under the radar on the puzzle of cells that go dormant—a state called senescence—and appear to be driving so-called “diseases of aging.” To coincide this week with the publication of research from the Mayo Clinic, which Unity has licensed, the firm launched with an undisclosed amount of funding .... It plans to develop small molecule drugs that kill senescent cells. The startup has programs aim to treat osteoarthritis, glaucoma, and other conditions, but the first tests in humans could be years away. [Alex Lash, xconomy.com, Feb 5, 16]
Universal Display up 23% [Feb 22, 19] increased its dividend by two-thirds
Universal Display down 21% [Nov 2, 18]
Universal Display up 14% [Aug 10, 18]
Omeros down 18% [Aug 10, 18]
Universal Display up 12% [May 4, 18]
Universal Display down 16% [Feb 23, 18] reported substantial growth in net income and doubled the dividend, but had a big charge from the terms of new Republican tax cut law. [company press release, Feb 23, 18]
Astellas Pharma (Japan) and s (Seattle, WA; at least one Phase II SBIR) announced that Astellas has acquired Universal Cells. Astellas will gain Universal Cells’ proprietary Universal Donor Cell technology to create cell therapy products that do not require Human Leukocyte Antigen (HLA) matching, potentially overcoming a huge treatment challenge by reducing the risk of rejection. ... will pay up to $102.5 million of upfront and milestones to acquire 100 percent ownership of Universal Cells depending on achievement of certain specified clinical milestones. [Astelllas press release, Feb 13, 18]
With shares of Universal Display (Trenton, NJ; $14M SBIR, founded 1994) up nearly 160% over the past year, you might be tempted to stay far away from the organic light-emitting diode (OLED) specialist. And with an annual yield of just 0.07%, its tiny dividend isn't exactly enough to inspire income-hungry investors at first glance. But as I pointed out when Universal Display initiated that dividend almost exactly year ago, management has repeatedly noted that it views the payout as a "good place to start," leaving room to increase capital returns as the world continues to adopt the company's flagship OLED technology. [Steve Symington, George Budwell, and John Bromels, The Motley Fool, January 30, 18]
Universal Display up 10% [Nov 3, 17]
Universal Display up 12% [Aug 30, 17]
Universal Display up 24% [May 5, 17]
Universal Display up 20% [Feb 24,17]
Kateeva (Newark, CA; no SBIR) announced that it has closed its Series E funding round with $88 million in new financing. The Silicon Valley technology leader disrupted the flat panel display industry when it launched a breakthrough equipment solution to mass-produce flexible Organic Light Emitting Diodes (OLEDs). ... has raised $200 million since it was founded in 2008 [company press release, May 19, 16] In SBIR-supported OLED, Universal Display (Ewing, NJ) had about $12M to lead funding total of about $30M.
Universal Display up 11% [Jan 29, 16]
Universal Display down 10% [Jan 15, 16]
Universal Display up 11% [Nov 19, 15]
Universal Display up 13% [Nov 6, 15]
Universal Display down 11% [Oct 16,15]
Universal Display up 10% [Oct 9,15]
Universal Display (Ewing, NJ; $16M SBIR) up 11% [May 8, 15]
Universal Display up 15% [May 9, 14]
Universal Display down 10% [May 5, 14]
Universal Display up 26% [Nov 8, 13]
Universal Display up 10% [Aug 13, 13]
Universal Display up 10% [Aug 12, 13]
Universal Display down 18% [May 10, 13]
Universal
Display up 12%
[Feb 28, 13]
Universal Display down 13% [Feb 25, 13]
Universal Display up 10% [Feb 1, 13]
Universal Display up 10% [Dec 6, 12]
Buyback critics. Bad as the deal C&D shareholders are getting on their buyback may be, it pales in comparison to the money being blown on buybacks at Universal Display. After surprising shareholders with a Q3 loss earlier this month and suffering a prompt downgrade on Wall Street, the OLED tech specialist tried to stanch the bleeding last week with an announced $50 million buyback plan. Terrible idea., Universal Display has plenty of cash to fund a buyback -- nearly $240 million at last report. This historical money-burner is even generating a bit of free cash flow these days, so that's good news. The problem is that UD just isn't nearly cheap enough to justify buying back stock at today's prices. Shares costs more than 80 times annual free cash flow and a whopping 110 times earnings. So even if the company hits Wall Street's long-term growth target of 25%, it's hard to justify a buyback.Plus, last time we checked, UD's growth rate was shrinking, rather than expanding. In this month's report, it cut 2012 revenue guidance from $100 million to as little as $80 million. If that's the best UD can do, it probably shouldn't be buying back shares at all. [Motley Fool, Nov 23] Although it would never be official policy, one criterion for when a small biz no longer needs, or should get, a government subsidy is stock buyback or dividend. If it won't invest its own free cash, it should not get investment from public funds that are based on a market failure theory.
Universal Display down 18% [Nov 8, 12] reported a surprise third-quarter loss and cut its revenue forecast for the year.
Universal Display down 12% [Nov 7, 12]
Universal Display up 19% [Aug 9, 12]
Universal Display down 10% [Jul 20, 12]
Universal Display up 10% [Jun 27, 12]
Universal Display down 11% [May 17, 12]
Universal Display down 10% [May 10, 12]
Universal Display down 10% [Feb 29, 12]
Universal Display down 11% [Jan 3, 12]
Universal Display up 17% [Nov 4, 11]
Universal Display down 13% [Oct 3, 11]
Universal Display up 12% [Sep 13, 11]
Universal Display up 11% [Aug 26, 11]
Universal Display up 16% [Aug 25, 11]
Universal Display up 17% [Aug 23, 11]
Universal Display
up 25% [Aug 22, 11]Universal Display down 12% [Aug 18, 11]
Universal Display up 10% [Aug 15, 11]
Universal Display up 12% [Aug 11, 11]
Universal Display down 11% [Aug 8, 11]
Universal Display up 19% [Mar 16, 11]
Universal Display up 10% [Aug 10, 10]
Universal Display up 18% [May 27, 10]
Universal Display down 10%
Universal Display down 20% [Aug 11, 09]
Universal Display up 13% [Apr 9, 09]
Universal Display up 14% [Mar 12, 09]
Universal Display up 10% [Mar 10, 09]
Universal Display up 10% [Jan 21, 09]
Universal Display down 13% [Jan 20, 09]
Universal Display up 10% [Jan 6, 09]
Universal Display up 26% [Dec 8, 08]
Universal Display down 12% [Dec 1, 08] On a stock bloodbath day
Universal Display up 10% [Nov 26, 08]
Universal Display up 17% [Nov 24, 08]
Universal Display down 15% [Nov 14, 08]/
Universal Display up 13% [Nov 13, 08]
Universal Display down 13% [Nov 12, 08]/
Universal Display down 10% [Nov 10, 08]
Universal Display down 13% [Oct 15, 08]
Universal Display down 21% [Sep 29, 08]
Universal Display up 13% [Sep 16, 08]
Organic light-emitting diodes have surpassed fluorescent lights in energy efficiency, according to Universal Display [which] announced it has created an OLED panel that produces 102 lumens, a measure of light output, per watt of electrical power. ...There are plenty of problems still to straighten out with OLEDs before they're practical light sources. The panels dim with a few hundred or thousand hours of use and they're difficult to produce in large quantities. [AP, Jun 23,08]
Universal Display down 12% [Mar 14, 08] after it reported a bigger loss wider than the Street expected.
Universal Display up 10% [Feb 13, 08]
Universal Display down 12% [Jan 8, 08]
Universal Display up 10% on a broker's upgrade. [Jun 19, 07]
Universal Display has not turned a profit. It has lost about $125M since its founding in 1994. ..It has no plans to manufacture products. Instead it will license its [OLED] technology to companies around the world. [Henry Holcomb, Philadelphia Inquirer, reprinted by Seattle Times, Feb 26] Holcomb's hopeful tale never mentions about $8M in SBIR.
Universal Display was up 10% after announcing a big improvement in operational lifetime for a green phosphorescent OLED device [Dec 27, 06]
I do believe
that more
flexible
robots such as those from Universal
Robots, Unbounded
Robotics
and Baxter from Rethink
Robotics
will have a major impact
on the
workplace. Estimating the global manufacturing labor costs at $6
trillion annually, McKinsey forecast that advanced robotics could have
an economic impact on the manufacturing sector of between $720 billion
to $1.45 trillion annually. [Colin Lewis,
http://robotenomics.com, Apr 23] No SBIR in those three.
Six companies have secured positions on a potential five-year, $45 million contract to provide support services to a U.S. Army center established to develop and engineer software for weapons, training and combat support systems. [GovConWire, Jul 8, 18] One firm, Universal Technical Resources (Cherry Hill, NJ), had $1M SBIR in 2013.
One of the region’s largest defense firms has landed another high-tech contract with the U.S. Air Force. Universal Technology (Dayton, OH, $100K SBIR in the the 1908s) $17M for R&D and tech support work at WPAB. [Caleb Stephens, Dayton Busiess Journal, Apr 27, 16]
Universal Technology (Beavercreek, OH; $100K SBIR in the 1980s, 230 employees) will get nearly $500Kto help the U.S. Air Force make advances in 3D printing. .... a two-year contract for additive manufacturing modeling ... mainly focused on research and development work for the military [Joe Cogliano, Dayton Business Journal, Mar 26, 15]
Universal Technology (Beavercreek, OH; $100K SBIR in 1988) which is mainly focused on research and development work for the military — saw less funding from some of its contracts while few new contracts were coming in ... In the last few years it has crept back up to 230 employees, including 200 locally, and is in a position to post significant revenue gains during the next few years, said Pat Adamson, president .... has about a dozen prime contracts with the U.S. Air Force and recently won a renewal on a big one: A five-year, $100 million deal to support national propulsion research .... The bigger “X” factor in the next few years, though, could come from the massive federal OASIS contract, in which Universal Technology won spots in four different categories. [Joe Cogliano, Dayton Business Journal, Sep 10, 14]
Universal Technology (Beavercreek, OH; $100K SBIR in 1987) [ the fifth largest defense contractor in the region with nearly $40 million in contracts] landed a $34 million five-year deal to manage a U.S. Air Force project. .... It involves enable collaborative research partnerships between Air Force Research Laboratory and academia and industry in areas such as materials and manufacturing and aerospace sensors. [Joe Cogliano, Dayton Business Journal, Aug 13, 13]
Universal Technology (Beavercreek, OH; three SBIRs in the 1980s) landed a $34 million deal to manage a U.S. Air Force project. .... involves enable collaborative research partnerships between Air Force Research Laboratory and academia and industry in areas such as materials and manufacturing and aerospace sensors. [Joe Cogliano, Dayton Business Journal, Aug 13, 13] Want big DOD contracts? Set up near the flagpole; learn the players and the lingo. Wright Patterson AFB near Dayton has about a $4.6 billion impact while the area’s largest 25 defense contractors account for 3,000 Dayton-area employees and more than $755 million in combined local Defense Department contract awards in the most recent year, according to Dayton Business Journal research.
Unleash Immuno Oncolytics (St Louis, MO; no SBIR) draws $3 million investment from Japanese biotech firm [St Louis Business Journal, Feb 20, 18] develops oncolytic virus immunotherapy products to treat cancer. The company offers UIO-512, an oncolytic virus designed to target malignant cells and tumor-associated stroma cells. [Bloomberg.com]
Unum Therapeutics (Cambridge, MA; no SBIR, founded 2014) focused on the development of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer, today announced the pricing of its [IPO to raise $69M] [company press release, Mar 28, 18] total funding $178M [crunchbase.com]
Unum Therapeutics (Cambridge, MA; no SBIR) , that just came out of the woodwork today with $12 million in backing from some of the Boston area’s biggest life sciences players. Unum has hauled in a $12 million Series A round led by [including] Sanofi-Genzyme BioVentures. It’s the second Series A an biotech has secured in two weeks. Another cancer treatment developer, Raze Therapeutics (no SBIR), announced a $24 million Series A round on Oct. 14. Unum is the latest startup touting a way to essentially reprogram the immune system to seek out and attack tumors.... Unum will use the cash to get its first candidate, which hasn’t been disclosed, through clinical proof-of-concept studies. [Ben Fidler, xconomy.com, Oct 21, 14]
When startup FireFly LED Lighting (Austin, TX; no SBIR) was accepted into the Austin Technology Incubator two years ago, its LED bulbs were still prototypes. Since then, the company has launched its product line, signed customers including Kerbey Lane Cafe and the University of Texas and received $3.4 million from backers including the Central Texas Angel Network and the Texas Emerging Technology Fund..... Since its founding in 1989 by legendary business leader George Kozmetsky, ATI has worked with more than 200 startups, helping them raise nearly $1 billion in investment capital. [Lori Hawkins, Austin American Statesman, Jan 26, 12] Graduates: Agile Planet, Atomometrics, Axelo, Calxeda, Dorsan Biofuels, Famigo, GameSalad, Ideal Power Converters, Itzbig, Nitero, Notice Technologies, Open Algae, Qcue, RFMicron, RRE Solar, Savara Pharmaceuticals, Spredfast, Terapio ($500K SBIR), Unwired Nation, WiMax.com.
Uptake Medical, (Seattle, WA; no SBIR, founded 2004) developing a medical device for the treatment of emphysema, has scored $17.5 million in a second round of financing. [John Cook, Puget Sound Business Journal, Jul 7, 10]
UQM Technologies (Longmont, CO; $6M SBIR) up10% [Denver Business Journal, Sep 4, 12]
Electric motor manufacturer UQM Technologies (Longmont, CO; $4.7M SBIR) has received a $3 million federal grant aimed at creating a new motor that avoids the use of rare-earth magnets. ... will add $1 million of its own money to the $3 million grant. Rare earths are used to manufacture small but powerful magnets used in a wide range of electric motors, including military defense equipment, cellphones, wind turbines and hybrid-electric vehicle motors. But nearly all rare earths mined in the world come from China, which has cut those exports in recent years. [Cathy Proctor, Denver Business Journal, Aug 11, 11]
Urbix Resources (Mesa, AZ,, no SBIR, founded 2014) raised $3.5M Series A funding as the Department of Energy says the company is one of five companies selected to receive a technology development voucher for preliminary work oriented towards the advancements of ultra-high purity isotropic graphite. [EIN presswire, May 1, 18]
Urigen Pharmaceuticals (Wilmington, DE; no SBIR) raised $750,000 in a debt financing, according to [SEC] documents ..... developing products for patients with urological ailments such as painful bladder syndrome, urethritis, nocturia and over active bladder. Urigen’s lead new drug candidate, the experimental painful bladder syndrome treatment URG101, is a proprietary combination of approved drugs that is instilled into the bladder. [John George, Philadelphia Business Journal, Jul 23, 13]
UroGen Pharma down 16% [Sep 25, 19]
UroGen Pharma up 10% [Jan 25,18]
Urogen Pharma up 16% [Jan 22,18]
Ovid Therapeutics (New York, NY; no SBIR) raised $75 million in an IPO, continuing a recent flurry of biotech offerings—among them BioHaven Pharmaceuticals (New Haven, CT; no SBIR) and UroGene Pharma (New York, NY; no SBIR) —that have all met or exceeded their share price projections. [Ben Fidler, xconomy.com, May 5, 17]
Uroplasty (Minnetonka, MN; no SBIR) and Vision Sciences (Orangeburg, NY; two SBIRs) entered into a definitive merger agreement under which the two companies will combine in an all-stock transaction to create a new company expected to generate revenue of approximately $50 million for the fiscal year beginning April 1, 2015. ... the combined company will conduct business as Cogentix Medical [joint press release, Dec 22,14]
Ursa Major Technologies (Berthoud, CO; one SBIR), manufacturer of propulsion solutions for the space community, raised $15 million in equity funding, according to a Form D filing. [Nick Greenhalgh, ColoradoInno, Feb 1, 21]
“Our job”, says Jan Kemper, “is to make cells happy.” Ms Kemper works at MedImmune (Gaithersburg, MD), [now] a subsidiary of AstraZeneca. Her laboratory contains 40 bioreactors—fluid-filled tanks of about three litres’ capacity. ... Barack Obama directed federal agencies to take action against antibiotic-resistant bacteria. A task-force, ordered to report in February, has been appointed. And the Department of Health and Human Services is putting up a $20m prize for a rapid, diagnostic test for such bacteria. ... MedImmune’s antibodies are aimed respectively at Pseudomonas aeruginosa and Staphylococcus aureus and bind, in the former case, to bugs themselves and in the latter to human cells, shielding them from bacterial toxins. ... As Steve Projan, who oversees MedImmune’s antibody project, eloquently puts it, “I’ve been working on staph for 34 years. I’m ready to beat the bastard.” [The Economist, Nov 12, 14] founded 1988 as Molecular Vaccines, $3.5M NIH SBIR 1989-1998, became MedImmune in 1990, raised $24M in 1991 IPO, FDA approval for pediatric use of RespiGam, acquired US Bioscience (no SBIR) in 1999, acquired Aviron (Mountain View, CA; $3M SBIR 1995-2002) in 2002, formed a VC subsidiary in 2003, FDA approved FluMist in 2003, won $170M HHS award for cell-based flu vaccine in 2006, acquired by AstraZenica 2007, joint Chinese venture 2012. [company website]
US Nanocorp (Farmington, CT; no previous SBIR) has a lithium-air battery in which the inspiration for the membrane came from artificial-blood research that produced a material that can carry oxygen. It also has a commercialization partner for its Phase II project in Ultralife Batteries, a major battery manufacturer that pledged $150,000 to help defray some development costs. [MDA Tech Update, Summer 08]
US Silicones, a start-up supplier of compounded silicone rubber materials for the medical, industrial, automotive and home appliance markets, will locate its manufacturing operations in Fort Wayne. The company, formed by Fort Wayne-based executive management firm Thistle Group, will invest more than $1.1 million to upgrade an existing 15,000 square-foot facility [Indianapolis Star, May 2, 08]
UTC Power, a (South Windsor, CT; no SBIR) manufacturer of fuel cell systems, has laid off employees as part of a 39 percent cut in the workforce of parent company ClearEdge Power. (no SBIR)... part of a company pivot away from mobile fuel cells that run in vehicles. ... Layoffs also occurred at ClearEdge's locations in Hillsboro, OR., Sunnyvale, CA, and Irvine, CA. [Brian Dowling, Hartford Courant, Mar 15, 13]
Rhode Island is luring an energy technology company from the west coast to its state with support from a $500,000 Renewable Energy Fund loan.Utilidata (Spokane, WA; no SBIR) is relocating to the Ocean State, bringing eight to 15 jobs in 2012, with help from the loan .... provides consulting, engineering, design, integration, control, data acquisition, energy conservation and energy management offerings to utilities. [Michelle Lang, Mass High Tech, Feb 7, 12]
Parts from Powder(Mar 20) BMDO SBIR company Utron (Manassas, VA) got some big press - a front page Wall Street Journal (Mar 19)- for its quick powder compaction into small parts. The competition will be fierce though from the many other powder pressers who want the Holy Grail of parts making - instant shape and properties to order. Inventors over the years have thought of many ways to press a powder into some wanted shape. Utron has had only one Phase 2 SBIR (BMDO) and that was for spraying powders rather than compressing them. Pressing powders is the kind of economics-driven SBIR that BMDO likes because it is likely to develop into a market-shelf technology that BMDO's system builders can get a free ride on private capital for their small scale developments done for them. Private capital is happy to oblige for the profit to be made in selling it to everyone except BMDO. Co-founders Dennis Massey and Doug Witherspoon say the phone was ringing yesterday. Doug is also a leader in a DC area tech entrepreneurs' network.
NCBiotech announced last week that it had awarded $1,060,352 through 17 grants and loans in the first quarter of its 2016-17 fiscal year. In total, four Triangle firms snagged funding. InnAVasc Medical (Durham, NC; no SBIR), 410 Medical Innovation (Durham, NC; no SBIR), UVision360 (Research Triangle Park, NC; no SBIR), and EpiCypher (Research Triangle Park, NC; no SBIR) each received a $250,000 small business research loan for applied research, NCBiotech said. [Jennifer Henderson, Triangle Business Journal, Oct 20, 16]